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Abstract 
Pancreatic cancer is common and aggressive: the main type is pancreatic ductal 
adenocarcinoma (PDAC). It is the fifth most common cause of cancer death in 
the UK with an overall five year survival of only 2-3%. Establishing the diagnosis 
of PDAC is important for optimal patient management but can be difficult and 
relies on imaging and cytology/pathology. Although imaging may be highly 
suggestive of PDAC, a pathological diagnosis is preferred prior to definitive 
treatment; therefore tissue samples are required. Cytology samples are obtained 
at endoscopy. Cytological analysis requires the identification of different cell 
types and in particular the distinction of malignant pancreatic epithelial cells 
from reactive pancreatic cells and other gastrointestinal contaminants. This 
requires experience and expertise and can be difficult. A tissue diagnosis is not 
achieved in a significant proportion of PDAC cases. Hence, an unmet clinical 
need exists for the diagnosis of PDAC from cytological samples. One potential 
way of improving the cytological diagnosis is to use immunohistochemistry (IHC) 
biomarkers as an adjunct to cytology in difficult to diagnose cases. Diagnostic 
IHC biomarkers have been investigated, but to date none has entered into 
routine clinical practice.  
The aim of this study was to improve the diagnosis of PDAC from cytology 
samples. It is hoped that the identification and validation of IHC biomarkers in 
PDAC will help their clinical translation. For biomarker identification a meta-
analysis of potential IHC diagnostic biomarkers investigated in PDAC was 
performed. Sixteen biomarkers were quantified in meta-analysis and the highest 
ranked biomarkers were KOC, maspin, S100P, mesothelin and MUC1. These 
biomarkers have not entered into clinical practice partly because they were 
investigated in separate studies with relatively small sample sizes and without a 
uniform and clinically appropriate cut-off.  
Biomarkers identified in the meta-analysis were validated in a resection cohort 
from patients with pancreatico-biliary adenocarcinoma. The aim was to identify 
better biomarkers and cut-offs that could potentially be investigated in cytology 
samples. KOC, S100P, mesothelin and MUC1 were investigated in one set of 
tissue microarrays, while maspin was investigated in another set. Five cut-offs 
were carefully chosen for sensitivity/specificity analysis using receiver operating 
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characteristics curve analysis. Using 20% positive cells as a cut-off achieved 
higher sensitivity/specificity values: KOC 84%/100%; S100P 83%/100%; mesothelin 
88%/92%; MUC1 89%/63%; and Maspin 96%/99%. Analysis of a panel of KOC, S100P 
and mesothelin achieved almost 100% sensitivity and specificity if at least two 
biomarkers were positive for both 10% and 20% cut-offs. 
Clinical translation of biomarker requires a reliable and reproducible cut-off for 
interpretation of IHC. We identified three cut-offs for investigation to establish a 
consensus based cut-off(s) that could potentially be used by pathologists for 
PDAC and other cancers. A series of IHC images of microarray cores were used to 
investigate observer agreements for 10%, 20% and +2/+3 cut-offs. Seven 
pathologists participated in this study. The inter- and intra-observer agreements 
using the three cut-offs were reasonably good. For all three cut-offs a positive 
correlation was observed with perceived ease of interpretations (p<0.01 for all 
cut-offs). Finally, cytoplasmic only staining achieved higher agreement than 
cytoplasmic/nuclear and cytoplasmic/membranous staining. All three cut-offs 
investigated achieve reasonable strength of agreement modestly decreasing 
inter and intra-observer variability in IHC interpretation but 10% is slightly better 
than 20% and +2/+3 cut-offs.  
Finally, KOC, maspin, mesothelin and S100P were investigated in archival 
cytology samples with the aim to generate a diagnostic panel which could 
potentially help as an adjunct to cytology. Using 10% cut-off achieved higher 
sensitivity/specificity values: KOC 92%/100%; maspin 54%/100% and mesothelin 
72%/100%. But no staining was observed for S100P. In addition, analysis of a 
panel of KOC, maspin and mesothelin achieved 82% sensitivity and 100% 
specificity for 10% cut-off if at least two biomarkers in the panel were positive. 
The inter-observer agreement for 10% positive cells as IHC cut-off in cytology 
samples was very good for all three biomarkers.  
In conclusion, a panel of KOC, maspin and mesothelin is a suitable diagnostic 
panel and 10% cut-off is a reasonable cut-off achieving high observer agreement. 
Their diagnostic accuracies approach those of optimal conventional cytology. 
These markers may be appropriate for further clinical validation and potentially 
routine use in difficult cases. 
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Definitions/Abbreviations (arranged alphabetically) 
AJCC American Joint Committee on Cancer  
CI confidence interval 
CP chronic pancreatitis 
CT computerized tomography 
DAB diaminobenzidine 
dH20 de-ionised and distilled water 
DNA deoxyribonucleic acid 
ERCP endoscopic retrograde cholangiopancreaticography 
ESPAC European Study of Pancreatic Cancer  
EUS endoscopic ultrasound 
FEM fixed effect model 
FFPE Formalin fixed paraffin embedded 
FNA fine needle aspiration 
FOLFIRINOX fluorouracil, leucovorin, irinotecan and oxaliplatin 
FP false positive 
H&E haematoxylin and eosin 
HIER heat induced epitope retrieval 
IHC immunohistochemistry 
IMP3 Insulin like growth factor messenger RNA binding protein 3 
IPMN Intra-ductal papillary mucinous neoplasia 
KOC K homology domain containing protein overexpressed in cancer 
MDT multi-disciplinary team 
Maspin mammary serine protease inhibitor 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
MUC1 mucin 1 
NP normal pancreatic tissue 
PEM polymorphic epithelial mucin 
PanIN pancreatic intraepithelial neoplasia 
PDAC pancreatic ductal adenocarcinoma 
PBA pancreatico-biliary adenocarcinoma 
PCR polymerase chain reaction 
QUADAS 
REM 
Quality Assessment of Diagnostic Accuracy Studies  
random effects model 
RevMan Review Manager 
RNA ribonucleic acid 
RT-PCR reverse transcription polymerase chain reaction 
S100P S100 calcium binding protein P 
TbT Tris buffered Tween 
TMA tissue microarray 
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TNM Tumour Node Metastasis 
TN true negative 
TP true positive 
US ultrasound 
5-FU 5-fluorouracil 
5% cut-off 5% positive cells and any staining intensity as IHC cut-off 
10% cut-off 10% positive cells and any staining intensity as IHC cut-off 
20% cut-off 20% positive cells and any staining intensity as IHC cut-off 
+2/+3 cut-off Moderate-strong staining intensity and any proportion of positive cells as IHC 
cut-off 
HS20 cut-off Histoscore 20 as IHC cut-off 
 
 
 
 
Units  
oC degree Celsius 
L litre 
m milli 
m meter 
µ micro 
rpm revolutions per minute 
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1 Introduction 
The term diagnosis comes from the Greek gnosis, which means knowledge. 
Diagnosis is the process of defining the nature of a disease or disorder and then 
differentiating it from other likely conditions. The diagnostic process involves a 
combination of clinical features, imaging and pathology. As the pancreas is 
located deep within the abdominal cavity, multiple imaging modalities are used 
to make a correct diagnosis of tumours arising in the pancreas. To differentiate 
benign from malignant disease and to provide a tissue diagnosis, cell samples are 
obtained from suspected pancreatic lesions during endoscopy. Confirmation of 
the diagnosis is thus achieved from interpretation of these cell samples and is 
important for patient management. However, there are instances when the 
morphologic interpretation of cell samples is challenging. 
Molecular diagnostics have emerged as a very important field in cancer 
diagnosis. Genomics and proteomics have enabled the identification of 
differentially expressed genes and proteins respectively in pancreatic cancer 
that could be used as diagnostic biomarkers. These biomarkers can be 
characterised at the protein level by immunohistochemistry (IHC). IHC is a 
routine technique in pathology laboratory. However, the amount of IHC 
biomarker research is not reflected in improving the clinical management of 
patients with pancreatic cancer. 
This introduction will first discuss the normal pancreas and then pancreatic 
ductal adenocarcinoma (PDAC) (the most common pancreatic cancer) including 
the diagnostic process and management of PDAC. The role of cytology in PDAC 
diagnostic management will then be outlined, including factors influencing 
cytology diagnosis and the unmet clinical need to improve cytology diagnosis. 
Finally, the potential role of IHC biomarkers to help diagnosis will be discussed 
with special focus on biomarker development and factors delaying the clinical 
translation of biomarkers. These factors revolve around the identification and 
validation of biomarkers and cut-offs for diagnosis. The aims, objectives and 
implications are outlined at the end of the introduction. 
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The candidate biomarkers were identified by meta-analysis, and then validated 
on tissue arrays and cytology samples with investigation of appropriate cut-offs. 
A suitable diagnostic IHC biomarker panel and cut-offs were then suggested.  
1.1 Pancreas anatomy and physiology 
The human pancreas is pear shaped and weighs approximately 80-100 grams. It 
lies deep in the upper abdomen with the head of pancreas lying adjacent to the 
duodenum and the body and tail extending behind the stomach, crossing the 
midline and reaching as far as the spleen (Figure 1.1) (1, 2). 
The pancreas is a compound gland containing both exocrine and endocrine 
tissue. The exocrine part is composed of two functional compartments: the acini 
(Latin, “grape” like) and ducts, and the endocrine part which is composed of 
islets of Langerhans (Figure 1.2 A&B).  
The major part of the gland is arranged as pancreatic exocrine acini which 
produce digestive enzymes that help in the digestion of proteins, carbohydrates 
and fats. Proteins are digested with the help of proteolytic enzymes trypsin, 
chymotrypsin, elastase, and carboxypolypeptidase that cleaves proteins into 
peptides. Carbohydrates are digested by amylase that cleaves them into di- and 
tri-saccharides and fat digestion is facilitated by lipase, phospholipase and 
cholesterol esterase. Furthermore, sodium bicarbonate and water are secreted 
by ductal epithelial cells to neutralize gastric acid (3). 
Acini secrete digestive enzymes into the ductal system which form the main 
pancreatic duct (duct of Wirsung). It is joined by the common bile duct to form 
the ampulla of Vater that opens into the second part of duodenum through the 
duodenal papilla guarded by the sphincter of Oddi. 
The endocrine part is scattered throughout the pancreas, constituting 
approximately 2% of total pancreatic mass and secretes a variety of hormones 
including insulin and amylin by β‐cells, glucagon by α‐cells, pancreatic 
polypeptide by γ‐cells and somatostatin by δ‐cells. Insulin and glucagon are 
major hormones that are responsible for glucose homeostasis (1-3) 
Chapter 1  23 
 
   
Histology of the pancreas is very important as it provides the knowledge of the 
normal structural features of the pancreas and studies that focus on pancreatic 
cancer are dependent on this knowledge. Pancreatic ductal adenocarcinoma 
(PDAC) is a malignant tumour that arises in the ductal epithelium. As I will be 
discussing the expression of biomarkers in normal pancreas and PDAC knowledge 
of pancreatic histology will help us in better understanding the interpretation 
and utility of tissue based biomarkers. 
1.2 Pancreatic Ductal Adenocarcinoma (PDAC) 
The term “pancreatic cancer” is conventionally used as an alternative name for 
pancreatic ductal adenocarcinoma (PDAC) as it accounts for more than 85% of 
pancreatic neoplasms (4). PDAC arises in ductal epithelium and in 70% cases it 
arises in the head of pancreas with an aggressive clinical course. 
1.2.1 Epidemiology 
In 2010, pancreatic cancer was the 10th most common cancer in the UK and 
ranked 12th in men and 8th in women. Around 8,500 new cases were diagnosed in 
2010 in the UK with a male to female ratio of almost 1:1. The crude incidence 
rate for pancreatic cancer is 14 new cases per 100,000 people. In 2010, an 
average of around 75% of cases were diagnosed in patients aged 65 years and 
over in the UK (5).  
The incidence rates of pancreatic cancer have remained stable in Great Britain 
since the 1970s. Moreover, the survival rates for pancreatic cancer have slightly 
increased since the 1970s. The 5-year survival rate for people diagnosed with 
pancreatic cancer is around 4% but younger patients have a relatively better 
survival than older patients. It is the 5th most common cause of cancer related 
deaths in UK and in 2011, 8300 patients died from pancreatic cancer (5, 6). This 
poor prognosis is partly due to late clinical presentation with advanced disease, 
when the treatment options are limited and relatively ineffective (7). 
1.2.2 Etiology 
Smoking is by far the most common risk factor causing an estimated 25% of cases 
of pancreatic cancer in the UK. Other non-hereditary risk factors are old age, 
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obesity, chronic pancreatitis and eating processed meat (8, 9). Recent onset of 
diabetes may be an early sign of cancer development and patients with type I or 
II diabetes have approximately twice the risk of developing pancreatic cancer. 
Family history is also an important risk factor and people with one first-degree 
relative with pancreatic cancer have almost twice the risk of developing the 
tumour as compared to those without any family history (10, 11). 
1.2.3 Tumorigenesis 
At present three main PDAC precursor lesions have been identified based on 
clinical and histopathological research: pancreatic intraepithelial neoplasia 
(PanIN); intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic 
neoplasm (MCN) (12, 13). The most common precursor lesion is pancreatic 
intraepithelial neoplasia (PanIN), which are a sequence of microscopic lesions 
generally arising in small pancreatic ducts (less than 5mm). PanIN-1 is a low 
grade lesion sub-classified as 1A (flat) and 1B (papillary) and characterized by 
nuclear atypia. PanIN-2 is an intermediate grade lesion with slightly more 
complex architecture compared to PanIN-1 and characterized by nuclear changes 
including nuclear crowding and pseudostratification, loss of polarity, 
pleomorphism and hyperchromasia. Mitoses in PanIN-2 are rare. PanIN-3 is a high 
grade lesion with widespread nuclear atypia, loss of nuclear polarity, frequent 
occurrence of mitoses and budding off of epithelial cells into the lumen. PanIN-3 
is a pre-invasive lesion and is also known as “carcinoma in situ” as it has not 
breached the basement membrane (14, 15). The sequence of morphologic and 
genetic changes suggests that PanIn might be a precursor lesion for infiltrating 
ductal adenocarcinoma (Figure 1.3) (12, 16). 
IPMN and MCN are macroscopic pre-invasive lesions. IPMNs are usually present in 
the head of pancreas and further classified as pancreatico-biliary, intestinal and 
gastric subtypes. MCN are usually solitary lesions found mainly in the body and 
tail of pancreas (17). 
1.2.4 Pathology of PDAC 
PDAC is a malignant neoplasm arising in the ductal epithelium of pancreas, 
showing glandular differentiation. It is a rapidly growing tumour and irrespective 
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of the size of the tumour, metastasizes to liver and lymph nodes. 
Macroscopically, they are typically solid tumours presenting as poorly 
circumscribed masses with an ill-defined and infiltrating margin.  
Microscopically, the neoplastic epithelial cells are highly infiltrative 
demonstrating various patterns of glandular arrangement. The tumour glands are 
irregularly distributed without following the lobular architecture and spatial 
organisation of normal ducts. In addition, there is often a prominent 
desmoplastic stroma surrounding the tumour (Figure 1.4A). Morphologically, two 
types of PDACs have been recognised: pancreatico-biliary and intestinal type 
with the former associated with a worse prognosis than the latter (18, 19). 
The diagnosis of PDAC can be challenging, both at the clinical and microscopic 
levels. The scirrhous (scar like) appearance of this tumour results from abundant 
host tissue stroma (desmoplastic stroma) (Figure 1.4A). This makes the 
differential diagnosis of PDAC from scarring inflammatory lesions like 
autoimmune pancreatitis and chronic pancreatitis (CP) difficult. Cytologic atypia 
induced by inflammation or degeneration of native ducts may mimic carcinoma. 
Conversely, well differentiated PDAC may resemble benign ducts (4, 20) (Figure 
1.4B). Thus the discrimination of PDAC from CP is considered as a challenging 
differential diagnosis in diagnostic pathology (18). Despite their highly aggressive 
nature, most PDACs are well or moderately differentiated (Figure 1.4B&C) as 
compared to poorly differentiated tumours (Figure 1.4D). Both perineural and 
vascular invasion are common during microscopic examination. 
About 60-70% of tumours develop in the head of pancreas; the rest arise in the 
body and tail of pancreas. PDAC arising in the head of pancreas presents earlier 
with jaundice and/or acute pancreatitis as compared to tumours arising in the 
body and tail of pancreas. Therefore, due to late clinical presentation, tumours 
arising in the body and tail are associated with poorer prognosis compared to 
pancreatic head tumours (7, 18, 19, 21). 
The poor prognosis of PDAC is due to late clinical presentation with so-called 
“red flag” symptoms appearing once the tumour has extended beyond the 
confines of the pancreas. Local invasion is common and often involves duodenal 
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wall, common bile duct, ampulla of Vater, spleen, stomach, adrenal gland, 
peripancreatic tissue and adjacent vessels (7, 19, 22). 
Knowledge of the pathology of the pancreas is important for understanding the 
current project. I will be validating the expression of IHC biomarkers in PDAC 
and this knowledge will help in observing and localising the differential 
expression of biomarkers in PDAC compared to normal tissue for potential 
diagnostic purposes. 
1.3 Diagnosis of PDAC 
Diagnosis of PDAC requires a combination of clinical findings, imaging and 
cytology/pathology. Here I will give an overview of the diagnostic process for 
PDAC but I will give a more detailed account of cytology in section 1.7, which 
will also provide the rationale for the current thesis. 
1.3.1 Clinical presentation 
Clinical presentation depends on the location of tumour and disease stage. 
Obstructive jaundice and weight loss are the commonest presenting features of 
tumours in the head of the pancreas. Abdominal pain and weight loss are the 
commonest presenting features of tumours arising in the body and tail. Pain is 
an important clinical symptom reported as a deep, dull and aching pain 
originating from the upper abdomen and radiating to the back.  
Pancreatic cancer can cause other signs and symptoms such as asthenia, 
anorexia, hyperglycemia, abnormal liver function, panniculitis and superficial 
venous thrombosis. Locally advanced tumours can cause gastric outlet 
obstruction, duodenal obstruction and rarely gastrointestinal bleeding (7, 22, 
23). 
1.3.2 Imaging 
Imaging contributes to the diagnosis of pancreatic cancer and is important for 
pre-treatment staging based on local invasion and metastases.  
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1.3.2.1 Non-invasive imaging 
Ultrasound, computed tomography scan, and magnetic resonance imaging are 
non-invasive imaging modalities for PDAC diagnosis with variable sensitivity and 
specificity. 
Abdominal ultrasound (US) is safe, inexpensive and helps to formulate a 
differential diagnosis for possible causes of obstructive jaundice (22, 24). 
Computed tomography (CT) scan is a well validated imaging tool used for the 
diagnosis and staging of patients with suspected pancreatic cancer. CT scan 
allows visualisation and assessment of vascular and surrounding organs 
involvement by tumour (24, 25). Magnetic resonance imaging (MRI) can also be 
used for the diagnosis and staging of pancreatic cancer (24). 
1.3.2.2 Invasive imaging 
Endoscopic retrograde cholangio-pancreato-graphy (ERCP) and endoscopic 
ultrasound (EUS) are minimally invasive imaging modalities to identify small 
mass lesions and abnormalities of pancreatico-biliary ductal systems not 
identified by non-invasive imaging (26-29). EUS and ERCP are also used to obtain 
cytology samples to confirm tissue diagnosis. 
1.3.3 Cytology and histopathology 
Imaging is suggestive of PDAC, but in the UK confirmatory tissue diagnosis is 
preferred for treatment planning purposes and is usually achieved from the 
interpretation of cytology samples obtained during ERCP and/or EUS. A detailed 
account of cytology is given in section 1.7/1.8. 
Histopathologic reporting of the tissue specimens is achieved only in patients 
with resectable disease (15-20% of PDAC cases). The distinction of PDAC from 
reactive pancreatic changes (especially chronic pancreatitis) and other primary 
pancreatic or metastatic tumour is important as the treatment, prognosis and 
follow-up significantly differs. Meticulous microscopic examination of the 
pathology specimens is the backbone of this work up. 
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1.4 Staging system for pancreatic cancer 
The staging system for pancreatic cancer shown in Table 1.1 is according to the 
most recent edition (7th Edition) of the American Joint Committee on Cancer 
(AJCC) (30). 
The staging system especially T stage is very important for predicting the 
surgical resectability of primary tumour. Stages T1, T2 and T3 tumours are 
potentially resectable and stage T4 corresponds to unresectable disease (7).  
Staging is an integral part of the diagnostic work up for the management of 
patients with PDAC and pathology reports on resection specimens clearly states 
the pathologic findings of staging. 
1.5 Management of pancreatic cancer 
The treatment for pancreatic cancer depends on the stage of the cancer, the 
location of tumour and fitness of the patient and is best managed by a 
multidisciplinary team (MDT). The MDT is usually composed of surgeons, 
oncologists, radiologists, pathologists and other staff including nursing and 
palliative care staff and dieticians etc. Surgical resection with adjuvant 
chemotherapy is indicated for patients with Stage I/II disease. Neoadjuvant 
therapy is indicated in patients with Stage III borderline resectable cancers and 
if the tumour is successfully downstaged to stage II disease the patient will be 
offered surgical resection (31, 32). Stage III locally advanced disease should be 
treated with chemotherapy or chemoradiotherapy. Patients with good health 
and stage IV disease receive systemic therapy, whereas patients with poor 
performance status may be given the best supportive therapy (33). 
1.5.1 Surgical resection 
The most widely used operation for the treatment of PDAC involving the head of 
the pancreas is a Whipple pancreatoduodenectomy, which involves removal of 
the distal stomach. A variant of the Whipple procedure preserves pylorus and is 
known as pylorus preserving proximal pancreatoduodenectomy (PPPP) (34, 35). 
Unfortunately, tumours of the head of pancreas are unresectable in the majority 
of the cases and only about 20% of patients are suitable for surgery (7, 22, 36, 
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37). In high volume tertiary centres the operative mortality is less than 6% but 
the morbidity rate is 40% (38). 
Tumours located in the neck and body of pancreas may require 
pancreatoduodenectomy, distal pancreatectomy or, rarely, a total 
pancreatectomy (39). 
1.5.1.1 Post-operative outcome 
The median 5 year survival rate after resection is 10-20% and the median survival 
is 10-19 months (40, 41). Tumour size more than 3cm, positive resection 
margins, high histologic grade and lymph node invasion negatively affect 
survival, however, surgical resection still remains the only potentially curable 
option (40). 
Generally, quality of life after PPPP is good apart from malabsorption which is a 
common complication and can require enzyme supplementation. 
1.5.2 Adjuvant therapy 
Adjuvant therapy may be given following curative resection of pancreatic 
cancer. The European Study Group for Pancreatic Cancer trial-1 (ESPAC-1) trial 
showed that adjuvant chemotherapy with 5- fluorouracil (5-FU) significantly 
improved the survival of patients with PDAC. The median survival was 20.1 
months in patients who received chemotherapy compared to 15.5 months in 
patients who did not receive chemotherapy (42).  
Another clinical trial, ESPAC-3 compared 5-FU with gemcitabine and found a 
median survival of 23 months and 23.6 months for patients treated respectively 
with 5-FU/folinic acid and gemcitabine (43). Gemcitabine has fewer side effects 
and is generally preferred over 5-FU. A further clinical trial, ESPAC-4 is in 
progress with the aim of comparing the survival after surgery for patients with 
PDAC treated with a combination of gemcitabine plus capecitabine with 
gemcitabine alone.  
In patients with metastatic pancreatic cancer two regimens have recently 
emerged. In one regimen, FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, 
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leucovorin) as compared to gemcitabine showed survival advantage in patients 
with metastatic pancreatic cancer. The median overall survival was 11.1 months 
in the FOLFIRINOX group compared to 6.8 months in the gemcitabine group (44). 
In the other regimen nab-paclitaxel plus gemcitabine significantly improved 
survival as compared to gemcitabine alone (45). The median overall survival was 
8.5 months in the nab-paclitaxel-gemcitabine group compared to 6.7 months in 
the gemcitabine group. There is a need to identify patients who will benefit 
from one of these treatment regimens. 
1.5.3 Neoadjuvant therapy  
The purpose of neoadjuvant therapy is to downstage locally advanced disease for 
potential resection, achieve R0 resections (clear resection margin) and reduce 
the recurrence of tumour (22, 46, 47). There is evidence that neoadjuvant 
therapy can enable resectability in up to 30%-40% of patients with locally 
advanced pancreatic cancer patients (47). Postoperative survival of these 
patients is comparable to patients with resectable disease. Patient selection is 
therefore an important aspect of neo-adjuvant therapy. Katz et al (48) reported 
that 78% (n=125) of patients (N=160) with borderline resectable pancreatic 
cancer received neoadjuvant therapy. These patients were then re-staged after 
neoadjuvant therapy and 41% (n=66) of these patients underwent 
pancreatectomy. The optimum regimen is not yet known, but combination 
chemotherapy and chemoradiotherapy have been used as neoadjuvant regimens. 
1.5.4 Palliative management 
Surgical, endoscopic, or radiological techniques are employed for palliative 
treatment of duodenal and biliary tract obstruction. A stent is put in the biliary 
duct and duodenum to relieve symptoms of obstructive jaundice and delayed 
gastric emptying. A palliative gastrojejunostomy is performed in patients found 
unresectable during laparotomy for resectable disease, and deemed to be at risk 
of developing gastric outlet obstruction (22, 49, 50). 
Pancreatic insufficiency is managed by pancreatic enzyme supplements. 
Pancreatic fistulas can occur with an incidence of 0-25% and can either be 
treated conservatively or a re-operation may be needed (51). 
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1.6 Diagnostic terms 
The terms ‘sensitivity’ and ‘specificity’ will be used throughout this thesis from 
the introduction, through to results and in the discussion. Therefore, it is 
necessary to define and discuss the importance of these terms for research 
diagnostics before going any further.  
Sensitivity and specificity are measures of the diagnostic accuracy of a test used 
to diagnose a disease. We need a test that can categorise the population at risk 
into one of the two groups: people likely to have the disease; and people 
unlikely to have the disease. 
1.6.1 Sensitivity  
Sensitivity is “the ability of a test to correctly identify those patients with the 
disease” or more formally “the probability of a positive test result if disease is 
present” and is calculated by the formula: 
Sensitivity=
True Positives
True Positives + False Negatives
 
OR  
Sensitivity=
TP (Patients with the disease correctly identified by the positive test)
TP+FN (Total number of patients with the disease)
 
True positive (TP): Patient with the disease is positive for test.  
False Negative (FN): Patient with the disease is negative for test. 
1.6.2  Specificity 
Specificity is “the ability of a test to correctly identify those patients without 
the disease” or more formally “the probability of a negative test result if disease 
is not present” and is calculated by the formula: 
Specificity=
True Negative
True Negative + False Positive
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OR  
Specificity=
TN (Patients without the disease correctly identified by the negative test)
TN+FP (Total number of patients without the disease)
 
True Negative (TN): Patient without the disease is negative for test.  
False positive (FP): Patient without the disease is positive for test. 
The specificity of a diagnostic test is considered relatively more important than 
sensitivity as low diagnostic specificity may categorise normal as diseased. 
Diagnostic tests are based on a continuous measurement or ordinal category but 
a cut-off is chosen for calculating sensitivity and specificity. Cut-points help in 
identifying an appropriate combination of sensitivity and specificity but 
generally as one increases, the other decreases (52-54). Table 1.2 can be used 
for calculating sensitivity and specificity. 
1.7 Role of cytology in PDAC diagnosis 
The role of cytology in the diagnosis and management of patients with PDAC is 
well established. Major developments in the sampling techniques have 
significantly improved the diagnostic management of these patients (55).  
1.7.1 Indications for cytological sampling 
Cytological sampling is most commonly indicated to confirm malignancy in 
patients with suspected pancreatic mass or stricture lesions on imaging. 
Confirmatory tissue diagnosis is necessary before chemotherapy or radiotherapy 
treatment, however a cytology specimen is not always required for resection 
when the suspicion of cancer is high; as generally, the resection will provide 
therapeutic benefit, and substantially delaying surgery to confirm a diagnosis 
may deny potentially curative treatment. Nonetheless, pre-operative tissue 
diagnosis provides more confidence to both the surgeon and patient and it allows 
optimal planning for surgery (28) (56-62). 
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1.7.2 Techniques of obtaining cytologic sampling 
Endoscopic ultrasound fine needle aspiration (EUS-FNA) is usually used for 
sampling pancreatic mass lesions. ERCP is the conventional method of obtaining 
cytology samples, via brushing, of suspected pancreatic duct and bile duct 
strictures (63).  
1.7.2.1 Endoscopic ultrasound fine needle aspiration (EUS-FNA)  
Endoscopic ultrasound (EUS), like upper gastrointestinal endoscopy, is an 
outpatient procedure in which suspected lesions in the pancreas are imaged 
from stomach and duodenum. It is considered an accurate diagnostic imaging 
modality for pancreatic mass lesions especially for lesions less than 2cm (26, 64-
66). However, EUS has low specificity in differentiating malignant from 
inflammatory pancreatic masses (29, 66). The addition of fine needle aspiration 
(FNA) provides samples for cytopathologic analysis. Indeed, this is a major 
advantage of EUS over other imaging modalities. 
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is used to obtain 
cytological samples from suspected pancreatic lesions, in particular mass 
lesions. It is a well-tolerated and minimally invasive procedure but the results 
are operator-dependent (67, 68). It has the ability to sample a wide area of a 
pancreatic mass lesion and allows multiple needle passes to be performed with 
low complication rate.  
Generally, EUS-FNA is a safe procedure. Complication rates of EUS-FNA are 0-2% 
and include bleeding, pancreatitis, infections and bile peritonitis (69-72). The 
risk of tumour seeding with EUS-FNA is very low as compared to FNAs obtained 
by the percutaneous approach (73). 
The sensitivity of EUS-FNA for diagnosing pancreatic mass lesions ranges from 
73% to 100% and the specificity ranges from 75% to 100% (57, 60, 68, 70, 74-80). 
The specificity of EUS-FNA is high (100%) in most studies but the reported 
sensitivity in most studies is 80%-90%, therefore negative results do not 
absolutely exclude malignancy (59, 70, 81). 
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These statistical figures thus show that the sensitivity of cytological diagnosis is 
not perfect and the diagnosis from inconclusive EUS-FNA cytology cases could be 
improved, perhaps through additional biomarkers. Investigation of markers may 
also open the door for personalised treatment in modern oncology. 
1.7.2.2 Endoscopic retrograde cholangiopancreatography (ERCP) with 
brushing 
Malignancies arising in the pancreatico-biliary (PB) ductal system may not be 
visible on radiographic imaging and thus may need endoscopic imaging (ERCP) 
(27, 63). Several benign PB conditions like chronic pancreatitis, primary 
sclerosing cholangitis and postoperative strictures can also present as stricture 
lesions. The distinction of malignant and benign lesions in the PB tree represents 
a diagnostic challenge (27). 
ERCP with brushing is a minimally invasive technique for sampling stricture 
lesions in the PB ductal systems (82-84). The cytological material obtained helps 
to confirm the diagnosis of either benign or malignant disease (55).  
The overall sensitivity of ERCP brushing cytology is less than EUS-FNA cytology 
with a range of 44-72%; however, the specificity approaches 100% with a range 
of 90%-100% (27, 60, 63, 85-89). 
The sensitivity of brush cytology is low and could be improved through the 
addition of ancillary tests to the diagnostic work-up of patients with an 
indeterminate cytology diagnosis. 
1.7.3 Evaluation of cytology samples 
Cytological samples thus obtained are interpreted and reported by a cytologist. 
The cytology samples contain a mixed population of normal and abnormal cells. 
Initial assessment of cells involves the identification of normal pancreatic ductal 
and acinar epithelial cells, and recognition of contaminations from duodenal or 
gastric epithelium (Figure 1.5). The abnormal cells from neoplastic and non-
neoplastic disease processes are assessed to make the cytology diagnosis. 
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The cytological features of PDAC include: irregular arrangement of cells in 
sheets, cluster, and three-dimensional cells and as single cells; overlapping 
pleomorphic nuclei, single and tall cells, high nuclear/cytoplasmic ratio, 
irregular nuclear membranes, macronucleoli, coarse and clumped chromatin, 
mitotic figures and necrosis (Figure 1.6) (90-92). 
1.7.3.1 Diagnostic categories of cytology 
Cytopathologists often use the following broad categories for cytological 
reporting: non-diagnostic, negative for malignancy, atypical, suspicious for 
malignancy and positive for malignancy (60).  
‘Non-diagnostic’ implies an overall low cellularity or a sample not appropriate 
for cytological evaluation due to blood or inflammatory cells. ‘Negative for 
malignancy’ means that the sample obtained contain normal or benign cells but 
this does not preclude malignancy and may possibly be a sampling error during 
the endoscopic procedure.  
‘Atypical’ cases are reported when there is a low suspicion of malignancy based 
on mild cytologic and/or architectural atypia. This often occurs in the setting of 
the inflammatory process, reactive or degenerative changes due to 
instrumentation or stent placement and a hypocellular sample. The ‘suspicious 
for malignancy’ cases are reported when there is a high probability of 
malignancy but the degree of cytologic atypia is not exclusively confirmatory of 
malignancy and a benign etiology cannot be excluded with complete confidence 
(60). The ‘positive for malignancy’ cases are reported when the cytologic and 
architectural atypia suggests malignancy, in this case adenocarcinoma. 
1.7.4 Factors affecting PDAC diagnosis from cytology samples  
As shown in the previous sections, neither EUS-FNA nor ERCP with brushing is 
100% sensitive in identifying the malignancy or 100% specific in excluding benign 
diseases. I will now discuss the factors leading to a decrease in the sensitivity 
and specificity of cytological interpretation. The factors influencing the 
diagnosis of PDAC form cytology samples are divided into quantitative and 
qualitative factors. 
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1.7.4.1 Quantitative factors 
Quantitatively, the cytological sample obtained may be of low cellularity with 
few, or even no malignant epithelial cells amongst a variety of cell types. This is 
related to sampling technique error. Adequate cellularity of samples can be 
achieved by training the endosonographer and the presence of an onsite 
cytopathologist for cytologic assessment (93). The British Society of 
Gastroenterology guidelines suggest an intensive year of training in EUS-FNA 
from a recognised skilled operator (94). Furthermore, the on-site evaluation of 
the specimen decreases the chances of inadequacy of sampling. This may also 
reduce the number of needle passes and hence the complications associated 
with FNA (95). Time and money are the most important factors precluding the 
on-site cytology evaluations in most institutions (93). 
1.7.4.2 Qualitative factors 
Qualitatively, the malignant epithelial cells can be morphologically similar to 
reactive pancreatic cells, especially in well-differentiated adenocarcinomas. 
Chronic reactive changes arising from atrophy or inflammation in pancreatitis 
are common, and also make diagnosis of adenocarcinoma difficult. 
PDAC in the setting of chronic pancreatitis poses a diagnostic challenge  
Chronic pancreatitis (CP) is an important benign differential diagnosis of PDAC. 
The clinical and imaging similarities between PDAC and CP may make the 
diagnosis difficult (96, 97). 
The sensitivity of EUS-FNA for diagnosing PDAC decreases to 62% in CP and to 
50% in CP and obstructive jaundice with a biliary stent (98). This occurs because 
patients presenting with obstructive jaundice ordinarily undergo ERCP and a 
biliary stent is placed to relieve symptoms before they are referred for EUS±FNA. 
The inflammatory and degenerative changes induced by instrumentation (ERCP) 
and biliary stent may mimic well differentiated adenocarcinoma and make 
cytologic interpretation troublesome (78, 99, 100). CP leads to both false 
positivity and false negativity in the diagnosis of pancreatic cancer.  
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Cytomorphologic features such as a disorganised honeycomb pattern of epithelial 
groups, variable degrees of anisonucleosis and irregular nuclear membranes may 
provide a diagnostic indication of pancreatic cancer (91), but the reactive 
process in CP induces cellular atypia with overlapping cytologic features similar 
to those resulting from a well differentiated PDAC (101). 
Therefore, chronic pancreatitis is by the far the most important confounding 
factor in the diagnosis of PDAC and caution should be exercised in a suspicious 
PDAC vs. CP scenario and again biomarkers may be helpful in such cases. 
Gastro-intestinal and pancreatic contaminants 
EUS-FNA can be performed via a transgastric or transduodenal route depending 
on the location of suspected lesion. A transduodenal approach is a common 
practice for lesions involving the head of pancreas, whereas the transgastric 
approach is generally used for lesions of the body and tail of the pancreas. The 
cytological samples thus obtained may contain gastric or duodenal contaminants 
and it is essential to recognise the morphology of these cells to avoid 
misinterpretation of cytology specimens (90). These epithelial cell contaminants 
may also originate from the adjacent normal pancreas and may contain blood 
which further renders the diagnosis challenging (68, 90). 
One study demonstrated the presence of normal duodenal, gastric and 
pancreatic acini in 52%, 30% and 94% of positive/suspicious, atypical, and 
negative cytology cases respectively (90). A mixture of normal and abnormal 
elements when normal cells are in abundance may mask the few malignant cells 
or may mimic malignant cytology. Thus differentiation between normal and 
abnormal cells particularly becomes troublesome in well-differentiated 
adenocarcinoma. Examination of hematoxylin and eosin (H&E) stained sections 
from cell blocks may help in the final diagnosis in such cases. Apart from 
morphological features, biomarkers expressed in PDAC and not in these 
gastrointestinal contaminants might potentially help to confirm or exclude the 
diagnosis of PDAC. 
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Cytopathologist expertise 
The interpretation of cytology specimens obtained via EUS-FNA or ERCP brushing 
is expertise dependent and can present many challenges for cytologists 
especially in institutions with a low number of cytology cases (102). One study 
evaluated the impact of experience of the cytopathologist on the sensitivity of 
EUS-FNA cytology. The sensitivity of difficult cytology cases improved after 
evaluations by an experienced cytopathologists (103). Well differentiated PDAC 
are especially difficult to diagnose from cytology specimens (104). 
1.7.4.3 False negative diagnosis leads to low sensitivity and is a relatively 
more significant problem than false positive diagnosis 
False negative diagnosis from EUS-FNA samples for suspected pancreatic cancer 
occurs in a significant proportion of patients (78, 90, 105-107). The false 
negative rate of EUS-FNA increases further in patients with obstructive jaundice 
and biliary stent compared to patients without obstructive jaundice and without 
a biliary stent at presentation (81). In biliary stent cases, this occurs due to 
secondary reactive cellular atypia confounding the diagnosis of well 
differentiated cancer. Therefore a negative diagnosis of malignancy may not 
exclude malignancy due to false negativity (89). The causes of false negativity 
include sampling error, chronic pancreatitis, cytological misinterpretation, 
reactive changes due to bile stent and epithelial cell contamination (89, 107). 
The false negativity of EUS-FNA in suspected pancreatic cancer could potentially 
limit its clinical utility as it may miss early resectable diseases (56, 108). These 
results suggest that the sensitivity of EUS-FNA cytology is not perfect and a false 
negative diagnosis can occur. Therefore, improving the sensitivity for patients 
with other ancillary tests, possibly biomarkers, will reduce the possibility of a 
false negative diagnosis and improve the sensitivity of the cytology diagnosis. 
1.7.4.4 False positive diagnosis leads to low specificity but is not a 
significant problem in PDAC cytology 
The currently accepted standard is that a positive EUS-FNA result of a suspected 
pancreatic lesion provides evidence of malignancy and the cytological positivity 
can be regarded as a “true-positive” result (109, 110). In addition, a high 
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specificity (98%) reported in a recent meta-analysis by Hewitt et al suggests that 
false positivity of EUS-FNA is rare (68). However, false positive results can occur 
in EUS-FNA specimens from pancreatic lesions suspected of PDAC and recognising 
this risk is important due to its impact on the surgical and/or medical 
management of patients (93, 110-112). 
A large retrospective cohort study (n=367) was conducted in a tertiary care 
referral hospital to assess the false positive rate of EUS-FNA cytology in patients 
presumed to have pancreatic cancer who underwent surgical resection. The false 
positive rate was 1.1% when “positive” cytology was interpreted as malignant 
but about 4% when both “positive” and “suspicious” cytology were interpreted 
as malignant. Among these false positive cases three were falsely diagnosed as 
positive for adenocarcinoma and six were falsely diagnosed as suspicious for 
adenocarcinoma (110). The causes of false positivity include chronic 
pancreatitis, cytological misinterpretation, reactive changes due to bile stent, 
tissue sampling technique error and epithelial cell contamination (111). 
False positive diagnosis increases further when atypical and suspicious cytology 
are included in the positive diagnosis (68). Therefore, improving the specificity 
of patients with other means (for example biomarkers) apart from morphological 
interpretation will reduce the possibility of a false positive diagnosis and 
improve the specificity of cytology diagnosis.  
1.7.5 Diagnosis is important for PDAC management 
The clinical management of patients with both false negative and false positive 
diagnosis leads to significant outcomes. False positive diagnosis leads to 
unnecessary surgical or oncological treatment and false negative diagnosis 
delays treatment for patients with potentially resectable disease (107). 
Pancreatoduodenectomy is a major surgical procedure and is associated with 
significant mortality and morbidity. The mortality rate ranges from 0% to 7% and 
the morbidity rate ranges from 21% to 59%, therefore unnecessary surgery of 
benign pancreatic lesions must be avoided (38, 61). 
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Preoperative EUS-FNA to confirm the diagnosis in every patient with resectable 
pancreatic cancer is debated (113, 114) but Kudo et al (61) showed that it does 
not adversely affect surgery or prognosis in these patients. Therefore, by 
providing a definitive diagnosis, EUS-FNA can potentially improve the outcomes 
of patients resected for pancreatic cancer.  
Diagnostic confirmation of PDAC is especially important for patients with 
unresectable disease (locally advanced and/or metastatic disease) or not fit for 
surgery, which may require neoadjuvant therapy. Therefore, the significance of 
a false negative diagnosis increases even further when the oncologist is 
considering neoadjuvant therapy. In addition, false positive diagnosis might lead 
to offering neoadjuvant therapies to patients with benign disease (for example 
CP) which could potentially have deleterious effects. Patients with a high 
suspicion of PDAC but with false negative FNA cytology should not be precluded 
from surgical intervention (28). However, there are cases in the reported 
literature where pancreatic cancer could not be confidently ruled out and 
surgery was performed for misdiagnosed focal pancreatitis (76, 77). False 
negative diagnosis limits the clinical utility of EUS-FNA as it could potentially 
lead to missing the early resectable disease in patients suspected of pancreatic 
cancer (56, 112, 115). ‘Atypical’ cytology raise the clinical suspicion of 
pancreatic cancer but ordinarily this may not be sufficient evidence to subject 
patients to surgical resection (112). However, positive for malignancy and 
suspicious cytology usually results in surgical intervention.  
The ‘atypical’ cytology diagnosis clearly decreases the sensitivity and leads to an 
indeterminate diagnosis and the sensitivity further decreases if ‘suspicious’ 
diagnosis is also included. Cytologic confirmation of a PDAC diagnosis is 
therefore very important for the management of patients with PDAC, and 
improving the diagnosis would mean improved PDAC management. 
1.8 The unmet clinical need 
The previous discussion indicates that the diagnosis of PDAC from EUS-FNA and 
ERCP brush cytology is not perfect and there is an unmet clinical need in 
improving the diagnosis (especially diagnostic sensitivity) of cytology. Improving 
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the diagnostic sensitivity will reduce the number of samples called ‘atypical’ or 
‘suspicious’. 
Management algorithms for PDAC are evolving and new strategies such as pre-
operative chemoradiation to achieve R0 resections (clear resection margins) are 
being investigated. Thus the importance of confirming pre-treatment diagnosis 
from cytology samples is further increasing. Using ancillary tests (such as 
biomarkers) as an adjunct to cytology could be an invaluable tool in assisting in 
refining the diagnosis of PDAC and improving the diagnostic sensitivity. 
1.9 Biomarkers could help improve the diagnosis of 
PDAC from cytology 
One potential way of improving the diagnosis of PDAC from cytology samples is 
to use biomarkers as an adjunct to cytology. Biomarkers might potentially be 
indicated in the following clinical scenarios: EUS-FNA or ERCP brush cytology is 
unable to distinguish PDAC from a benign mass in the setting of chronic 
pancreatitis; hypocellular material from FNA; indeterminate cytological 
diagnosis but a high clinical suspicion of PDAC (110).  
Therefore, in the subsequent sections I will discuss what are biomarkers? What 
are the phases of biomarker development from identification to validation and 
to clinical use? Why is IHC an attractive platform for biomarker investigation? 
What is the role of IHC biomarkers in improving the diagnosis of PDAC from 
cytology?  
Then I will discuss: what are the major reasons or factors delaying or hindering 
the clinical translation of these biomarkers? What is the significance of meta-
analysis in gathering, synthesising and ranking the published evidence on IHC 
biomarkers in PDAC? And why are TMAs an excellent high throughput platform 
for validation of biomarkers?  
1.9.1 Tumour biomarkers 
According to the Biomarkers Definitions Working Group (2001) (116), a biomarker 
is defined as “A characteristic that is objectively measured and evaluated as an 
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indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.”  
Tumour markers are molecules produced by cancer cells and either 
endogenously present in the cellular compartments of cancer cells or are 
secreted from the cells. They are measured in blood, urine, stool, body fluids 
(for example pancreatic cyst fluid), or tissues of patient with cancer. Tumour 
markers are often proteins but genetic changes (gene mutations) and changes in 
gene expression patterns are also used as tumour biomarkers. The alterations in 
the tumour biomarkers help in the categorisation of patients into distinct groups 
(117). 
Biomarkers are used in the clinical management of patients with tumours and 
can broadly be classified as: susceptibility biomarkers that help in the 
identification of individuals at risk of developing cancer; screening biomarkers 
that help in the early detection of cancer in the general or at risk populations of 
developing overt disease (i.e. detects subclinical disease); diagnostic biomarkers 
that help in the diagnosis of patients with the disease; prognostic biomarkers 
that help to predict the course of disease (for example survival); predictive 
biomarkers that help to predict response to therapy (for example a drug or 
surgical intervention) or monitor the efficacy of a therapy (116, 118-120); and 
pharmacogenomics biomarkers which are “measurable DNA and/or RNA 
characteristics that are indicators of normal biologic processes, pathogenic 
processes, and/or a response to therapeutic or other interventions” (121). 
Some of these markers are already used in routine clinical practice (122-125). 
Perhaps the earliest markers to help in the clinical diagnosis were 
carcinoembryonic antigen (CEA) in colon carcinomas (126) and prostate specific 
antigen (PSA) (127) in prostate cancer. 
1.9.2 Phases of biomarker development from identification to 
validation and to clinical use 
Biomarker development passes through several phases of development from 
discovery to clinical practice (128). It involves a series of identification and 
validation steps before clinical application (Figure 1.7). 
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1.9.2.1 Identification of biomarkers 
The first phase in biomarker development is the identification of suitable 
candidate biomarkers (129). Here I will discuss the identification of biomarkers 
through differential expression patterns of genes and proteins. Identification 
passes through the following stages. 
Discovery: Broadly two approaches can be used for biomarker identification. 
The first approach is to identify biomarkers based on current knowledge of 
pathophysiology of the disease through ‘deductive reasoning’. The second 
approach is using molecular profiling techniques to identify candidates based on 
the differential expression between tumour and normal tissue (128). 
Differentially expressed genes between PDAC and normal or reactive pancreatic 
duct are identified through high throughput genomic and proteomic studies (130, 
131).  
Demonstration: High throughput technologies generate a list of potential 
biomarkers but based on different statistical models the biomarker list is further 
refined and selected biomarkers are demonstrated by molecular techniques. The 
differential expression of genes is demonstrated by DNA microarray and 
polymerase chain reaction (132, 133), whereas, differentially expressed proteins 
are demonstrated by gel electrophoresis and mass spectrometry (134-136).  
Qualification: the purpose of the qualification phase is to confirm the 
differential expression of biomarkers using alternative techniques such as 
western blot and immunohistochemistry (134-137). 
The purpose of the identification phase of biomarker development is to identify 
potential candidates with high sensitivity for detection. The emphasis therefore 
is to establish the association between biomarker expression and the tumour of 
interest. Biomarker identification thus uses a significant amount of resources, 
cost and utilizes modern technology. 
1.9.2.2 Validation of biomarkers 
After identification, the next phase is validation of biomarkers which is an 
important pre-requisite for clinical translation. ‘Omics’ technologies allow 
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identification of promising biomarkers but these biomarkers require verification, 
prioritisation and validation before they are used in clinical practice (138). 
Verification: Biomarker verification is carried out to test whether the candidate 
biomarker has sufficient potential for future validation studies. Pilot studies in a 
relatively small sample size are used to investigate biomarker expression in both 
tumour and normal samples from a variety of patients (139, 140). Verification 
begins to assess the specificity of biomarkers but still focuses on optimum 
sensitivity (128). This helps the researchers to select more specific candidates 
that are highly expressed in tumour for which they can invest their time, energy 
and money.  
Prioritisation of candidates: Prioritisation of candidate biomarkers from a list 
of potential biomarkers is very important for further clinical validation studies 
due to cost and limited clinical resources (129). The role of the candidate 
biomarker in tumour biology greatly facilitate this selection process as markers 
involved in the progression of tumour will prove potentially more useful in 
clinical practice (123, 141). 
Validation of selected candidates in large-scale studies: Biomarkers 
achieving a suitably good combination of sensitivity and specificity from pilot 
studies in the verification and prioritisation phases may be selected for further 
validation in large-scale studies. The further validation processes consist of 
three phases: analytical validation ensures the intra- and inter-laboratory 
reproducibility of the assay (for example IHC) achieving similar expression 
patterns; clinical validation ensures the diagnostic sensitivity and specificity of 
the biomarker is consistent for the outcome (for example differentiation 
between benign and malignant disease); and clinical utility of the biomarker 
assesses whether it improves the diagnostic management of patients (142). 
Early validation studies are carried out on archival pathology specimens (tumour 
and normal). These samples are retrospectively identified and used to observe 
the expression and clinical utility of candidate biomarkers. These retrospective 
studies typically overestimate the actual sensitivity and specificity of 
biomarkers. Most of the reported literature on biomarker studies uses archival 
pathology samples (143, 144). However, the clinical utility of biomarkers can be 
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more clearly assessed in a prospectively designed study. But validation on 
archival samples is a pre-requisite before biomarker investigation in prospective 
clinical studies. Prospective clinical studies and biomarker trials lead to the 
qualification of biomarker for clinical use. Finally, biomarkers are used in 
clinical practice for the intended clinical use and they are monitored for their 
effectiveness. Figure 1.7 shows the path that a biomarker is likely to take from 
discovery to clinical use.  
Importance of validation studies: Biomarker validation is therefore an 
important but expensive and lengthy process and depends on the type of 
samples used for assessing the clinical utility. Successful implementation of 
biomarkers in clinical practice requires robust evidence from independent 
validation studies. A single study is unlikely to provide sufficient evidence for 
adoption of a biomarker in clinical practice. In a study (145) the magnitude of 
the effect size of proposed biomarkers in highly cited papers was examined. It 
was found that primary studies often report a larger effect size compared to the 
subsequent meta-analysis assessing the same associations (145). Therefore, 
clinical evidence from biomarker studies should be interpreted carefully and 
healthy scepticism is suggested (145). More large-scale and outcome-oriented 
validation studies expedite the clinical translation of biomarkers by providing a 
strong ‘evidence base’. 
In summary, careful identification of biomarkers and then validation in well-
designed retrospective and prospective studies is a systematic strategy for 
developing clinically useful biomarkers. 
1.9.3 Immunohistochemistry biomarkers in cancer pathology 
Immunohistochemistry (IHC) is a tissue based method that allows the 
visualisation of specific antigens in tissues and cellular compartments based on 
antigen-antibody reaction using microscopy (122). IHC remains an important 
diagnostic tool even in the era of genomics and high throughput molecular 
diagnostics. IHC was first introduced in the 1960s and since then the amount of 
literature has increased exponentially. IHC has been used both in research and 
clinical settings. IHC characterises the expression of genes at the protein level 
and allows the observation and localisation of protein expression simultaneously 
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in tissue and cellular compartments (146, 147). It is a routine technique used in 
diagnostic pathology and is relatively inexpensive with widespread expertise in 
the technique. Therefore, biomarkers identified and validated by IHC have an 
enormous potential for clinical translation. In surgical pathology a range of 
biomarkers in clinical use is assessed by IHC (122, 123, 148).  
Biomarkers identified by IHC have the advantage of defining the role of markers 
in the tissue context. They give insight into the expression of markers in specific 
cell types of tissue (malignant cells, stroma, and adjacent normal cells or other 
cell types) and the distribution of the marker in subcellular compartments 
(nuclear, membranous or cytoplasmic). Biomarker expression in a specific cell 
type (e.g. epithelial cells) or subcellular compartment (e.g. cytoplasm) might 
then be associated with tumour diagnosis. Biomarker expression in tumour can 
also be associated with the clinical follow-up (e.g. survival of patient) or the 
clinicopathologic characteristics (e.g. lymph node invasion) of the patient (149, 
150). 
Over the last few decades many IHC biomarkers have been investigated for 
improving the diagnosis and prognosis of tumours. The diagnostic IHC biomarkers 
help in the diagnosis and sub-classification of tumours. IHC biomarker c-kit helps 
in the diagnosis of gastrointestinal stromal tumours (GISTs) (124). p63 helps to 
detect the presence of basal cells which indicate normal prostate gland (125, 
151). Furthermore, nuclear immunostaining of ki-67 as a proliferation marker 
(152), chromogranin A, CD56 and synaptophysin for the diagnosis of 
neuroendocrine tumours (153, 154) and the use of E-Cadherin in the 
differentiation of ductal and lobular carcinomas of the breast (155) are used in 
clinical practice.  
An ideal diagnostic IHC biomarker should be 100% sensitive and specific which is 
almost never achieved as sensitivity increases at the expense of specificity and 
vice versa. The panel of biomarkers are thus becoming more relevant. These 
include CK20, P53, CK5/6, CD138, and Her2/Neu in the diagnosis of urothelial 
carcinoma in situ (156), a panel of napsin-A, Thyroid transcription factor 1, 
Cytokeratin 5, and P63 in differentiating adenocarcinoma from squamous cell 
carcinoma of the lung (157, 158)) and a panel of S100P and XIAP in the 
differentiation of pancreatic cancer from non-neoplastic pancreatic tissue (159). 
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In addition, IHC biomarkers are used for predicting the survival of patients, 
predicting the response to specific therapies and subsequent stratification of 
patients for different treatment options. Estrogen receptor (ER), progesterone 
receptor (PR) and HER-2/neu are used for the management of patients with 
breast cancer (123, 160-162). Panel of biomarkers are also used for prognostic 
and predictive purposes e.g. IHC4 (a panel of ER, PR, HER2 and Ki-67) is an assay 
which estimates recurrence risk for early stage breast cancer patients (163). 
IHC biomarkers are therefore useful tools that could potentially be translated to 
clinical practice if suitable biomarkers are identified and validated in 
independent cohorts. 
1.9.4 The role of IHC biomarkers in PDAC cytology diagnosis 
The molecular profiles of PDAC identified through genomic and proteomic 
studies increase hopes that clinically useful biomarkers can be developed for 
PDAC. Genes showing differential expression between PDAC and normal pancreas 
could potentially be used as biomarkers (130). These genes are characterised at 
the protein level by IHC. IHC biomarkers have great translational potential in 
improving the diagnosis of PDAC from cytology samples. 
For this project, the purpose of IHC diagnostic biomarkers in cytology samples is 
to differentiate PDAC from benign disorders and not the distinction of PDAC from 
other pancreatic or extra-pancreatic neoplasms. Importantly, these biomarkers 
are not intended to replace the cytomorphology but if used as an adjunct to 
cytology they could help improve sensitivity of PDAC diagnosis and subsequent 
surgical or oncological management. 
It is evident from the PDAC literature that both resection and cytology 
specimens have been used for the investigation of potentially useful IHC 
biomarkers (164-167). A candidate diagnostic IHC biomarker may pass through 
different stages of identification and validation. Validation studies are 
performed first on resection specimens from patients with PDAC to optimise IHC 
methodology and to study the expression patterns of biomarkers in various tissue 
and cellular compartments. Biomarkers with high expression levels resulting in 
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higher sensitivity without compromising specificity are then validated in cytology 
specimens. 
Cytological specimens processed into formalin fixed paraffin embedded cell 
blocks provide an ideal platform for IHC. Cell block sections may perhaps display 
better morphology of cells  than direct smears and can also show a mixed 
population of benign and malignant cells (168).  
A wide range of IHC biomarkers has been investigated in pancreatic resection 
specimens and EUS-FNA and biliary brush cytology specimens (141, 169-172). 
These candidate diagnostic IHC biomarkers have been investigated both as single 
biomarkers and as part of biomarker panels to improve the diagnosis of PDAC. 
(159, 170, 172-177). 
However, despite the extensive amount of research on diagnostic IHC biomarkers 
for PDAC, none of these biomarkers has yet entered routine clinical practice. 
This increases the importance of identifying and addressing factors delaying the 
clinical translation of these biomarkers. Therefore, in the next section, I will 
discuss these issues hindering the clinical translation of IHC biomarkers. 
1.10 Reasons delaying the clinical translation of 
biomarkers 
Clinical translation of basic research is a priority for both academia and industry 
(178). Translational research has gained more importance from the fact that the 
level of investment in research is not reflected in clinical practice, and there is 
a concern that the benefit from the ‘genetic revolution’ is slow. 
The amount of diagnostic biomarker research in every cancer type is enormous 
but unfortunately the translation of biomarkers to clinical practice is 
comparatively low (162). I have outlined below six major reasons or factors that 
contribute to the delay in the clinical translation of the candidate diagnostic 
biomarkers under investigation (Figure 1.8). All these reasons revolve around the 
identification and validation of biomarkers and their scoring systems and 
thresholds. These reasons are not limited to biomarkers in pancreatic cancer but 
can be applied to other cancers. 
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1.10.1 Lack of synthesis and quantification of existing 
evidence 
The most important first step is identification of existing diagnostic biomarkers. 
Biomarkers have been investigated purposefully to address a clinical problem 
(157, 179) and in some cases they have been investigated in more than one study 
(174, 180). The results of some of these studies show promising results for 
differentiating one tumour type from another tumour type (179) or subtypes of 
the same tumour (157). These studies also show the utility of biomarkers in the 
differentiation of benign disease from malignant disease (132, 166). However, 
the synthesis of evidence and quantification of biomarker performance is 
described less in the literature especially for diagnostic biomarkers. Therefore, 
there may be a need to perform more focused systematic reviews and 
subsequent meta-analysis of biomarkers intended for specific clinical 
(diagnostic) problems. The clear advantage of this approach is the identification 
of suitable candidate biomarkers that have previously been investigated. The 
other important advantage of this selection process is that biomarkers 
investigated in different studies showing promising results are compiled for 
investigation in one potential validation study. This will surely provide more 
strength for a future validation study investigating these better biomarkers in a 
single setting. 
1.10.2 Inadequate sample size 
The sample size for biomarkers reported in literature is relatively small and this 
is especially true for novel biomarkers assessed in pilot studies (142, 181). This is 
realistic because a vast tissue resource will not be available for a new biomarker 
under investigation. Sufficient statistical power is thus not reached in most of 
these pilot studies which could potentially lead to promising biomarkers being 
overlooked in the enormous biomarker research field. Biomarkers identified in 
the meta-analysis might be carefully investigated in a sufficiently powered study 
using a large sample size. Obviously, investigation of biomarker expression in 
large sample size will further elucidate the diagnostic performance (sensitivity 
and specificity) of biomarkers. Biomarker expression is not homogenous in 
tumour tissue extracted from different patients (182, 183). This Inter-tumour 
heterogeneity of expression of biomarkers can be shown more clearly if the 
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sample size is large. This will help in better defining the diagnostic role of 
biomarkers in cancer. Biomarkers showing more inter-tumour heterogeneity are 
less sensitive in identifying the disease and are thus less accurate.  
The other issue with sample size is the distribution of the number of samples 
between the two groups (disease and normal) investigated (142). For example, a 
diagnostic biomarker tested to differentiate between benign and malignant 
disease. The true diagnostic potential of a biomarker in this case can be 
measured if (ideally) the sample size is equally distributed between benign and 
malignant samples. 
1.10.3 Lack of an optimal scoring system and threshold 
Interpretation of IHC requires a robust and comprehensive scoring system that is 
able to quantify the extent of biomarker expression. From this scoring scheme, 
then, thresholds or cut-offs can be investigated for categorising patients into 
one of the two diagnostic categories (for example benign vs. malignant). There 
is no single uniform scoring system and researchers have used a wide array of 
scoring systems (157, 184-186). These scoring systems are based on: staining 
intensity; percentage of positively stained cells; combination of both staining 
intensity and positive cells; and semi-quantitative Histoscores; (160, 171, 187, 
188). A semi-quantitative Histoscore (takes into account both intensity and 
proportion of staining) could possibly emerge as a standard scoring system. 
Histoscore quantify the expression level of biomarkers and allow for calculation 
of various potential cut-offs for diagnostic purposes. 
The next issue after scoring is choosing an appropriate cut-off that is easy to use 
by practising pathologists. An optimal cut-off should be reliable and reproducible 
among pathologists. A systematic way of choosing a cut-off is to perform a 
receiver operating characteristic (ROC) curve analysis which provides diagnostic 
sensitivity and specificity of biomarkers on a range of cut-offs (189, 190). This 
helps the researcher to select an optimal cut-off which has both diagnostic 
potential and is easily scored by observers. This cut-off can then be used in 
future validation studies and studies involving observer variations between 
different scorers. 
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1.10.4 Limited use of panels of biomarkers 
An ideal diagnostic biomarker should have homogenous expression within and 
between tumour tissue from the same cancer type (for example PDAC), but both 
intra-tumour and inter-tumour heterogeneity of biomarker expression exists 
(191). A single candidate biomarker is thus unlikely to work as a perfectly 
sensitive and specific biomarker (122, 192) in all patients. A panel of biomarkers 
is thus a plausible solution to address both inter- and intra-tumour 
heterogeneity. Most of the researchers in reported literature have investigated 
biomarkers singly with a limited panel approach. The panel approach has not 
been reported in instances when more than one biomarker was investigated in a 
single study (173). 
Identification of suitable biomarkers and then exploring their diagnostic 
performance as a panel in a single experimental setting is a more powerful 
approach. The obvious strength of the panel approach is that it allows for the 
comparison of accuracy between biomarkers and panels of biomarkers. This 
comparison then determines an appropriate panel of biomarkers for future 
validation and clinical translational studies. Different biomarkers stain different 
cellular compartments and using a panel of biomarkers has this additional 
advantage of staining all major sub-cellular compartments. Clearly, a panel with 
more than one positive biomarker provides more confidence to the pathologist 
reporting the disease. 
1.10.5 Technical differences in IHC between laboratories 
Optimisation of IHC in biomarker research is very important to achieve 
appropriate staining in the tissue. The manufacturers normally provide 
information and suggested protocols for IHC but most research laboratories 
optimise antibodies. The aim of optimisation is to increase the strength and 
specificity of the signal while suppressing background signals and artefacts (122, 
146). 
Research laboratories usually employ different IHC experimental conditions 
including clone of primary antibodies, antigen retrieval methods (heat induced 
epitope retrieval vs. enzymatic retrieval), primary antibody dilutions and manual 
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or automated platforms (193). All these factors significantly contribute to the 
different sensitivity and specificity values reported for a candidate biomarker 
investigated in different studies. Studies have addressed this issue and have 
compared: different clones of antibodies; different PH of antigen retrieval 
buffers (for example pH 6 vs. pH 8) and dilutions of primary antibodies (for 
example 1/50 vs. 1/100) (194-197). These studies provide an insight for choosing 
better conditions for the optimisation of antibodies. 
One approach to addressing the issue of technical heterogeneity is to 
systematically search the literature to identify IHC parameters for a biomarker 
that achieved an optimum combination of sensitivity and specificity. These 
parameters could then be used as a starting point for further optimisation. 
Assay development is a critical component in the qualification of biomarker. 
Sometimes biomarkers fail to enter the list of potential biomarkers not because 
of the underpinning science, but because of issues around assay development 
and a lack of validation studies (178, 198). 
1.10.6 The need for well-designed validation studies 
Validation of potential IHC diagnostic biomarkers in independent tissue cohorts 
is probably the most important factor delaying clinical translation (181). 
Researchers investigate promising biomarkers, publish their work and sometimes 
leave excellent biomarkers without designing further validation studies. More 
focused and aim oriented validation studies could expedite the journey of 
biomarkers from bench to clinic (128, 142). 
Validation studies in a step-wise fashion can be as follows. Validation of 
biomarkers in independent laboratories and patient cohorts, using the same IHC 
methodology, and the same scoring system and cut-offs. The expression level 
and subsequent diagnostic sensitivity and specificity should broadly be similar in 
validation studies. This will help to establish the reproducibility of the IHC 
methodology and cut-offs used for diagnostic purposes. Then establishing a 
multi-institutional validation study group and carrying out validation studies and 
addressing technical and other issues (199). For example a study group 
developed in pancreatic cancer research is ‘European Study Group for Pancreatic 
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Cancer’ (ESPAC) (200). Finally, a prospective clinical study for investigating the 
optimum biomarker panel will provide more confidence to translational 
scientists and pathologists for further validation. In fact, academic-industry 
collaborations can further facilitate and expedite validation studies from bench 
to clinic.  
In summary, biomarker development from identification to validation and 
clinical application would require: pooling of already existing data; synthesis and 
then analysis of evidence; identification of known promising biomarkers; 
addressing factors such as sample size, scoring systems and cut-offs that 
influence the validation of biomarkers; and finally using a panel approach and 
best IHC methodology in well-designed and aim oriented validation studies. 
In the next section, I will discuss the importance of systematic review and meta-
analysis in identifying suitable biomarkers that are already at the verification or 
validation stage of biomarker development. 
1.11 Importance of systematic review and meta-analysis 
Cancer biomarker discovery through ‘omic’ technologies has generated a long 
list of biomarkers. However, a labour intensive and costly filtering process is 
required to screen all biomarkers and identify potentially useful candidates. 
Various factors are involved in identifying suitable candidates including 
sensitivity i.e. the overexpression of biomarkers in cancer, specificity i.e. no or 
low expression in normal tissue and other tumour types and an appropriate assay 
(201). 
One potential way of addressing the issues hindering the clinical translation is to 
identify biomarkers that have already passed through some phases and have 
been validated by IHC. The sensitivity and specificity values of these potential 
biomarkers will facilitate in further filtering the most suitable candidates. Thus, 
at the identification step of this project we performed a systematic review and 
meta-analysis of potential IHC diagnostic biomarkers. 
Due to the scattered nature of literature on biomarker studies it was necessary 
to collect the existing evidence on diagnostic IHC biomarkers for PDAC. Every 
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time a novel diagnostic biomarker is reported or a validation study for an 
existing biomarker is reported, the translational scientist and pathologist 
compare it with the current evidence to assess its clinical significance. But 
simply summarising the scattered scientific information from the literature may 
not be enough. In addition, relying on the results of a single ‘good’ quality study 
especially if performed at one institution may not provide a rationale for the 
clinical use of a candidate diagnostic biomarker.  
Systematic review and meta-analysis of randomised controlled trials is the 
highest level of evidence in ‘evidence based medicine’. Systematic review 
attempts to identify the best research evidence from literature, appraise it 
critically, synthesise evidence for clinical practice and identify papers for meta-
analysis (202, 203). Most of the reported studies in PDAC diagnostic biomarker 
research are either cohort (PDAC and non-neoplastic adjacent tissue from the 
same patient) or case control studies (PDAC and non-neoplastic tissue from 
separate groups of patients). Therefore, the best available evidence that could 
potentially be provided for diagnostic IHC biomarkers will be a systematic review 
and meta-analysis of cohort and case control studies. 
Systematic review and meta-analysis not only quantifies and ranks the 
performance of potential IHC biomarkers but also assesses the quality of primary 
studies investigating biomarkers. It helps to evaluate primary studies by asking 
questions like: What is the design of the study? What is the sample size of 
primary studies and what is the sample distribution between malignant and 
benign samples? What is the IHC methodology and has the technique been 
described in sufficient detail to allow reproducibility in independent studies? 
Which scoring system and cut-off has been used and how much is their 
heterogeneity between studies? Were biomarkers investigated singly or in a 
panel? Indeed the answer to all these questions will help in evaluating the 
existing evidence, identifying issues with primary validation studies and making 
suggestions for future validation studies. 
In summary, systematic review and meta-analysis is an invaluable tool for the 
identification of potential biomarkers from the literature, identifying 
translational issues with biomarker validation and providing a good base for 
future validation studies. After identification, these biomarkers were then 
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validated utilising tissue microarray technology. In the next section I will discuss 
the significance of tissue microarrays in biomarker research. 
1.12 Tissue microarrays 
Biomarkers identified through molecular profiling approaches or literature 
searches require independent validation in large scale tumour samples before 
clinical application. Previous tissue based validation platforms were whole tissue 
sections. But validation of IHC biomarkers on whole tissue sections is time 
consuming and is reagent and sample intensive. A high throughput platform 
exists for biomarker validation and it is called tissue microarrays (TMAs) (204, 
205). 
1.12.1 TMA technology  
Utilising TMA technology allows for the examination of several hundred tissue 
cores from a number of patients on a single standard microscope slide (206). 
Briefly, TMAs are constructed by arraying small cores (0.6mm in diameter) of 
paraffin embedded tissue samples in a recipient wax block. Sections cut from 
the TMA block could then be stained by IHC using standard protocols.  
The first step in the construction of TMAs is to identify formalin fixed paraffin 
embedded (FFPE) whole tissue blocks to act as donor blocks. The corresponding 
haematoxylin and eosin (H&E) section of tissue blocks is used to mark 
representative areas of tissue on the slide. Then FFPE blocks are sorted and 
arranged for array construction. The layout of the TMA is made with control 
samples from other tissue types to help orientate the subsequent sections after 
staining. The marked H&E sections are used to identify areas of interest in the 
donor block. A hollow needle is inserted into the donor block to ‘sample’ a 
tissue core. Another hollow needle is inserted into the recipient wax block and 
hole is created for insertion of the donor tissue core. This process is used 
following the TMA layout to create a full TMA block. 
A very important consideration in the array design is taking into account the 
intra-tumour heterogeneity. The representative areas of the given tumour from 
multiple locations should be ‘sampled’ from a few donor blocks of the same 
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patient. The sampling of more cores from patient tissue blocks is associated with 
better representation of intra-tumour heterogeneity of biomarker expression. In 
a study it was shown that staining of one, two, three, four, six and ten cores 
represented the whole tissue section staining in 92%, 96%, 98%, 99%, 100% and 
100% of cases (207).  
Analysing multiple biomarkers on consecutive tissue sections can lead to rapid 
exhaustion of precious clinical material. Tissue cores ‘sampled’ for the 
construction of TMAs do not compromise the tissue block that could be retained 
in case it may be required for future diagnostic purposes such as immunostaining 
(204). In addition, multiple tissue cores can be sampled from one tissue block, 
generating multiple replicates of TMA blocks. For example, if we have 10 whole 
tissue blocks and each tissue block can be used for staining of 100 tissue sections 
then the total number of sections from these tissue blocks can be 10×100=1000. 
Now if we take multiple tissue cores from each of these 10 tissue blocks and 
constructs 5 replicates of TMAs. The resulting number of section from 5 TMA 
blocks will be 5×10×100=5000. Hence the number of replicates of TMA slides can 
significantly increase from a set of clinical tissue specimens utilising TMA 
technology. 
TMAs are thus a speedy and cost-effective approach for biomarker research in 
molecular pathology that ensures the abundant supply of tissue for multiple 
techniques. Figure 1.9A shows an H&E image of a TMA section and Figure 1.9B&C 
show magnified view of TMA cores. 
1.12.2 Uses of TMAs 
TMAs are now routinely used at most research institutions for IHC based 
biomarkers in a high throughput fashion across large cohorts. In the past decade 
a wealth of research emerged utilising TMAs for validating diagnostic, prognostic 
and predictive biomarkers (208, 209). 
The design of arrays differs for addressing different clinical questions and 
researchers have used tailor-made arrays to investigate specific research 
questions. TMAs designed specifically for diagnostic biomarkers have an array of 
tumour and normal tissue cores (210). They may also consist of different 
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histologic tumours from the same organ (157). Multi-tumour TMAs consist of 
tumour types from different organs and can be used for screening of biomarker 
expression patterns. TMAs have been used for assessing biomarker expression in 
a tumour progression model for example PanIn model of pancreatic cancer (211). 
TMAs can provide efficient platforms for investigation of prognostic and 
predictive biomarkers. The survival and clinicopathologic variables of patients 
including chemotherapy or other interventions are linked to tissue cores on 
TMAs. This enables the assessment of biomarker expression on TMAs in relation 
to patient survival, prediction of therapy and clinicopathologic variables (212, 
213). TMAs also allow the standardisation of IHC parameters and assay 
development (214). TMAs provide an excellent and efficient platform for 
investigation of a panel of candidate biomarkers, thereby helping to 
demonstrate the most reasonable panel discriminating a disease process from 
normal or an optimum panel predicting survival and response to specific 
therapies.  
In summary, TMAs can substantially accelerate the validation of novel molecular 
discoveries coming from genomic and proteomic research. The clinical, 
pathological, follow-up and therapy response information from cancer patients 
can be quickly and efficiently correlated with multiple biomarkers. They can 
also be used as an invaluable tool for sub-classification of tumours which could 
subsequently lead to more personalised medicine approaches. TMAs thus enable 
assessment of biomarker in a high throughput manner saving clinical material, 
time and cost. 
1.13 Project aim, objectives and implications  
As described in the above sections, cytology samples obtained via EUS-FNA and 
ERCP with brushing are very important for confirming the diagnosis of PDAC. 
However, cytology diagnosis is not perfect and false positive and false negative 
diagnoses have significant influence on the management of patients with 
suspected pancreatic cancer. 
Clearly, there is an unmet clinical need in PDAC diagnosis potentially leading to 
increased risk of ‘incorrect’ or ‘missed’ diagnosis and need additional diagnostic 
modalities such as tissue based biomarkers (172, 215-217). Therefore, the 
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identification and validation of diagnostic biomarkers in PDAC is vital to 
improving the management of this deadly disease. IHC biomarkers have long 
been established in clinical laboratories and provide an excellent and efficient 
platform for potential diagnostic biomarkers. The workflow of the current PhD 
project is illustrated in Figure 1.10. 
1.13.1 Aim 
The overall aim of the project is the identification of potentially diagnostic IHC 
biomarkers for PDAC and then validation of their diagnostic utility for improving 
the diagnostic management of patients with suspected PDAC from cytology 
samples. 
1.13.2 Objectives  
The following is a list of specific objectives: 
Identification of biomarkers 
1. To review the current evidence on diagnostic IHC biomarkers investigated 
in PDAC literature. 
2. To identify candidate diagnostic IHC biomarkers through quantification 
and ranking in a meta-analysis 
3. To assess the quality of primary papers reporting diagnostic IHC 
biomarkers and to assess the heterogeneity of IHC methodology, 
microscopic interpretation of immunostaining and diagnostic cut-offs.  
Validation of biomarkers 
4. To evaluate the expression level and validate the sensitivity and 
specificity (singly and in panel) of candidate diagnostic IHC biomarkers 
identified in meta-analysis in local PDAC and cholangiocarcinoma (CCC) 
resection tissue specimens.   
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5. To investigate and determine appropriate diagnostic cut-offs resulting in 
suitable sensitivity and specificity through receiver operating 
characteristics curve. 
6. To investigate various IHC cut-offs for observer agreement amongst 
practising pathologists and to identify factors influencing the 
interpretation and scoring of different cut-offs. 
7. To develop a resource of ‘needling’ cytology samples to enable 
optimisation of candidate IHC biomarkers for use in pancreatico-biliary 
cytology specimens. 
8. To evaluate the expression level and validate the sensitivity and 
specificity (singly and in panel) of selected biomarkers in archival cytology 
samples.  
Through this systematic approach it is envisaged that this project will identify 
and validate biomarkers with a potential to support cytological diagnosis and 
improve patient management. 
1.13.3 Implications 
The pre-treatment diagnosis of patients in suspected pancreatic cancer remains 
a challenge. This unmet clinical need could potentially be improved with IHC 
biomarkers. IHC is a routine and well established tool in pathology laboratories. 
Therefore, the identification and validation of potential IHC biomarkers with a 
higher diagnostic sensitivity and specificity will improve the current diagnostic 
management of patients with pancreatic cancer. Importantly, these biomarkers 
are not intended to replace cytomorphology but their proposed use as an 
adjunct to cytology could help diagnose the indeterminate or difficult to 
diagnose cases. 
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Table 1.1: Pancreatic cancer staging  
Stage Tumour 
Grade 
Nodal 
Involvement 
Distant 
Metastasis 
 
Stage 0 Tis N0 M0 Carcinoma in situ (also includes PanIN-3) 
Stage IA T1 N0 M0 Tumour limited to the pancreas, ≤2 cm in 
longest dimension 
Stage IB T2 N0 M0 Tumour limited to the pancreas, >2 cm in 
longest dimension 
Stage IIA T3 N0 M0 Tumour extends beyond the pancreas 
but does not involve the celiac  axis or 
superior mesenteric artery 
Stage IIB T1, T2 or 
T3 
N1 M0 Regional lymph node metastasis 
Stage III T4 N0 or N1 M0 Tumour involves the celiac axis or the 
superior mesenteric artery  
(unresectable disease) 
Stage IV T1, T2, T3 
or T4 
N0 or N1 M1 Distant metastasis 
Note: T= Primary tumour, N= Lymph nodes and M=distant metastases. (American Joint Committee 
on Cancer 7
th
 Edition (30)) 
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Table 1.2: The 2×2 table for calculating the sensitivity and specificity 
  True diagnosis of the disease (Histopathology or Clinical 
Follow up) 
  D+ D- 
   
   
   
B
io
m
ar
ke
r 
B+ a (TP) b (FP) 
B- c (FN) d (TN) 
  Sensitivity a/a+c Specificity d/b+d 
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Figure 1.1: Anatomy of pancreas 
Figure Legend: Pancreas Anatomy, Art. By courtesy of Encyclopaedia Britannica, Inc., copyright 
2003; used with permission. 
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Figure Legend: A) Normal pancreatic tissue. Red arrows= normal pancreatic ducts are lined with 
cuboidal-low columnar epithelium, Orange arrows=normal pancreatic acini arranged in lobules 
constitute majority of the parenchyma. The apical portion of the cells is lightly eosinophilic (pink) 
due to the presence of zymogen granules and the basal part of cytoplasm has basophilia (purple). 
The nucleus is polarized to the periphery and the cells are arranged in round units to form acinus. 
B) Red arrows= Islet’s of Langerhans consist of round collection of endocrine cells which have 
amphophilic cytoplasm and nuclei have fine dotted chromatin organization. 
Figure 1.2: Histology of normal pancreas 
A 
B 
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Figure 1.3: PanINgram 
Figure Legend: “A PanINgram illustrating our current understanding of the molecular changes in 
the multistep progression model of pancreas adenocarcinomas” Reprinted by permission from 
Macmillan Publishers Ltd:  Modern Pathology, Maitra et al. © 2003 (211). 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Figure legend: A) Pancreatic ductal adenocarcinoma is characterised by infiltrating tubular glands 
(red arrow) which are embedded in desmoplastic stroma (orange arrow), B) Well differentiated 
pancreatic ductal adenocarcinoma. Well-formed glandular structures lined by cuboidal cells similar 
to non-neoplastic ducts (red arrows). C) Moderately differentiated pancreatic ductal 
adenocarcinoma. The degree of cytologic and nuclear atypia is more and there is loss of polarity 
with irregular glandular arrangement (red arrows), D) Poorly differentiated pancreatic ductal 
adenocarcinoma. The degree of cytologic and nuclear atypia (orange arrow) is more with less 
glandular arrangement (red arrow). 
 
 
 
 
 
 
 
 
Figure 1.4: Haematoxylin and eosin images of PDAC 
A 
D 
B 
C 
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Figure 1.5: Benign pancreatic cytology 
Figure Legend: A&B) Normal pancreatic ductal epithelial cells: flat sheet of cells with regular and 
evenly spaced nuclei (orange arrows), C) Normal pancreatic acinar epithelial cells: Group of cells 
forming acini (red arrows). Cells have epical eosinophilic cytoplasm and nuclei are oriented 
peripherally, D) Normal duodenal epithelial cells contamination of cytology samples: Columnar 
epithelium (orange arrow) with goblet cells (blue arrow) and brush border microvilli. 
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Figure 1.6: Fine needle aspiration cytology samples of PDAC.  
Figure Legend: A&B) Cluster of malignant cells (blue arrows), nuclear pleomorphism (red arrows), 
prominent nucleoli (orange arrow), loss of polarity (green arrow) and nuclear overlapping 
(heamatoxylin and eosin of cell blocks), B) drunken honeycomb appearance (irregular, enlarged, 
crowded ductal epithelial sheets). 
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Figure 1.7: The pathway of biomarker development from discovery to clinic.  
 
  
Figure Legend: The sequential stages from discovery to clinical diagnostics are shown in the 
middle vertical block. Furthermore, each stage is further elaborated in the right side vertical block.  
Adapted from a model based on Lee et al 2007 (119). 
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Figure 1.8: Diagrammatic representation of reasons delaying clinical translation of 
biomarkers 
 
 
 
 
 
 
 
 
Reasons 
Delaying 
Clinical 
Translation 
of biomarker 
Lack of 
synthesis & 
quantification 
of evidence 
Inadequate 
sample size 
Lack of 
optimal 
scoring 
system and 
threshold 
Limited use of 
panel of 
biomarkers 
Technical 
Differences in 
IHC between 
labs 
Need of well 
designed 
validation 
studies 
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Figure 1.9: Tissue microarrays (haematoxylin and eosin) 
Figure Legend: A) an image of a tissue microarray (TMA) section containing both tumour (PDAC) 
and normal cores (normal pancreas). Tissue cores in the bracket are from other tumour types to 
help orientate the slide. B) A tumour core from patient with PDAC showing invading glands (orange 
arrow) and dense stroma (red arrow). C) A normal core from the adjacent normal pancreas from 
patient with PDAC showing normal duct (orange arrow), normal acini (red arrow) and Islet of 
Langerhans (blue arrow). 
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Figure 1.10: Experimental flow chart of current PhD project. 
 
Chapter 1 Introduction  
What is already known: Diagnosis of pancreatic cancer involves imaging 
followed by endoscopy with cytology, and is important for patient management. 
Cytology involves the distinction of PDAC from non-neoplastic pancreas, which 
can be difficult, especially in chronic pancreatitis. Immunohistochemical (IHC) 
biomarkers could help but none is yet routinely used.  
What this project adds: Identification and validation of diagnostic IHC 
biomarkers for clinical application in PDAC cytology. 
Chapter 3 
Systematic review and meta-analysis of IHC 
diagnostic biomarkers for PDAC 
 
 
Chapter 4 & 5 
Expression of biomarkers in pancreatico-biliary 
adenocarcinomas: development and utility of a 
potential diagnostic IHC panel. 
 
 
Chapter 6 
Investigating various thresholds as IHC cut-offs 
for observer agreement  
Chapter 8 Conclusion 
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biomarkers 
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Chapter 7  
A panel of KOC, maspin and mesothelin is good 
working IHC panel for PDAC diagnosis from        
cytology samples 
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2.1 Materials 
Materials used for the current PhD project that helped to carry out four studies 
discussed in chapter 3, 4, 5 and 6 of this thesis are described below. 
2.1.1 Systematic review and meta-analysis of 
immunohistochemistry (IHC) diagnostic biomarkers 
2.1.1.1 Softwares and Databases 
The Cochrane Collaboration (Oxford, UK) 
The software package RevMan 5.1 for systematic review and meta-analysis 
www.cochrane.org 
The R project for statistical computing 
R 2.15 with MADA package (Meta-Analysis of Diagnostic Accuracy) 
www.r-project.org/ 
Meta-DiSc: software for meta-analysis of test accuracy data 
MetaDisc version 1.4 
www.hrc.es/investigacion/metadisc_en.htm 
Ovid database (New York, USA)  
Ovid MEDLINE®, Coverage: 1948 - Present 
Embase, Publisher: Elsevier, Coverage: 1974 - Present 
www.ovid.com 
National Center for Biotechnology Information (NCBI) 
www.ncbi.nlm.nih.gov/pubmed/  
Microsoft Office (Reading, UK) 
          Excel spreadsheet programs 
2.1.2 Statistical analysis of diagnostic biomarkers 
2.1.2.1 Softwares 
IBM Corp, SPSS. (New York, USA) 
SPSS version 21.0  
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GraphPad Software, Inc. (California, USA) 
Version 5 
Minitab (Coventry, UK) 
Version 16 
Microsoft Office (Reading, UK) 
         Excel spreadsheet programs 
2.1.3 Equipment 
The equipment that is standard in most research laboratories were used for this 
project and is not separately listed by supplier, but included: refrigerators, 
−20OC freezers, wet and dry ice, vortex mixers, microcentrifuge, microwave 
oven, pressure cooker, glass pipettes, bottles, staining troughs, universal 
container, measuring cylinders and flasks. 
Other instruments used are listed below. 
Anachem Ltd (Luton, UK) 
Pipettes (2μl, 20μl, 200μl, 1000μl) 
DAKO (Ely, UK) 
DAKO Autostainer Link 48 
        DAKO Pre-Treatment (PT) module 
Leica Biosystems (Milton Keynes, UK) 
Multistainer Leica ST5020 
Hamamatsu (Japan) 
NanoZoomer Digital Pathology Scanner 
Millipore (Watford, UK) 
Milli-Q plus PF water purification system 
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2.1.4 General plasticware and needles 
Elkay laboratory Products (UK) Ltd (Basingstoke, UK) 
Microcentrifuge tubes (0.5, 1.5 and 2.0ml, both flip-cap and screw cap) 
Standard pipette tips (10μl, 20μl, 200μl and 1000μl) 
Bectin Dickinson (Oxford, UK) 
Disposable Needles (22 gauge) 
Disposable Syringes (5 mls) 
2.1.5 Chemicals, buffers and solutions 
Stock solutions were made up with distilled water. 
Hayman Ltd (James Borrough) (Witham, UK)  
Absolute alcohol (ethanol, analytical reagent grade, 100%, 70% solutions)  
Cell Path 
Haematoxylin Z 
Gill’s Haematoxylin 
Putts Eosin 
Sigma-Aldrich (Dorset, UK) 
Scott’s Tap Water substitute 
Leica Biosystems (Milton Keynes, UK) 
Acid Alcohol 
DPX mounting medium 
Sodium Citrate Buffer (0.1M Sodium citrate) 
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) buffer 
(1mM EDTA (pH 8.0)) 
Tris EDTA buffer (1mM EDTA (pH 9.0)) 
TBS/Tween  
2.5ml Tween 
Xylene  
         Thrombin 
Chapter 2                                                                                                     76 
 
   
Hologic (West Sussex, UK) 
         PreservCyt solutions 
2.1.6 Tissue microarrays 
Two sets of tissue micorarrays (TMAs) were used for investigating the expression 
of biomarkers. One set contain 3 TMAs and the other set contain 7 TMAs. In 
addition, a test array called ‘PDAC practice TMA’ was used for optimisation of 
antibodies for IHC. A detailed account of these TMAs is outlined in the Methods 
section 2.2.2. 
2.1.7 Cytology 
Two sets of cytology samples were used for investigation of biomarkers. One set 
was called ‘needling’ samples and was used for optimisation of antibodies and as 
control samples. The other set was archival cytology samples and was used to 
evaluate the diagnostic utility of biomarkers. A detailed account of these 
cytology samples is outlined in the Methods section 2.2.3. 
Sectioning of sections-Leica Microsystems (UK) Ltd (Milton Keynes, UK) 
1512 Rotary microtome 
2.1.8 Immunohistochemistry 
2.1.8.1 Primary antibodies 
DAKO Ltd (Ely, UK) 
KOC/IMP3 (Monoclonal Mouse Anti-Human; L523S, Clone 69.1) 
Leica microsystems (Novocastra antibodies) (Milton Keynes, UK) 
Mesothelin (Monoclonal Mouse Anti-Human; Clone 5B2) 
MUC1 (Monoclonal Mouse Anti-Human; Ma695) 
BD Bioscience (Oxford, UK) 
S100P (Mouse monoclonal Anti-Human; clone 16) 
Maspin (Mouse monoclonal Anti-Human; clone G167-70) 
Other reagents from DAKO (Ely, UK) for immunohistochemistry 
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 EnVision™ Detection Systems  
 Peroxidase block 
 Diaminobenzidine (DAB+) chromogenic substrate system 
 Secondary anti-mouse antibody 
2.1.9 Tissue Microarray Scoring 
2.1.9.1 Tissue microarray image acquisition and archiving  
Slidepath (Dublin, Ireland) 
Digital Image Hub and Distiller version 2.2 are software that were used for 
archiving tissue microarray images for scoring purposes, capturing images and 
labelling of samples. 
2.2 Methods 
The methods are divided into six sections to facilitate the understanding of 
methodology of subsequent results chapters. The subsections are: Systematic 
review and meta-analysis of IHC diagnostic biomarkers; tissue microarrays 
resource; cytology resource; IHC optimisation and staining of sections; 
microscopic assessment and scoring of IHC; and observer variations in the 
assessment of cut-offs for IHC biomarkers. 
2.2.1 Systematic review and meta-analysis of IHC diagnostic 
biomarkers 
2.2.1.1 Search strategy and identification of papers 
The aim of the search was to retrieve papers describing tissue based IHC 
biomarkers having diagnostic potential and showing differential expression 
between PDAC and non-neoplastic pancreas.  
The literature was searched using EMBASE and MEDLINE databases from inception 
to March 2012. Table 2.1 shows the search terms and MeSH headings used for 
retrieving relevant literature. The reference lists of papers judged relevant were 
searched to ensure the identification of additional papers missed by our primary 
search. The papers identified were then screened for systematic review and 
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meta-analysis. The papers selected for meta-analysis were also checked for 
methodological quality. A detailed account of this selection process and quality 
of papers is outlined in chapter 3. 
2.2.1.2 Meta-analysis of biomarkers 
The meta-analysis aimed to generate a list of diagnostic biomarkers for PDAC, 
assessed in either surgical or cytology specimens, ranked by sensitivity and 
specificity.  
To achieve this, first, coupled Forest plots were generated for biomarkers 
separately in resection specimens and in cytology samples. These Forest plots 
display within study estimates and confidence intervals for sensitivity and 
specificity for each biomarker.   
Second, bivariate summary estimates for sensitivity and specificity were 
generated for each biomarker. For a biomarker described in at least 3 studies, 
we used a bivariate random effects model (REM) to get combined summary 
estimates for sensitivity and specificity (218); for a biomarker described in only 
two studies, we used a bivariate fixed effect model (FEM) (219). (By definition, 
no biomarkers described in only one study progressed to meta-analysis.) 
Third, combined summary receiver operating characteristic (ROC) curves were 
generated, as follows. For each biomarker, the sensitivity of each study was 
plotted against (1 minus specificity) to yield an individual point in a space plot, 
which is the basis of a ROC curve. For each biomarker, the individual points for 
each of the multiple studies were placed in one plot, and then a summary ROC 
curve (SROC) was drawn. This provides a meta-analytical summary for a given 
biomarker and displays any variation between studies. Then, for all biomarkers 
assessed in one specimen type, all SROC curves were drawn in a so-called 
combined SROC plot and compared. This combined SROC plot, together with the 
bivariate summary estimates, provides a ranked list of biomarkers ordered 
according to pooled sensitivity and specificity. 
The software package RevMan 5.1 (from The Cochrane Collaboration) (220) was 
used to generate coupled Forest plots and combined summary ROC curves.  R 
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2.15 with MADA package (Meta-Analysis of Diagnostic Accuracy) (221, 222) was 
used for bivariate REM; and MetaDisc version 1.4 (223) was used for bivariate 
FEMs. 
2.2.2 Tissue microarray resource 
Two sets of tissue microarray (TMA) sections were used for analysing the 
expression of diagnostic biomarkers investigated in this thesis. One set of TMAs 
from surgical specimens was constructed by the researcher Simon Denley (SD) (a 
full list of contributors identified by initials appears at the beginning of the 
thesis) and the use of these TMAs for biomarker studies has been previously 
described (224). The second set of TMAs from surgical specimens was 
constructed by researcher Nigel Balfour Jamieson (NBJ) and the use of these 
TMAs for biomarker studies has been previously described (225). For the purpose 
of this thesis the former set was called ‘SD TMAs’ and the latter as ‘NBJ TMAs’. 
These two sets of TMAs were used because the TMAs from ‘SD TMAs’ had a loss 
of TMA cores and hence the staining for one biomarker was performed on TMAs 
constructed from ‘NBJ TMAs’. Both sets of TMAs are from the same surgical and 
pathology units in Glasgow and the details are presented below. 
2.2.2.1 SD TMAs 
Histological sections from three tissue microarrays (TMAs) containing samples 
from 99 surgically resected pancreatico-biliary adenocarcinoma (PBA) patients 
(Pancreatic ductal adenocarcinoma (PDAC) =85, Cholangiocarcinoma (CCC) = 14) 
were used for IHC. All resectional surgery was performed in the West of Scotland 
Pancreatic Unit (WSPU), Glasgow Royal Infirmary (GRI), UK, during a 10-year 
period (1995 to 2004). All patients were consecutive but tumours from other 
pancreatic pathologies for example intra-ductal papillary mucinous neoplasms 
and neuroendocrine tumours were excluded. Formalin fixed paraffin embedded 
(FFPE) tumour specimens were archived in the Department of Pathology, GRI and 
were used for the construction of TMAs. These TMAs contain five tissue cores (3 
tumours and 2 normal) for each patient. Tumour cores are adenocarcinoma cores 
from patients with PBA, whereas normal cores are from adjacent normal ducts 
and acini. The male to female ratio was almost 1:1 and the median age of 
Chapter 2                                                                                                     80 
 
   
patients was 65 (range, 38-77) years. These TMAs were used for IHC staining of 
KOC, S100P, mesothelin and MUC1.  
2.2.2.2 NBJ TMAs 
Histological sections from seven TMAs containing samples from 137 surgically 
resected PBA patients (PDAC=114, CCC= 23) were used for IHC. All resectional 
surgery was performed in the WSPU, GRI, UK, during a 15-year period (1992 to 
2007). All patients were consecutive but tumours from other pancreatic 
pathologies for example intra-ductal papillary mucinous neoplasms and 
neuroendocrine tumours were excluded. FFPE tumour specimens were archived 
in the Department of Pathology, GRI and were used for the construction of TMAs. 
The use of these TMAs has been previously described (225). These TMAs contain 
eight tissue cores (6 tumours and 2 normal) for each patient. Tumour cores are 
adenocarcinoma cores from patients with PBAs, whereas normal cores are from 
adjacent normal pancreatic ducts and acini. The male to female ratio was 
almost 1:1 and the median age of patients was 65 (range, 41-77) years. These 
TMAs were used for the staining of maspin. 
2.2.2.3 PDAC practice TMA 
The PDAC practice TMA was used for optimisation of antibodies. This microarray 
contained 20 tissue cores from patients with PDAC. 
Sectioning of TMAs: The tissue microarray blocks were sectioned using Leitz 
1512 microtome. A 2.5µm thick section was cut from each TMA block and put 
onto a “charged slide”. These slides were then baked at 65˚C for one hour and 
stored at 4˚C. These TMA blank sections were prepared by CO (senior lab 
scientist) and were used for IHC of biomarkers. 
2.2.2.4 Ethical approval 
Ethical approval has been granted by the North Glasgow University Hospitals NHS 
Trust Ethics Committee and by the National Health Service Greater Glasgow and 
Clyde Ethics Committee. This ethics approval includes the use of archival 
pathology specimens, where the patients were not given the opportunity to 
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donate their tissue. The ethical approval for the use of TMAs for research 
purposes for SD TMAs and NBJ TMAs was obtained by SD and NBJ respectively. 
2.2.3 Cytology resource 
Two sets of cytology samples were used for optimising and analysing the 
expression of diagnostic biomarkers investigated in this thesis. One set of 
cytology samples was called ‘needling’ samples generated from obtaining cells 
from fresh Whipple resections. The second set of cytology samples was retrieved 
from the cytology archives in the form of FFPE cell blocks. The former set was 
used for optimising the diagnostic antibodies and the latter set was used for 
evaluating the diagnostic sensitivity and specificity of biomarkers. The details of 
these cytology samples are presented below. 
2.2.3.1 ‘Needling’ cytology samples 
The cytology samples were obtained by ‘needling’ the fresh Whipple specimens 
(tumour, adjacent normal pancreas and normal duodenum) using a sterile and 
disposable needle with syringe attached to it. These samples were therefore 
called ‘needling’ cytology samples. Sample collection was under the guidance of 
the on-duty pathologist (Fraser Duthie (FD), Alan K Foulis (AKF), Sarah Bell (SB) 
and Karin A Oien (KAO)) for the gastrointestinal team, with help as required 
from the author Asif Ai (AA). 
The primary tumours were surgically resected at the WSPU, GRI, UK during a 5-
month period (22 October 2013 to 17 March 2014). Immediately following 
surgical resection the tissue specimens were transported on ice by the bio-bank 
staff to the Department of Pathology, Southern General Hospital (SGH), 
Glasgow, UK. ‘Needling’ cytology samples were prospectively collected from ten 
Whipple resections. Samples obtained were processed into FFPE ‘cell blocks’ and 
archived in the Department of Pathology, SGH. The male to female ratio was 
1.5:1 and the median age of patients was 70 (range, 50-80) years. The method 
used to generate this resource is outlined below. 
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2.2.3.2 Generating ‘needling’ cytology resource 
The technique of obtaining the cell samples and processing into cell block was 
performed as close as possible to the fine needle aspiration in a routine clinical 
practice. A needle of similar gauge (22 gauge) to that used in fine needle 
aspiration of the pancreas was used and on average 8-10 needle passes with and 
without aspiration via a syringe was performed for each ‘needling’ sample. Such 
samples were obtained from three different sites i.e. pancreatic tumour, normal 
adjacent pancreas and normal duodenum. The ‘needling’ specimens obtained 
were then put in three different and labelled universal containers containing the 
“PreservCyt” solution. These samples obtained were then quickly transferred to 
the Department of Cytology, SGH, Glasgow, UK. 
These samples were then processed into FFPE cell blocks by a team of cytology 
colleague (Lisa Irvine (LI), John McCorriston (JM)) who are also involved with 
processing the pancreatic and other cytology samples in routine clinical 
practice. The processing of ‘needling’ samples into cell blocks was performed in 
a way exactly similar to the routine pancreatic cytology samples. Briefly, saline 
was added to the top of universal container with fragments of cell/tissue, 
centrifuged, decanted and three such saline washes were performed. 
Afterwards, two drops of human plasma and then two drops of thrombin solution 
were added to the cell pellet with the help of a disposable pipette. The cell 
pellet was left until a cell clot was formed. The cell clot was then gently tipped 
and put in universal container filled with formalin. The fixation in formalin was 
carried out for 12 hours and the specimen was then embedded in paraffin to 
form a “cell block”. This procedure is similar to that used for routine diagnostic 
cytology samples, thus the resulting samples should be comparable to standard 
cytology and enable their use for optimisation and as control samples for IHC or 
other research techniques. The methodology of obtaining these ‘needling’ 
samples is shown in Figure 2.1. 
The ‘needling’ samples were obtained from ten Whipple resections i.e. six PDAC, 
one ampullary carcinoma (AC), one neuroendocrine tumour (NET), one 
intraductal papillary mucinous neoplasm (IPMN) and one serous cystadenoma. 
The ‘needling’ samples were procured from tumour, adjacent normal pancreas 
and normal duodenum from PDAC, AC and IPMN cases. This makes a total of 27 
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‘needling’ samples processed into cell blocks and archived in the Department of 
Cytology, SGH, Glasgow, UK for this project and future research. 
Furthermore, the corresponding resections specimens of PDAC ‘needling’ 
samples were also obtained from the Department of Pathology. The H&E 
sections of these cases were retrieved from the Department of Pathology, SGH, 
Glasgow, UK and were reviewed on a multi-header microscope by a pathologist 
(SB) and the author (AA). After careful inspection, from the H&E sections, tissue 
blocks with malignant tissue and adjacent normal pancreas were identified. 
These tissue sections will allow the comparison of biomarker expression in 
cytology and corresponding tissue sections. 
The purpose of the ‘needling’ resource was to optimise diagnostic IHC antibodies 
before staining the archival cytology specimens and to use as control specimens. 
However, this resource is not limited to this project and could potentially be 
used for future biomarker research. 
2.2.3.3 Archival cytology samples 
The archival cytology samples for the immunostaining were carefully selected. 
After discussion and with the help of gastro-intestinal pathologists (KAO, FD and 
SB), the cytology files of 57 patients were reviewed. The heamatoxylin and eosin 
(H&E) stained sections of cell blocks of 57 cytology samples obtained by EUS-FNA 
and ERCP brushing for suspected PDAC between May 2012 and October 2012 
were identified from the cytology files of Department of Cytology, Southern 
General Hospital, Glasgow, UK.  
The H&E sections of cytology samples were then checked for adequacy of 
cellularity on a multi-header microscope with the help of pathologists FD and SB. 
FD in particular is an expert on pancreatic cytology. The criteria for adequacy of 
cellularity from H&E stained sections was the presence of cytologically distinct 
sheets/groups of malignant  and benign cells respectively in malignant and 
benign cytology samples. By applying this criterion to H&E sections, 36 cases 
with insufficient/scant cellularity were excluded from this study. The remaining 
21 cases included in the study were: ten patients with a cytology diagnosis of 
adenocarcinoma, one patient suspicious for malignancy and ten patients with 
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benign cytology diagnosis. The male to female ratio was almost 1:1 and the 
median age of patients was 69 (range: 46-86) years.  
Sectioning of cell blocks: FFPE cell blocks from both ‘needling’ and archival 
resource were sectioned using Leitz 1512 microtome. A 4µm thick section was 
cut from each cell block and put onto a “charged slide”. These slides were then 
baked at 65˚C for one hour and stored at 4˚C. These cytology sections were 
prepared by RF (senior lab scientist) and were used for IHC of biomarkers. 
2.2.3.4 Ethical approval 
The author (AA) gained ethical approval for both ‘needling’ cytology and archival 
cytology samples from National Health Services, Greater Glasgow and Cylde (NHS 
GG&C), Bio-repository Ethics Committee. Three ethical applications were 
sequentially written by the author (AA): one application was for the ‘needling’ 
cytology project; the second application was an amendment of the ‘needling’ 
cytology project to allow for the procurement of corresponding surgical 
pathology specimens for comparing biomarker expression in tissue vs. cell 
samples; and the third application was for staining the archival cytology samples 
for the final and proposed biomarker panel. The approvals of all three ethical 
applications are present in the Appendix. 
2.2.4 IHC optimisation and staining of sections 
This section is divided into three subsections as follows: the IHC methodology; 
the optimisation of IHC on tissue sections; and the optimisation of IHC on 
‘needling’ samples. 
2.2.4.1 Immunohistochemistry methodology  
The technique of IHC was the same for both TMA sections and cytology sections 
and is presented below. IHC was performed using an automated platform (DAKO 
Autostainer Link48) for KOC, maspin, mesothelin, MUC1 and S100P antibodies. 
The steps are detailed below. 
De-waxing and rehydration: The purpose is to remove the wax and hydrate the 
tissue to allow the aqueous solutions to penetrate the sections. FFPE sections 
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were de-waxed in xylene for 5 minutes and then rehydrated for 1 minute each in 
graded alcohols, 100%, 100% and 70%. Sections were then washed in deionised 
water for 5 minutes. 
Antigen Retrieval: Formalin fixation leads to cross-linking within tissue which 
might mask the antigenic site of the protein. Antigen retrieval is therefore 
necessary to unmask the antigen for the antigen-antibody reaction. In this thesis 
two methods were used for antigen retrieval i.e. heat induced epitope retrieval 
(HIER) and enzyme digestion. HIER was performed on sections requiring KOC, 
maspin, mesothelin and MUC1 antibody staining using DAKO’s Pre-Treatment 
(PT) module. Sections were incubated in different retrieval buffer solutions 
depending on the antibody and tissue or cell section used at 98ºC for 25 minutes. 
Enzymatic digestion using proteinase-k for 10 minutes at room temperature was 
used for the antigen retrieval of S100P antibody. Sections were then washed 
with Tris Buffered Tween (TbT). 
Blocking the endogenous peroxidase activity: Endogenous Peroxidase was 
blocked using DAKO EnVision Peroxidase block for 5 minutes. Sections were then 
washed with TbT.  
Antibody incubation: Primary antibody was applied for 60 minutes with final 
antibody dilutions after optimisation. After incubation, the sections were 
washed with TbT. Secondary antibody (DAKO EnVision, anti-mouse) was then 
applied to the sections for 40 minutes. Sections were then washed with TbT.  
Visualisation method: Visualisation of the antigen-antibody reaction is required 
to identify the location and intensity of staining. For all antibodies 3,3’-
Diaminobenzidine tetrahydrochloride (DAB) was applied for 10 minutes to 
achieve brown staining in subcellular compartments (cytoplasm, cell membrane 
and/or nucleus). The reaction was then terminated by placing the sections into 
deionised water. 
Counterstaining: This is required to stain areas in the sections without antibody 
to allow visualisation of other cellular and stromal elements. For this purpose 
Haematoxylin Z was applied for 7 minutes to stain nuclei. Sections were then 
washed in tap water for 1 minute, dipped once in 1% acid alcohol for 2 seconds, 
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washed again in tap water for 30 seconds, placed in Scotts tap water substitute 
solution for 2 minutes and finally washed in tap water for 1 minute. 
Dehydration and mounting: After staining the slides are dehydrated and put in 
xylene before mounting to preserve the tissue for microscopic examination. The 
sections were dehydrated for 1 minute each in graded alcohols 70%, 100% and 
100% and then put in 3 changes of xylene for 5 minutes each. DPX mountant was 
used to attach a glass coverslip to the slide.  
The counterstaining and cover-slipping was performed on a Lecia Autostainer 
ST5020). Slides were allowed to dry for 30 minutes and examined under the 
microscope. 
2.2.4.2 Optimisation of IHC on tissue sections 
All antibodies were optimised before staining the final microarrays. The plan of 
optimisation was to review the literature (Table 2.2) and identify preferred IHC 
parameters reported for each antibody. This provided a starting point for 
optimisation with some modifications. The IHC conditions with variable 
parameters as shown in Table 2.3 were then used to stain the FFPE tissue 
sections from patients with PDAC. The IHC conditions achieving optimal staining 
were then repeated on PDAC practice TMA containing 20 tissue cores. The 
optimal staining was defined as diffuse and strong intensity staining in malignant 
ducts, very low or no staining in normal tissue and lowest possible background 
staining. 
Four biomarkers KOC, mesothelin, MUC1 and S100P were used to stain the SD 
TMAs.  One biomarker maspin was used to stain the NBJ TMAs due to the loss of 
cores in SD TMAs in the later sections used for the current and other research 
projects. The Optimisation of IHC and the final staining of SD TMAs for KOC, 
mesothelin and MUC1 were performed by a laboratory scientist VB under the 
supervision of KAO. The Optimisation of IHC and the final staining of SD TMAs for 
S100P and NBJ TMAs for maspin were performed by the author (AA) and CN. 
Nevertheless, scoring of all immunostaining was independently performed by the 
author (AA). The optimisation is outlined as follows. 
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SD TMAs were used for staining of KOC, mesothelin, MUC1 and S100P: For 
KOC, the HIER (pH6, citrate buffer) was evaluated against three primary 
antibody dilutions 1/50, 1/100 and 1/200. Optimal staining on tissue sections 
was achieved using HIER (pH6, citrate buffer) and a 1/50 antibody dilution. This 
optimised protocol was then repeated on a practice TMAs again achieving 
optimal staining. Finally the three SD TMAs were stained with appropriate 
positive and negative control sections. The staining was expected in the 
cytoplasm based on the literature and product datasheet and this pattern was 
achieved in this study.  
For mesothelin, the HIER (pH6, citrate buffer) was evaluated against three 
primary antibody dilutions 1/20, 1/40 and 1/80. Optimal staining on tissue 
sections was achieved using HIER (pH6, citrate buffer) and a 1/20 antibody 
dilution. This optimised protocol was then repeated on a practice TMA again 
achieving optimal staining. Finally the three SD TMAs were stained with 
appropriate positive and negative control sections. The staining was expected to 
be both cytoplasmic and membranous based on the literature and product 
datasheet and this pattern was achieved in this study.  
For MUC1, the HIER (pH6, citrate buffer) was evaluated against three primary 
antibody dilutions 1/50, 1/100 and 1/200. Optimal staining on tissue sections 
was achieved using HIER (pH6, citrate buffer) and a 1/200 antibody dilution. This 
optimised protocol was then repeated on a practice TMA again achieving optimal 
staining. Finally the three SD TMAs were stained with appropriate positive and 
negative control sections. The staining was expected to be both cytoplasmic and 
membranous based on the literature and product datasheet and this pattern was 
achieved in this study. 
For S100P, the enzymatic antigen retrieval (Proteinase k for 10 minutes) was 
evaluated against three primary antibody dilutions 1/50, 1/100 and 1/200. 
Optimal staining on tissue sections was achieved for proteinase k and a 1/100 
antibody dilution (Figure 2.2). This optimised protocol was then repeated on a 
practice TMA again achieving optimal staining. Finally the three SD TMAs were 
stained with appropriate positive and negative control sections. The staining was 
expected to be both cytoplasmic and nuclear based on the literature and 
product datasheet and this pattern was achieved in this study. 
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NBJ TMAs were used for staining of maspin: The HIER (PH6, citrate buffer) was 
evaluated against two primary antibody dilutions 1/75 and 1/150. Optimal 
staining on tissue sections was achieved using HIER (PH6, citrate buffer) and a 
1/75 antibody dilution (Figure 2.3). This optimised protocol was then repeated 
on a practice TMA again achieving optimal staining. Finally the seven NBJ TMAs 
were stained with appropriate positive and negative control sections. The 
staining was expected to be both cytoplasmic and nuclear based on the 
literature and product datasheet and the same was achieved in this study. 
The final IHC conditions to stain the TMAs are outlined in Table 2.4 and they 
were called ‘IHC parameters optimised for TMAs’. 
2.2.4.3 Optimisation of IHC on ‘needling’ samples 
All antibodies were optimised before staining the archival cytology samples. The 
‘needling’ samples (tumour, normal pancreas and normal duodenum) from five 
patients with PDAC were used for optimisation purposes. The optimisation was 
carried out in two phases as follows. 
First Phase: In the first phase, the ‘IHC parameters optimised for TMA’ (Table 
2.4) were used to stain the ‘needling’ cytology samples. The staining achieved 
for KOC, mesothelin and maspin on PDAC ‘needling’ samples was considered sub-
optimal (detailed immunostaining and scoring results will follow in Chapter 7). 
For S100P no staining was achieved in all samples stained. 
Second Phase: In the second phase, the IHC conditions were changed to achieve 
optimal staining. These optimised IHC parameters were called ‘IHC parameters 
optimised for cytology’. The IHC parameters including antigen retrieval and 
antibody dilutions were adjusted to achieve optimal staining and the 
optimisation parameters are shown in Table 2.5. The following is an outline of 
the optimisation of KOC, mesothelin, maspin and S100P for cytology. 
For KOC optimisation for cytology, the antigen retrieval buffers were compared 
i.e. HIER (pH6, citrate buffer) with HIER (pH9, Tris EDTA buffer). The rest of the 
IHC conditions exactly matched the ‘IHC parameters optimised for TMAs’. 
Optimal staining was achieved with HIER (pH9, Tris EDTA buffer). This optimised 
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protocol was then repeated on one ‘needling’ sample achieving similar staining. 
Finally the 21 archival cytology samples were stained with appropriate positive 
and negative ‘needling’ control sections. The staining was expected in cytoplasm 
based on the TMA work in this thesis, literature and product datasheet and the 
same was achieved in this study in archival cytology samples.  
For mesothelin optimisation for cytology, again the antigen retrieval buffers 
were compared i.e. HIER (pH6, citrate buffer) with HIER (pH8, EDTA buffer). The 
rest of the IHC conditions exactly matched the ‘IHC parameters optimised for 
TMAs’. Optimal staining was achieved with HIER (pH8, EDTA buffer). This 
optimised protocol was then repeated on one ‘needling sample’ achieving similar 
staining. Finally the 21 archival cytology samples were stained with appropriate 
positive and negative ‘needling’ control sections. The staining was expected in 
both the cytoplasm and in the membrane based on the TMA work in this thesis, 
literature and product datasheet and the same was achieved in this study in 
archival cytology samples.  
For S100P optimisation, three different antigen retrieval conditions i.e. 
proteinase k for 10 minutes, HIER (pH 6.0, citrate buffer), and HIER (pH 9.0, Tris 
EDTA buffer) were compared. In addition, two antibody dilutions 1/50 and 1/100 
were used for each of the three antigen retrieval conditions. The rest of the IHC 
conditions exactly matched the ‘IHC parameters optimised for TMAs’. However, 
no staining was observed in any samples stained with S100P antibody. 
For maspin optimisation, the antibody dilution was changed i.e. 1/75 dilution 
was compared with 1/150 dilution. The rest of the IHC conditions exactly 
matched the ‘IHC parameters optimised for TMAs’. Optimal staining was 
achieved with 1/150 antibody dilution. This optimised protocol was then 
repeated on one ‘needling’ sample achieving similar staining. Finally the 21 
archival cytology samples were stained with appropriate positive and negative 
‘needling’ control sections. The staining was expected in both the cytoplasm and 
in the nucleus based on the TMA work in this thesis, literature and product 
datasheet and the same was achieved in this study in archival cytology samples.  
Staining of the corresponding tissue sections: The corresponding resection 
specimens of the ‘needling’ cytology samples for all antibodies including S100P 
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showed optimal and expected staining in both the first and second phase of 
optimisation. 
The detailed immunostaining and scoring results of optimisation will follow in 
Chapter 7. The final IHC conditions (‘IHC parameters optimised for cytology’) to 
stain the archival cytology samples are outlined in Table 2.6. 
2.2.5 Microscopic assessment and scoring of IHC 
The H&E and IHC staining of TMAs and cytology samples were microscopically 
assessed. This section is divided into four subsections: TMA scoring; cytology 
scoring; evaluation of immunostaining; and statistics and data analysis. 
2.2.5.1 TMA scoring 
Microscopic analysis was undertaken blinded to the diagnosis or other 
parameters. The expression of KOC, mesothelin, MUC1, S100P and maspin across 
all TMAs was independently scored by the author (A.A).  The scoring of tumour 
and normal tissue cores was performed based on the morphology of tissue and, 
with help, as required from the corresponding H&E stained core. A consensus 
was reached on cores found difficult to score with a consultant histopathologist 
(KAO). 
Stained TMA sections were scanned (Hamamatsu Slide Scanner) and images 
uploaded in Distiller 2.2 (Leica Biosystems). This allowed the Distiller 2.2 to 
function as a digital microscope to visualize and score the TMAs. The OpTMA 
module in the Distiller 2.2 allows the user to view, navigate, annotate, zoom and 
score digital images. Digital images were opened in OpTMA and each tissue core 
in the TMA was presented with a scoring sheet allowing manual scoring using set 
criteria (Table 2.7- Scoring sheet). The scores for tissue cores were 
automatically saved after navigating to the next image in the folder. In addition, 
the scores from each tissue core were linked to a unique patient ID to allow 
matching scoring from different cores to a patient. All scores were exported in 
an Excel spreadsheet from Distiller 2.2 for analysis. 
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Digital pathology role in TMA scoring 
The sampling strategy of TMA technology provides a high degree of 
sophistication by arraying small and regularly sized and shaped tissue cores 
(225). The staining of TMAs can thus be easily scored using both traditional 
microscope and digital pathology software that act like a digital microscope. 
Traditional microscope based scoring of TMAs is sometimes challenging due to 
large number of densely packed cores on one slide (Figure 1.9). This can also 
result in a tiresome user interaction while developing consensus on difficult 
cores (unless it is a multi-header microscope). In comparison, digital pathology 
provides an efficient platform for scoring of TMAs which facilitates easy 
orientation of TMA slide for scoring and excellent user interaction on a personal 
computer (236).  
Using a digital microscope, tissue cores on TMAs can be scored in a blinded 
fashion without knowledge of the nature and clinical information of the core. 
The scoring is automatically saved as one move along a TMA and if interrupted 
scoring can be resumed at anytime from anywhere with internet access and a 
computer. The scoring of TMA tissue cores is linked to patients’ clinical data 
which can be exported in an excel spread-sheet. The TMA scoring and clinical 
data are arranged on a per core and per patient basis for subsequent analysis. 
These digital microscopes also allow zooming in and out of images and provide 
high quality annotated images of publication quality.  
An additional advantage of some of these digital microscopes (for example 
Distiller and Digital Image Hub, Leica Microsystem) is that they provide dynamic 
images (with flexibility of zooming in and out) that can be emailed to a 
colleague for opinion. The scoring of multiple biomarkers on the same TMAs 
scanned into digital microscope facilitates assessing different panels of 
biomarkers. 
Therefore, in a research setting digital pathology provide attractive platforms 
for scoring of TMAs and analysis of biomarker expression. This greatly facilitates 
and speeds up the analysis of the clinical utility of biomarkers. 
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2.2.5.2 Cytology scoring 
The assessment and interpretation of cytology samples and the resulting IHC 
staining was undertaken in conjunction with pathologists (F.D and SB). One 
pathologist (FD) in particular has significant expertise in pancreatico-biliary 
cytology. All scoring was performed using a light microscope. 
The purpose of scoring of ‘needling’ cytology samples was to compare the level 
of staining for different IHC parameters. The scoring performed by the 
pathologist was such that in a ‘needling’ sample with a mixed population of cells 
only atypical and malignant cells were scored for IHC staining. This was carried 
out with a corresponding H&E stained section available for each IHC stained 
section.  
The scoring of archival cytology samples was performed by the pathologist (SB) 
and the author (AA). Scoring was performed independently and the scorers were 
blinded to the final diagnosis. Moreover, the scorers were asked to score the IHC 
staining without paying attention to the cellular morphology. However, if there 
were very distinct populations of normal and abnormal cells, it was scored twice 
for both normal and malignant cells.  
2.2.5.3 Evaluation of immunostaining 
The biomarker expression in both tumour and normal tissue was recorded 
utilising a semi-quantitative Histoscore. The Histoscore takes into account both 
the staining intensity (0=absent, 1=weak, 2=moderate and 3=strong) and 
proportion of positive cells with each of these staining intensities. A Histoscore 
is calculated by the formula [0 × % negative cells + 1 × % weakly stained cells + 2 
× % moderately stained cells + 3 × % strongly stained cells]. The Histoscore thus 
has a range of possible scores between 0 and 300. As an example, a tissue core 
having 30% cells (of interest) with weak staining intensity; 40% cells with 
moderate staining intensity and 30% cells with strong staining intensity will have 
a total Histoscore of: (30x1)+(40x2)+(30x3) = 200. Histoscore provides a better 
estimate of biomarker expression than simply reporting the staining intensity or 
proportion of positive cells. A Histoscore was generated for each tissue core on 
TMAs and each cytology sample. 
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TMAs: A median Histoscore was taken as a final score for a patient with multiple 
tissue cores. As an example the final Histoscore of 180 was taken for diagnostic 
purposes for a patient with Histoscores of 150, 180 and 200 respectively for 
three tumour cores. Following IHC semiquantitative analysis of protein 
expression, three different scoring systems were used to assess expression level 
of biomarkers and sensitivity/specificity analyses. All three scoring systems were 
basically derived from the Histoscores as follows: scoring based on Histoscore 
value (range, 0-300); scoring based on percentage of positive cells (range, 0%-
100%); scoring based on staining intensity (1=weak, 2=moderate, 3= strong). 
Cytology: Again for scoring of the cytology samples the same three scoring 
systems were used as follows: scoring based on Histoscore value (range, 0-300); 
scoring based on percentage of positive cells (range, 0%-100%); scoring based on 
staining intensity (1=weak, 2=moderate, 3= strong). However, an additional 
scoring system based on categorical cut-off of 10% positive cells was also used. 
In this case, the scorers were asked to score a cytology case as ‘positive’ if more 
than or equal to 10% cells in the cytology sample were positive for a biomarker. 
While scoring a cytology case as ‘negative’ if less than 10% cells in the cytology 
sample are positive for a biomarker. Finally, the inter-observer agreement 
between two scorers (SB, a pathologist and AA, the author) for 10% cut-off was 
assessed using kappa statistics. 
2.2.5.4 Statistics and data analysis 
The mean expression of each biomarker in the PBA tumour cores was compared 
with the mean expression in normal tissue cores. Statistical significance was 
calculated using an independent sample t-test to generate the p value. The 
independent sample t test was used rather than the paired sample t test 
because a full set of matching tumour and normal tissue cores was not available 
for approximately 5% of patients. This was due to loss of tissue cores during 
processing, which is expected in a proportion of samples. Sensitivity/specificity 
analyses were carried out for biomarkers, both individually and in panels of 2-4 
biomarkers, and compared. We used two different panel approaches for 
sensitivity/specificity analyses. One approach assigns the case into the positive 
category if the tumour expresses only one biomarker in the panel. The other 
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approach assigns the case into the positive category if the tumour shows staining 
for at least 2 biomarkers in the panel. 
A combined summary receiver operating characteristic (SROC) curve was 
generated to compare different panels of biomarkers. P value <0.05 was 
considered statistically significant. SPSS-21 and RevMan-5.1 were used for 
statistical analysis. Observer variations in the assessment of cut-offs for IHC 
biomarkers were also considered. 
2.2.6 Investigating various thresholds as immunohistochemistry 
cut-offs for observer variations 
The study was conducted to examine the inter-observer and intra-observer 
agreements between pathologists as an indicator of reliability and 
reproducibility of cut-offs (thresholds). The intra-observer part of the study 
examined individual pathologists’ responses in a test-retest setting with 
retesting conducted three weeks after the inter-observer part and with all 
images re-arranged in different order to remove recall bias. 
2.2.6.1 PDAC images 
A series of 36 images of pancreatic cancer tissue microarray cores for four 
diagnostic IHC biomarkers (nine images each from KOC, maspin, mesothelin and 
S100P) were used for this study. These cores have previously been studied and 
were retrospectively identified for the current study. These cores were carefully 
selected for each biomarker based on a variable range of staining intensity and 
proportion of positive cells. Some cores with no immunostaining were also 
included. The expression of KOC was cytoplasmic, maspin has both cytoplasmic 
and nuclear expression but the scorers were asked to score only cytoplasmic 
staining for maspin and disregard nuclear staining, mesothelin expression was 
cytoplasmic and/or membranous and, S100P expression was cytoplasmic and/or 
nuclear.  
2.2.6.2 Participants 
Seven pathologists (3 experienced pathologists and 4 junior pathologists) 
participated in the study. Experienced pathologists have clinical pathology 
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experience of more than 15 years, while junior pathologists have 3-7 years of 
experience. Pathologists were coded as A, B, C, D, E, F and G.  
2.2.6.3 Scoring cut-offs 
A PowerPoint presentation containing these 36 images was prepared by the 
author (A.A). The images were arranged based on biomarkers with reference 
staining intensities (weak, moderate, severe) provided at the start for each 
biomarker. A scoring sheet with instructions on scoring was prepared with the 
help of pathology colleagues (Table 2.8). All the participating pathologists 
participated in one session for the inter-observer part of the study.  
After a short presentation (5-10 min) on the purpose of this study, the scoring 
sheets were distributed between all seven pathologists.  Each image was shown 
for only one minute. The pathologists were asked to interpret the 
immunostaining of each image for the three cut-offs as a binary categorical 
variable, “present” or “absent”. The three cut-offs were: 10% cut-off (10% 
positive epithelial cells of any staining intensity), 20% cut-off (20% positive 
epithelial cells of any staining intensity) and +2/+3 cut-off (moderate or strong 
staining of any cells). For example, a 10% cut-off is “present” when more than 
equal to 10% cells are positive in the desired subcellular compartment and is 
“absent” when less than 10% cells are positive. Each core was also recorded as 
being easy (1) or challenging (2) to score. The scoring sheet was also provided 
with a column for any comments by the scorers. 
All seven pathologists participated in the intra-observer part of the study three 
weeks after inter-observer session. The tissue core images were the same but 
rearranged in different order to remove recall bias. 
2.2.6.4 Statistics and data analysis 
Inter-observer agreement 
To determine inter-observer agreement for each of the three cut-offs, each 
pathologist’s interpretation of immunostaining was compared with that of the 
other pathologists in a pairwise manner. This generated three sets of inter-
observer kappa (k) scores: one each for the 10%, 20% and +2/+3 cut-offs.  
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k scores generated served as a measure of strength of agreement between 
pathologists for all three cut-offs. k scores reflect strength of agreement 
between two observers adjusted for chance agreement. k scores range from 0 to 
1 and we used the standards suggested by Landis and Koch (226) for the 
interpretation of strength of agreement. k scores are shown in six categories 
from 0-1 and each category is colour coded. White: 0, no agreement; greyscale 
indicates increasing agreement in the ranges 0.01-0.20= slight agreement 
(lightest grey), 0.21-0.40 fair agreement; 0.41-0.6, moderate agreement; 0.61-
0.8, substantial agreement; 0.81-1.0, almost perfect (black). To determine 
whether these three cut-offs are statistically different from each other, the 
paired sample t test (for large sample size) and Wilcoxon signed ranked test (for 
small sample size) were used to compare the pairwise k scores.  
Perceived ease of scoring 
To determine which cut-off is most easily scored, these three cut-offs as 
predictor variables were put in a linear regression model against perceived ease 
of scoring as dependant variable. 
Intra-observer agreement  
To determine reproducibility of these three cut-offs, kappa scores were 
generated comparing scoring and re-scoring of the same image arranged in 
different order three weeks apart for each pathologist. The intra-observer part 
was carried out in two sessions with three pathologists participating in one 
session and four participating in another session. 
A p value <0.05 was considered statistically significant. SPSS version 21 was used 
for statistical analyses. 
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Table 2.1: Search Terms and Mesh Headings.  
Study Population: 
 1. exp Pancreatic Neoplasms/ 
 2. (pancrea* adj5 neoplas*).tw. 
 3. (pancrea* adj5 cancer*).tw. 
 4. (pancrea* adj5 carcin*).tw. 
 5. (pancrea* adj5 adenocarcin*).tw. 
 6. 1 or 2 or 3 or 4 or 5 
Study Type: 
 7. exp Diagnosis/ 
 8. diagnos*.tw. 
Other diagnostic terms important for search. 
 9. exp "Sensitivity and Specificity"/ 
 10. sensitivity.tw. 
 11. specificity.tw. 
 12. predictive value*.tw. 
 13. likelihood ratio*.tw. 
 14. diagnostic accuracy*.tw. 
 15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
Study Intervention: 
 16. exp Immunohistochemistry/ 
 17. (immunohistoch* or immunostaining or immunocytoch* or IHC).tw. 
 18. (biomarker* or marker* or protein).tw. 
 19. 16 and 17 and 18 
Combining terms: 
 20. 19 and 15 
 21. 20 and 6 
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Table 2.2: IHC conditions used for antibodies in PDAC in literature. 
Protein 
Assayed 
Primary 
antibody 
Antigen 
retrieval 
Antibody 
dilutions 
Incubation 
time 
Incubation 
temperature 
KOC Mouse 
Monoclonal, 
Clone 69.1 
HIER 
Citrate buffer 
pH 6.0 and Tris 
EDTA pH 9.0 
1/50, 1/500 45, 60 minutes RT 
Mesothelin  Mouse 
monoclonal,  
Clone 5B2 
HIER 
Citrate buffer 
pH 6.0 and 
EDTA pH 8.0 
1/15, 1/20, 
1/30 
Not available 
for most 
studies, 
Overnight 
RT, 4°C 
MUC1 Mouse 
monoclonal 
Clone DF3, 
Clone Ma695, 
Clone Mh1 
HIER 
Citrate buffer 
pH 6.0  
1/75, 1/100, 
1/200, 
60 minutes, 
overnight 
RT, 4°C 
S100P Mouse 
monoclonal, 
Clone 16 
Proteinase K 
(10 min)  
1/100 30minutes, RT 
Maspin Mouse 
monoclonal,  
Clone G167‐70 
and Clone, 
EAW24 
HIER 
Citrate buffer 
pH 6.0 
1/20, 1/50,  
1/75, 1/800, 
1/3000 
60 minutes, 12 
hours 
RT 
Note: the IHC conditions used for resection specimens and cytology specimens appears to be the 
same in the studies.  
Abbreviations: HIER= Heat induced epitope retrieval, RT= room temperature. 
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Table 2.3: The IHC conditions from literature review used as a starting point for IHC 
optimisation on tissue sections in our laboratory 
Protein 
Assayed 
Primary 
antibody 
Antigen 
retrieval 
Antibody 
dilutions 
Incubation 
time 
Incubation 
temperature 
KOC Mouse 
Monoclonal, 
Clone 69.1 
HIER 
Citrate buffer 
pH 6.0  
1/50, 1/100, 
1/200 
60 minutes RT 
Mesothelin  Mouse 
monoclonal,  
Clone 5B2 
HIER 
Citrate buffer 
pH 6.0  
1/20, 1/40, 
1/80 
60 minutes RT 
MUC1 Mouse 
monoclonal 
Clone Ma695,  
HIER 
Citrate buffer 
pH 6.0  
1/50, 1/100, 
1/200, 
60 minutes RT 
S100P Mouse 
monoclonal, 
Clone 16 
Proteinase K 
(10 min)  
1/50, 1/100, 
1/200 
60 minutes RT 
Maspin Mouse 
monoclonal,  
Clone G167‐70  
HIER 
Citrate buffer 
pH 6.0 
1/75, 1/150 60 minutes RT 
Abbreviations: HIER= Heat induced epitope retrieval, RT= room temperature. 
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 Table 2.4: Details of the final IHC parameters used on TMA sections for five antibodies 
Antibody Company Clone of 
antibody 
Antigen 
Retrieval 
Antibody 
Dilution 
Incubation 
temperature 
Duration of 
incubation 
SD TMAs staining 
KOC/IMP3 
 
DAKO L523S, 
69.1 
HIER (Citrate 
buffer pH 6) 
1/50 25 C̊ 60 min 
S100P BD 
Biosciences 
16 Proteinase K 
(10 minutes) 
1/100 25 C̊ 60 min 
Mesothelin Novocastra 5B2 HIER (Citrate 
buffer pH 6) 
1/20 25 C̊ 60 min 
MUC1 Novocastra Ma695 HIER (Citrate 
buffer pH 6) 
1/200 25 C̊ 60 min 
NBJ TMAs staining 
Maspin BD 
Biosciences 
G167-70 HIER (Citrate 
buffer pH 6) 
1/75 25 C̊ 60 min 
Abbreviations: HIER= Heat induced epitope retrieval, RT= room temperature. 
 
 
 
 
 
 
 
 
Chapter 2                                                                                                     101 
 
   
Table 2.5: The IHC conditions used for optimisation on ‘needling’ cytology sections 
Protein 
Assayed 
Primary 
antibody 
Antigen 
retrieval 
Antibody 
dilutions 
Incubation 
time 
Incubation 
temperature 
KOC Mouse 
Monoclonal, 
Clone 69.1 
HIER 
Citrate buffer 
pH 6.0  
Tris EDTA 
buffer pH 9.0 
1/50 60 minutes RT 
Mesothelin  Mouse 
monoclonal,  
Clone 5B2 
HIER 
Citrate buffer 
pH 6.0  
EDTA buffer pH 
8.0 
1/20 60 minutes RT 
S100P Mouse 
monoclonal, 
Clone 16 
Proteinase K 
(10 min) , 
Citrate Buffer 
pH 6.0, Tris 
EDTA pH 9.0 
1/50, 1/100 60 minutes RT 
Maspin Mouse 
monoclonal,  
Clone G167‐70  
HIER 
Citrate buffer 
pH 6.0 
1/75, 1/150 60 minutes RT 
Abbreviations: HIER= Heat induced epitope retrieval, RT= room temperature. 
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Table 2.6: Details of the final IHC parameters used on archival cytology sections for three 
antibodies 
Antibody Company Clone of 
antibody 
Antigen 
Retrieval 
Antibody 
Dilution 
Incubation 
temperature 
Duration of 
incubation 
KOC/IMP3 DAKO L523S, 
69.1 
HIER (Citrate 
buffer pH 9) 
1/50 25 C̊ 60 min 
Maspin BD 
Biosciences 
G167-70 HIER (Citrate 
buffer pH 6) 
1/150 25 C̊ 60 min 
Mesothelin Novocastra 5B2 HIER (Citrate 
buffer pH 8) 
1/20 25 C̊ 60 min 
Abbreviations: HIER= Heat induced epitope retrieval 
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Table 2.7: Scoring sheet for TMA cores with an example highlighted in red 
Core Type          
  Tumour Tumour       
  Normal         
Scorable Tissue           
  Yes Yes       
  No         
Biomarker expression           
  Categories  Absent Weak Moderate Strong 
  1-5%         
  6-10% 10%     10% 
  11-25%   20%     
  26-40%         
  41-60%     60%   
  61-75%         
  76-90%         
  91-100%         
Final IHC Positvity 90%         
Final  Histoscore 170         
Overall Staining Intensity Absent  Weak Moderate  Strong   
       Moderate     
Scorer Comment           
            
Note: This algorithm of scoring has previously been used by our group (Denley et al 2013) (224). 
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Table 2.8: Scoring sheet for observer agreement (Biomarker with cytoplasmic staining) 
Core# 10% + cells 20% + cells 
Moderate-Strong 
intensity (+2/+3) 
Interpretation: Easy 
(1), Challenging (2) 
Comments 
1.       
2.       
3.       
4.       
5.       
6.       
7.       
8.       
9.       
Instructions for scoring: Kindly mark each core as either + OR 
_
 for the 3 thresholds i.e. 10% 
positive cells, 20% positive cells and moderate-strong staining intensity. Score the ease of 
interpretation as 1 (easy) OR 2 (Challenging). If you wish to make comments, please use the last 
column. 
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Figure 2.1: The methodology of ‘needling’ cytology samples collection. 
 
Figure legend: A) Opening pancreatic specimen B) Tumour visible on sectioning C) Collecting 
“needling cytology” sample D) Putting cells into PreservCyt solution. 
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Figure 2.2: Optimisation of S100P on PDAC resection specimens 
Figure Legend: Optimisation of S100P antibody for IHC on malignant ducts and adjacent normal 
ducts and acini from PDAC tissue sections. Note the strong and diffuse cytoplasmic and nuclear 
staining of S100P in malignant ducts for 1/50 and 1/100 dilutions. The staining intensity decreases 
with 1/200 dilution. No staining in normal ducts and normal acini was observed with any antibody 
dilution. 
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Figure 2.3: Optimisation of maspin on PDAC resection specimens 
Figure Legend: Optimisation of maspin antibody for IHC on malignant ducts and adjacent normal 
ducts and acini from PDAC tissue sections. Note the strong and diffuse cytoplasmic and nuclear 
staining of maspin in malignant ducts for 1/75 and 1/150 dilutions. No staining in normal ducts and 
normal acini was observed with any antibody dilution. 
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3 Systematic review and meta-analysis of 
immunohistochemical diagnostic biomarkers for 
PDAC 
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3.1 Chapter Summary 
Pancreatic ductal adenocarcinoma (PDAC) has an overall five year survival of 
only 2%. Diagnosis involves imaging followed by endoscopy with cytology, and is 
important for patient management. Cytology involves the distinction of PDAC 
from non-neoplastic pancreas, which can be difficult, especially in chronic 
pancreatitis.  Immunohistochemical (IHC) biomarkers could help but none is yet 
routinely used.  This study provides a systematic review and meta-analysis on 
diagnostic IHC biomarkers for PDAC. 
The literature was searched using EMBASE and MEDLINE databases from inception 
to March 2012. The publications on IHC markers differentially expressed between 
human PDAC and non-neoplastic pancreas were sought. The study characteristics 
including specimen type, biomarkers assessed and staining results were 
catalogued. In the meta-analysis, for each biomarker, coupled Forest plots, 
bivariate summary estimates and combined summary receiver operating 
characteristic curves were generated, in turn, then compared and ranked 
according to pooled sensitivity/specificity. 
2089 papers were initially identified.  64 studies reporting 49 biomarkers were 
selected for systematic review. From these, 45 studies reporting 16 biomarkers 
progressed to meta-analysis. Meta-analysis of IHC biomarkers assessed in 
resection specimens showed 12 differentiating PDAC from non-neoplastic 
pancreas. The highest ranked biomarkers according to pooled 
sensitivity/specificity values were: S100P (100% sensitivity/100% specificity); 
maspin (92%/97%); KOC (IMP3) (85%/98%); and MUC4 (82%/93%). Meta-analysis of 
cytology specimens showed seven biomarkers. The highest ranked were: KOC 
(85%/100%); SMAD4 (80%/100%); S100P (91%/91%); mesothelin (64%/92%); and 
MUC1 (83%/77%). 
The highest ranking IHC markers for PDAC were KOC, S100P, maspin, mesothelin 
and MUC1. Their diagnostic accuracies approach those of optimal conventional 
cytology. These markers may be appropriate for further clinical validation and 
potentially routine use in difficult cases. 
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3.2 Introduction 
Establishing the diagnosis of PDAC is important for optimal patient management 
but can be difficult and relies on imaging and pathology. Pre-treatment 
confirmation of diagnosis is achieved from cytology samples but the diagnosis 
from morphological interpretation of cytology is not perfect. This unmet clinical 
need in PDAC diagnosis from cytology samples has been discussed in detail in 
chapter 1. In this chapter, I will discuss the identification of potential diagnostic 
biomarkers that could help us improve the diagnosis of PDAC. The identification 
will involve a systematic review and meta-analysis of potential biomarkers 
already investigated in PDAC. Better biomarkers identified will then be validated 
in our surgical and cytology cohorts. 
We know that many genes are differentially expressed between benign pancreas 
and PDAC and could potentially be used as an adjunct to cytology to improve 
diagnostic accuracy (132, 133, 227). These genes are characterised at the 
protein level by IHC (147). IHC is a standard technique in pathology and a wide 
range of IHC biomarkers has been investigated in pancreatic resection specimens 
and EUS-FNA and biliary brush cytology specimens (169-172, 228). No biomarker 
has yet entered routine clinical practice but, used as an adjunct to cytology, 
they could help to increase diagnostic accuracy in indeterminate or otherwise 
difficult-to-diagnose cases (172). 
As mentioned earlier, a wide range of diagnostic IHC biomarkers have been 
published and I believe that a review of these biomarkers is the first step in the 
identification and selection for clinical translation. Although, outstanding 
reviews (229-231) on IHC biomarkers have been published for PDAC, none has 
specifically evaluated and quantified diagnostic IHC biomarkers. 
3.2.1 Aims 
The aim was to explore the current evidence on diagnostic IHC biomarkers in 
PDAC literature and to review, quantify and rank the performance of these 
biomarkers for PDAC. A further aim was to assess the quality of primary papers 
reporting diagnostic IHC biomarkers and to observe the range of IHC 
methodology, microscopic interpretation of immunostaining and diagnostic cut-
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offs. This should enable us to identify suitable candidate biomarkers to be 
investigated for their clinical utility for PDAC diagnosis. 
3.3 Results 
The results are reported in four main sections. The first section describes the 
screening process and selection of papers for systematic review and meta-
analysis. The second section presents the meta-analysis of 16 potentially 
diagnostic biomarkers for PDAC. The third section describes the remaining 33 
biomarkers from the systematic review not included in the meta-analytical 
model. The fourth section provides an overview of the scoring systems used to 
evaluate immunostaining and the cut-offs used for diagnostic purposes. 
3.3.1 Screening and selection of papers based on inclusion and 
exclusion criteria 
The prisma (http://www.prisma-statement.org/) flow chart was used as a 
template for the screening and selection of papers. At initial screening, 
duplicate publications were removed. The titles and abstracts of papers were 
inspected for potential eligibility for inclusion by the author (A.A). For the 
papers which passed this screening process, full text articles were then retrieved 
and checked for suitability.   
The inclusion criteria were: studies on tissue biomarkers which showed 
differential expression between PDAC and non-neoplastic pancreas (normal 
pancreas, chronic pancreatitis or both); assessment of tissue biomarkers using 
IHC; studies on cytology samples, surgical resection specimens or both; either 
prospective or retrospective study designs; reference diagnosis confirmed 
through either tissue histology or death from PDAC; and availability of either 
absolute numbers for biomarker sensitivity and specificity or of the raw data (for 
example a 2×2 table) to enable their calculation.  
The exclusion criteria were: studies reporting tumours which were not PDAC for 
example cholangiocarcinoma, ampullary or duodenal adenocarcinoma, and 
pancreatic neuroendocrine or acinar tumours or tumours from other organs; 
studies reporting only benign pancreatic pathology; studies reporting biomarkers 
which were not potentially diagnostic for example prognostic, predictive or 
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related to tumorigenesis only; studies on fluids for example pancreatic cyst fluid 
or juice, bile or serum; and molecular markers tested in tissue but not validated 
by IHC. 
3.3.1.1 64 studies reporting 49 biomarkers were included in the systematic 
review; and from these, 45 studies reporting 16 biomarkers 
progressed to meta-analysis. 
Figure 3.1 presents a prisma flow chart describing in detail the process of 
selection of studies for systematic review and meta-analysis based on the 
inclusion and exclusion criteria. 2089 studies were initially identified and 1618 
studies remained after the removal of duplicates. Further studies were screened 
out based on abstract and title, to leave 227 studies which were checked at the 
full text level for eligibility. Eventually 64 studies reporting 49 biomarkers were 
included in the systematic review; and from these, 45 studies reporting 16 
biomarkers progressed to meta-analysis.   
The general characteristics of the 64 selected studies including reference, year 
and country of publication, biomarker investigated either in resection specimens 
or cytology specimens or both, biomarker investigated in either a PDAC vs. 
normal pancreas or PDAC vs. chronic pancreatitis comparison or both and the 
design of study are summarized in Table 3.1.  
Next I will discuss the meta-analysis of 16 biomarkers, the outcome variables for 
each biomarker from the primary papers included in the meta-analysis and the 
methodological qualities of primary papers included in the meta-analysis. 
3.3.2 Sixteen biomarkers studied by IHC were reported in more 
than one study and were therefore included in the meta-
analysis  
The meta-analytical results are reported separately for biomarkers studied in 
resection specimens and for those studied in cytology samples. This grouping of 
biomarkers into different specimen types is based on the way that these 
biomarkers were reported in primary papers. The analysis is further subdivided 
into biomarkers differentiating PDAC from normal pancreas and biomarkers 
differentiating PDAC from chronic pancreatitis. Again this categorisation is based 
on the manner that biomarkers were reported in primary papers. It is important 
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to note here that there is overlap of biomarkers between resection specimens 
and cytology specimens i.e. a biomarker will be assessed both in resection 
specimen and cytology specimens. 
3.3.2.1 Twelve out of sixteen biomarkers which progressed to meta-analysis 
were tested in resection specimens  
These 12 biomarkers are: maspin (171, 172, 232-235), mesothelin (172, 173, 236-
239), KOC (IMP3) (186, 240, 241), fascin (172, 242, 243), COX2 (185, 244, 245), 
S100P (159, 166), claudin18 (227, 246), S100A6 (166, 247), S100A4 (166, 248), 
PSCA (249, 250), CEACAM6 (172, 251) and MUC4 (171, 173, 252). The sensitivities 
and specificities of these biomarkers are shown in the coupled Forest plots in 
Figure 3.2. Out of these 12 biomarkers for PDAC, 11 were compared with normal 
pancreas, four were compared with chronic pancreatitis and three were 
compared with both (Table 3.2). 
Eleven out of twelve biomarkers tested in resection specimens in the 
literature differentiated PDAC from normal pancreas 
11 biomarkers differentiated PDAC from normal pancreas (Table 3.2).  For five 
biomarkers, maspin, mesothelin, KOC, fascin and COX2, three or more studies 
were available and so a random effects model (REM) could be applied. Overall 
sensitivities were 83-92% and overall specificities were 89-98%. Pooled 
sensitivity/specificity (Table 3.2) and combined SROC curve (Figure 3.3A) were 
used to rank the biomarkers according to combined sensitivity/specificity. 
Maspin was highest ranked with a pooled sensitivity of 92% and pooled specificity 
of 97.5%, followed by mesothelin, KOC, fascin and COX2.  
For six biomarkers, S100P, claudin18, S100A6, S100A4, PSCA and CEACAM6, only 
two studies were available and so a fixed effect model (FEM) could be applied. 
Overall sensitivities were 75-100%, and overall specificities were 72-100%. 
Pooled sensitivity/specificity (Table 3.2) and combined SROC curve (Figure 3.3B) 
were used to rank the biomarkers according to combined sensitivity/specificity.  
S100P was highest ranked with pooled sensitivity and specificity of 100%, 
followed by claudin 18, S100A6, S100A4, PSCA and CEACAM6. 
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The biomarker expression in PDAC compared to normal pancreas provides an 
insight into the diagnostic role of biomarkers. A biomarker highly expressed in 
PDAC is likely to be highly sensitive in identifying the malignancy and a 
biomarker with less expression in normal pancreas is likely to be highly specific. 
In summary, maspin, KOC, mesothelin and S100P are good candidates as they 
achieve a higher diagnostic accuracy in categorising PDAC and normal pancreas 
in resection specimens. 
Four out of twelve biomarkers tested in resection specimens in the literature 
differentiated PDAC from chronic pancreatitis 
Furthermore, four biomarkers differentiated PDAC from chronic pancreatitis 
(Table 3.2).  For three biomarkers, KOC, mesothelin and maspin, three or more 
studies were available and so REM could be applied. Overall sensitivities were 
85-87% and overall specificities were 68-98%. Pooled sensitivity/specificity 
(Table 3.2) and combined SROC curve (Figure 3.3C) were used to rank the 
biomarkers according to combined sensitivity/specificity. KOC was highest 
ranked with a pooled sensitivity of 87% and pooled specificity of 98%, followed 
by mesothelin, and maspin.  
One biomarker MUC4 was assessed in 2 studies was suitable for FEM 
differentiating PDAC from chronic pancreatitis (Table 3.2 and Figure 3.3D). 
Pooled sensitivity and specificity for MUC4 were 82% and 93% respectively.  
The biomarker expression in PDAC compared to chronic pancreatitis provides a 
further insight into the diagnostic role of biomarkers. A biomarker with less 
expression in the reactive process makes it a desirable candidate for 
differentiating PDAC from a reactive but benign disease process. In summary, 
both KOC and mesothelin are primarily good candidates as they achieve a higher 
diagnostic accuracy in categorising PDAC and chronic pancreatitis in resection 
specimens. 
Overall, 12 potentially diagnostic biomarkers with reasonable diagnostic 
accuracy were investigated in resection specimens from patients with PDAC and 
non-neoplastic pancreas. The high ranking biomarkers were KOC, maspin, 
mesothelin and S100P. The ranking was based on best combination of sensitivity 
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and specificity values which was facilitated by SROC curves. Next I assessed the 
potential diagnostic utility of these and other biomarkers in cytology specimens 
reported in the literature.  
3.3.2.2 Seven out of sixteen biomarkers which progressed to meta-analysis 
were tested in cytology specimens  
These seven biomarkers are: KOC (IMP3) (186, 217, 240, 253), mesothelin (172, 
173, 254, 255), MUC1(170, 176, 188), p53 (165, 187, 256-259), SMAD4 (139, 228), 
S100P (159, 177), and MUC5AC (176, 188). The sensitivities and specificities of 
these biomarkers are shown in the coupled Forest plots in Figure 3.4. Out of 
these seven biomarkers for PDAC, two were compared with normal pancreas, 
and six were compared with chronic pancreatitis and one was compared with 
both (Table 3.3). 
Two out of seven biomarkers tested in cytology specimens in the literature 
differentiated PDAC from normal pancreas 
For two biomarkers, KOC and SMAD4, only two studies were available and so FEM 
could be applied. The pooled sensitivity and specificity of KOC was 85% and 
100%. The pooled sensitivity and specificity of SMAD4 was 80% and 100% (Table 
3.3). SMAD4 was higher ranked than KOC based on the combined SROC curve 
(Figure 3.5A). 
Although the KOC offers better sensitivity indices, SMAD4 is higher ranked due to 
comparatively large sample size. In summary, both KOC and SMAD4 are good 
candidates as they achieve a higher diagnostic accuracy in categorising PDAC and 
normal pancreas in cytology samples. The 2 studies reporting SMAD4 are from 
the same research group. 
Six out of seven biomarkers tested in cytology specimens in the literature 
differentiated PDAC from chronic pancreatitis 
Six biomarkers differentiated PDAC from chronic pancreatitis (Table 3.3). For 
four biomarkers, KOC, mesothelin, MUC1 and p53, three or more studies were 
available and so REM could be applied. Overall sensitivities were 64-84% and 
overall specificities were 77-92%. Pooled sensitivity/specificity (Table 3.3) and 
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combined SROC curve (Figure 3.5B) were used to rank the biomarkers according 
to combined sensitivity/specificity. KOC was highest ranked with a pooled 
sensitivity of 84% and pooled specificity of 92%, followed by mesothelin, MUC1 
and P53. 
For two biomarkers, S100P and MUC5AC, only two studies were available and so 
FEM could be applied. The pooled sensitivity and specificity of S100P was 90.9% 
and 90.9%. The pooled sensitivity and specificity of MUC5AC was 87.3% and 58.8% 
(Table 3.3). S100P was higher ranked than MUC5AC based on the combined SROC 
curve (Figure 3.5C). 
In summary, KOC, SMAD4, S100P, mesothelin and MUC1 are good candidates as 
they achieve a higher diagnostic accuracy in categorising PDAC and chronic 
pancreatitis in cytology samples. 
Overall, seven potentially diagnostic biomarkers with reasonable diagnostic 
accuracy were investigated in cytology specimens from patients with PDAC and 
non-neoplastic pancreas. The high ranking biomarkers were KOC, SMAD4, 
mesothelin, S100P and MUC1. The ranking was based on best combination of 
sensitivity and specificity values which was facilitated by SROC curves.   
3.3.2.3 Linking meta-analytic results: The highest ranking candidate 
diagnostic IHC biomarkers are KOC, S100P, maspin,  mesothelin and 
MUC1 
In total, 16 biomarkers were quantified and ranked to identify high ranking 
candidates for potential clinical translation. As reported in the literature, 
biomarkers have been investigated in resection and cytology specimens. 
Therefore, I performed analysis separately for resection and cytology specimens. 
In addition, sub-classification was done based on whether biomarker expression 
in PDAC was compared with normal pancreas and/or chronic pancreatitis as 
described in primary research studies.  
Twelve biomarkers investigated in resection specimens were suitable for meta-
analysis. Five biomarkers: KOC, maspin, mesothelin, S100P and claudin 18 
appear promising in differentiating PDAC from non-neoplastic pancreas (normal 
pancreas and chronic pancreatitis). They achieve reasonable diagnostic 
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sensitivity and specificity. Similarly, seven biomarkers investigated in cytology 
specimens were found suitable for meta-analysis. The five biomarkers KOC, 
SMAD4, mesothelin, S100P and MUC1 appear to be superior in differentiating 
PDAC cytology from benign cytology.  
KOC, mesothelin and S100P have been extensively investigated in both resection 
and cytology specimens. KOC was found to have similar diagnostic accuracy; 
however, the specificity of mesothelin remained the same but the sensitivity 
differed between resection and cytology specimens. The sensitivity and 
specificity of S100P dropped in cytology specimens as compared to resection 
specimens. 
These biomarkers are intended to improve the diagnosis of cytology samples and 
in particular the distinction of PDAC from chronic pancreatitis. Thus I used the 
following criteria to select the high ranking candidates: pooled sensitivity and 
specificity values from meta-analysis; ranking by SROC curves; investigation in a 
PDAC vs. chronic pancreatitis category; and validation in cytology samples by 
independent laboratories. Based on the above criteria KOC, S100P, mesothelin, 
maspin and MUC1 are high ranking potential candidates. It might be useful to 
further validate these biomarkers ideally in one experimental setting.  
3.3.2.4 The outcome variables for each biomarker from the primary papers 
included in the meta-analysis 
The outcome variables of all 16 biomarkers have been detailed in Table 3.4.  
Each biomarker is reported with study details, including sample size, 
microscopic assessment and scoring system, threshold of immunostaining for 
positive or negative diagnosis, staining compartment of cell (cytoplasmic, 
nuclear and membranous) and the diagnostic sensitivity and specificity values in 
the type of specimen (cytology and/or resection specimen).  
These factors are important in evaluating the biomarkers for potential clinical 
translation. Sample size is undoubtedly the most important factor giving the 
effect size of the study. Scoring system and microscopic assessment of 
immunostaining is the first step in evaluating a potential IHC biomarker and as 
evident from Table 3.4 a variety of scoring systems have been used. The next 
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step is the cut-off point whereby categorisation of two conditions (for example 
malignant vs. benign) based on immunostaining is performed. In addition, Table 
3.4 outlines the sensitivity and specificity values of biomarkers reported or 
calculated in various studies. These values were used to pool evidence from 
various articles to quantify and rank the performance of biomarkers which were 
used in different meta-analytical models. 
Finally, in Table 3.5 I have provided the details of the IHC methodology reported 
in primary papers for each biomarker included in the meta-analysis. These 
details include the primary antibody used with supplier details, the method of 
antigen retrieval used and the dilution of primary antibody used for IHC. 
3.3.2.5 Methodological quality of included studies evaluated by QUADAS 
checklist showed varying pattern of quality for 10 items assessed 
The aim of meta-analysis is to review and quantify the available research 
evidence on a particular objective from primary studies. If these primary studies 
are biased then synthesising evidence from them without any consideration to 
their quality will introduce bias to the meta-analysis. Quality assessment should 
thus be an integral part of a meta-analysis that allows assessing the effect of 
different biases and sources of variations (260, 261). 
The aim of diagnostic accuracy studies is to assess a particular test in identifying 
a diseases process and these studies have the following basic structure. An 
“index test” is the test of interest used to identify a disease process and to 
exclude normal processes, while a “reference standard” is the gold standard for 
diagnosis and the index test is compared to this gold standard (261). These terms 
will be used for assessing the quality of primary studies included in the current 
meta-analysis. For the purposes of this current project, the index test is 
biomarker, the reference standard is histopathology and/or clinical follow up, 
the disease process is PDAC and normal process is non-neoplastic pancreas. The 
performance of the index test is calculated using various statistics such as 
sensitivity, specificity, and receiver operating characteristic (ROC) curves. 
The methodological quality of primary studies included in the meta-analysis was 
therefore assessed using the QUADAS (Quality Assessment of Diagnostic Accuracy 
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Studies) checklist (261).  This list of ten questions is intended to confirm study 
quality, on topics including: selection criteria; identification of potential sources 
of bias; description of the index test; suitability of the reference standard; and 
reporting of indeterminate cases and withdrawal (Table 3.6). These factors can 
impact on the accuracy of diagnostic tests. 
One paper was written in the Chinese language only and was not assessed for 
quality; this left 44 studies for assessment.  Figure 3.6 and 3.7 are graphical 
presentation of the methodological quality of included studies. 
The following is an assessment of the primary papers for ten items in the 
QUADAS checklist. Representative spectrum and sufficient description regarding 
the selection of patients were found in 35%, while it was not clear in rest of the 
papers (item 1). Almost all studies verified all their samples by an acceptable 
reference standard (histopathology and/or death from pancreatic cancer) (item 
2, 3). But in 50% of the included studies differential verification was present, 
which means that the verification of true disease status was not performed 
solely by one reference standard. In almost 45% of the papers the true disease 
status was verified by death from pancreatic cancer (item 4).The incorporation 
of an index test as an aid to reference standard was avoided in almost all 
included studies (item 5).  
We used the minimum criteria in reporting the antigen retrieval method, 
primary antibody used and antibody dilution for assessing the reproducibility of 
IHC methodology for the index test (item 6). We found that sufficient details of 
IHC methodology was reported in nearly 85% of the papers; while sufficient 
details were not provided in the rest of the primary papers.  
In almost all cases the reference test was interpreted without knowledge of the 
index test (item 7). However, in 55% of the papers it was not clear whether the 
index test results were interpreted with or without knowledge of the reference 
standard (item 8). Finally, reporting of uninterpretable results and withdrawal of 
specimens was clear in 60% and 75% of the studies respectively (item 9 & 10). 
In summary, some of the primary studies are good quality but most of them have 
issues related to the reporting of selection criteria and representative samples, 
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differential verification, insufficient details of IHC methodology for assessing the 
index test for reproducibility, interpretation of the index test without knowledge 
of the reference standard and the reporting of uninterpretable and withdrawal 
cases. Addressing these issues in primary studies might greatly facilitate 
improving the quality of IHC biomarker research in PDAC. 
Next I will discuss a review of important biomarkers investigated in only one 
paper. These biomarkers by definition were not eligible for meta-analysis. 
3.3.3 Thirty three biomarkers studied by IHC were reported in 
only one study and were included in the review.  
The 33 biomarkers reported in only one study by IHC were found suitable for 
review and are detailed as follows: 14 biomarkers with reasonable sensitivity 
and/or specificity; 11 negative biomarkers for PDAC (biomarkers expressed in 
normal ducts but not in PDAC); additional eight important biomarkers but with 
low sensitivity and/or specificity.  
3.3.3.1 Fourteen biomarkers with reasonable sensitivity and/or specificity 
were reported in only one study. 
Fourteen IHC biomarkers with reasonable sensitivity and/or specificity were 
reported in only one study and are as follows: 14 3-3 σ (172), annexin A8 (227), 
B7-H4 (165), bcl2 (262), CK19 (139), claudin 4 (250), CXCL16 (263), Fas-L (264), 
HMGI(Y) (265), HSP47 (243), ICAM1 (266), PAP (267), RCAS1 (268) and XIAP (159).   
Ten biomarkers i.e. annexin A8, bcl2, claudin4, CXCL16, Fas-L, HMGI(Y), HSP47, 
ICAM1, PAP and RCAS1 have been studied in resection specimens only, two 
biomarkers i.e. B7-H4 and CK 19 have been studied in cytology specimens only, 
and two biomarkers i.e. 14 3-3 σ and XIAP have been studied in both. Promising 
biomarkers in resection specimens with their corresponding sensitivity and 
specificity values are HMGI(Y) (sensitivity=100% and specificity=100%), XIAP 
(100% and 100%), 14 3-3 σ (80% and 100%) and Fas-L (100% and 90%). While 
favourable markers in cytology specimens are 14 3-3 σ (100%/80%) and CK 19 
(100% and 100%). 
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Three studies reporting CEACAM6 (184), COX2 (269) and maspin (270) reported 
biomarker sensitivity only. Nonetheless, they were included in the review due to 
the presence of these biomarkers in meta-analysis. In addition, KOC (271) 
facilitate the differentiation of PDAC from various benign pancreatic lesions (for 
example inflammatory cyst, mucinous cystadenoma, serous microcystic 
adenoma) with 88% sensitivity and 100% specificity. However, this study was not 
included in the meta-analysis because we aimed for biomarkers comparing PDAC 
with normal pancreas and/or chronic pancreatitis. 
All 14 biomarkers with their outcome variables are outlined in Table 3.7. 
3.3.3.2 Eleven negative biomarkers for PDAC (biomarkers expressed in 
normal ducts but not in PDAC) were reported 
The expression of “negative biomarkers” is absent or very low in PDAC but their 
expression is high in normal pancreatic ducts; thereby, helping to exclude PDAC 
and identify normal ducts. These biomarkers are as follows; amylase (272), Bcl10 
(272, 273), CDX2 (274), CEH (carboxyl ester hydrolase) (272), chromogranin A 
(274), HPK1 (Hematopoietic progenitor kinase 1) (275), lipase (272), MUC2 (276), 
synaptophysin (274), trypsin (272) and von Hippel-Lindau gene product (pVHL) 
(166). As an example, 0% sensitivity would mean no staining in PDAC for a 
biomarker, whereas 0% specificity would mean diffuse positive staining in normal 
pancreatic ducts for a biomarker. 
All 11 biomarkers with their outcome variables are outlined in Table 3.8. 
3.3.3.3 Eight important diagnostic biomarkers with low sensitivity and/or 
specificity were reported 
We also included eight biomarkers that were investigated as diagnostic 
biomarkers for PDAC but their sensitivity and/or specificity was lower than 
expected. These biomarkers are; CA19-9 (277, 278), CA-50 (278), CD10 (279), 
CDX2 (276), CK7 (274, 276), CK 17 (276), CK20 (276) and MUC6 (176). 
All eight biomarkers with their outcome variables are outlined in Table 3.9. 
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3.3.4 Scoring systems and cut-offs reported in primary studies 
are variable 
The scoring of immunostaining and then establishing a cut-off for diagnostic 
purposes is an important part of biomarker research. The microscopic 
interpretation of staining is significantly different between studies as evidenced 
from a variety of scoring systems reported for biomarkers in this review. After 
scoring, a cut-off is established to categorise patients into cancer or normal 
groups. The cut-offs reported for biomarkers in primary studies and compiled in 
this review clearly show significant variations in cut-offs (Table 3.4, 3.7, 3.8, 
3.9). These variations exist sometimes for the same biomarker.  
Let us take the example of mesothelin for heterogeneity of scoring systems and 
cut-offs. Mesothelin has been reported in seven studies and all studies have used 
different scoring systems and cut-offs. The scoring systems are based on staining 
intensity (164, 255), proportion of positive cells (238) or a combination of both 
staining intensity and the proportion of positive cells (173, 236, 237, 239, 254). 
Now let us take the staining intensity as a scoring system for mesothelin. 
McCarthy et al (255) have reported two categories (positive and negative) based 
on staining intensity. The positive staining is regarded as a strong diffuse 
cytoplasmic staining, while negative staining is regarded as no labelling over 
background. Agarwal et al (164) have reported four categories based on staining 
intensity as follows: 0 (no staining); 1 (faint); 2 (definite) 3 (intense) and 4 (very 
intense). Clearly, this scoring heterogeneity demonstrates the adoption of 
different and ‘novel’ style of scoring by different labs that makes clinical 
translation less straightforward. This variation may also contribute to the 
variable diagnostic sensitivity and specificity of biomarkers. 
Cut-offs or positive thresholds for mesothelin are also heterogeneous and are as 
follows: simple positive or negative staining (164, 236, 238, 255); focal staining 
(>1% positive cells) (237); >5% positive cells (239); and >5% positive cells and 
moderate staining intensity (173). Again these different cut-offs for the same 
biomarker for the same outcome (PDAC diagnosis) make it difficult to compare 
and to select a reasonable cut-off. This also leads to the variable diagnostic 
sensitivity and specificity of biomarkers. The scoring systems and cut-offs for all 
biomarkers reported in this review are outlined in Table 3.4, 3.7, 3.8 and 3.9. 
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This heterogeneity of scoring systems and cut-offs is not restricted to mesothelin 
but applies to most of the biomarkers reported in our systematic review. This 
inconsistency between different labs makes it more difficult for translational 
scientists and pathologists to select a scoring system and cut-off for future 
validation studies. A standardised and well validated scoring system and cut-off 
is an important factor for clinical translation of biomarkers.  It is evident based 
on the results of this review that a range of scoring systems and cut-offs exist for 
biomarkers for PDAC diagnosis. 
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3.4 Discussion 
We systematically reviewed the available evidence on diagnostic IHC 
biomarkers that are able to differentiate PDAC from non-neoplastic pancreas. 
64 studies reporting 49 IHC biomarkers were selected for systematic review.  
From these, 45 studies reporting 16 biomarkers progressed to meta-analysis.  
Reporting the methodology and meta-analytical results of the included studies 
presented some challenges; however, we successfully reported them by a variety 
of statistical models. These models are well established in the literature (223, 
280, 281) but the description is lacking in the diagnostic IHC for PDAC and 
probably for any cancer literature. 
Meta-analysis was performed separately for biomarkers investigated in 
resection specimens and cytology specimens. This grouping was based on the 
approach adopted by the primary papers included in the meta-analysis. In 
addition, biomarkers investigated in each specimen type were reported in two 
different comparisons in primary papers: PDAC compared to normal pancreas; 
and PDAC compared to chronic pancreatitis. The meta-analysis was thus 
performed mirroring the primary papers reporting these biomarkers. Clearly, this 
will make the interpretations from the meta-analysis easy and clinically 
oriented. Using this approach, the meta-analysis of resection specimens showed 
four promising diagnostic biomarkers KOC, S100P, maspin and mesothelin. These 
biomarkers could potentially diagnose PDAC with high sensitivity and specificity. 
A relative decrease in sensitivity and sharp decrease in specificity for maspin 
was observed in the PDAC versus chronic pancreatitis category compared to the 
PDAC versus normal pancreas category in resection specimens. This apparent 
difference is probably due to a different clone of primary antibody (EAW24) used 
by Agarwal et l 2008 (172) compared to the clone (G167-70) used in other studies 
reporting maspin (233-235).  
Meta-analytical results of cytology specimens showed five promising biomarkers 
KOC, SMAD4, S100P, mesothelin and MUC1. SMAD4 has a pooled 80% sensitivity 
and 100% specificity but the 2 studies reporting SMAD4 were carried out by the 
same research group (139, 141) introducing subjective bias to the results.  
MUC5AC has a reasonable sensitivity but it has relatively very low pooled 
specificity of 58.8%, which means that it might classify benign lesions as 
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malignant. SMAD4 and MUC5AC are thus not desirable candidates. This left three 
biomarkers KOC, S100P and MUC1 as better candidates for further validation. 
Importantly, there is an overlap of various markers between different 
scenarios. KOC, maspin, mesothelin and S100P have been investigated in both 
resection and cytology specimens. The diagnostic accuracy indices for KOC are 
optimal and consistent across all scenarios investigated (174, 175, 180, 186, 217) 
making it a favourable diagnostic candidate for future clinical validation. 
Although S100P was 100% sensitive and specific in resection specimens, the 
sensitivity and specificity dropped to 91% in cytology specimens (159, 166, 177). 
In addition, the sensitivity of mesothelin reduced by about 20%-30% in cytology 
compared to resection specimens (173, 236, 238, 254, 255). This probably 
reflects that some biomarkers (KOC) are consistent in expression pattern 
between resection and cytology specimens but others (mesothelin, S100P) might 
show a different expression pattern in the two specimen types. This might be 
attributed to the differences in the processing of these specimen types or to the 
very few malignant cells in some cytology samples. The expression level of 
biomarkers in resection specimen might predict expression level in cytology 
specimens. A biomarker showing strong and diffuse expression in malignant ducts 
in tissue sections might likely show higher expression levels in malignant cells in 
cytology. The reporting of the expression level of a potentially diagnostic 
biomarker on a continuous scale for example a Histoscore (0-300) (282, 283) may 
perhaps be helpful. This might provide more information into the potential 
utility of a biomarker for diagnostic purposes than simply reporting sensitivity 
and specificity. 
Meta-analysis for each biomarker comprised of coupled Forests plots, 
bivariate summary estimates and combined SROC curve. Coupled Forest plots 
were prepared to provide an overview of the ranges of sensitivity and specificity 
of biomarkers. Bivariate summary estimates of various biomarkers were 
estimated by assuming random effects and fixed effect models depending on the 
number of studies for a biomarker. The bivariate summary estimates of 
biomarkers were interpreted in pairs for sensitivity and specificity. Finally, the 
SROC curve helped to compare and rank the diagnostic accuracy of various 
biomarkers in a given scenario (280, 281). This comprehensive meta-analytical 
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approach is rare in diagnostic biomarker research and is novel for PDAC 
literature. This approach might help translational research in other cancer 
types. 
Methodological limitations in the primary studies have introduced bias and 
variability to the diagnostic accuracy of the biomarkers under evaluation. A 
significant deficiency was observed in the reporting of selection criteria and the 
representativeness of the included specimens. Almost two third of the included 
studies did not achieve the minimum criteria of consecutive sampling, age 
distribution and male to female ratio of the included participants. Moreover, 
sample size for some of these included studies was low (139, 174, 217, 238, 245, 
258) decreasing the power of the studies. Differential verification bias is present 
in half of the included studies due to two different reference standards 
(histopathology and/or clinical follow up). The reason for having two reference 
standards is the fact that not all patients undergoing cytology receive surgical 
treatment and therefore death from pancreatic cancer due to locally advanced 
or metastatic disease confirms the diagnosis of pancreatic cancer. However, 
clinical follow up is an acceptable reference standard (172, 217, 255). Moreover, 
in most studies it was not clear whether the interpretation of the index test was 
‘blinded’. Similarly, reporting of un-interpretable results and the withdrawal of 
samples has not been mentioned for some studies. Both these factors introduce 
subjective bias into the diagnostic accuracy of a study. The quality of primary 
studies evaluating potential diagnostic IHC biomarkers could potentially be 
improved by addressing the issues outlined in the QUADAS assessment (261). 
Reporting all the QUADAS items in primary research studies is important. 
Nonetheless, sample size, providing sufficient details of IHC methodology for 
independent reproducibility and the interpretation of immunostainng without 
knowledge of true disease state are the most important factors. 
Among the papers included in our study heterogeneity exists in the reporting 
of IHC and cut-offs for positivity. Scoring of the immunostaining of tissues 
needs special attention. There is no uniformity of scoring for the assessed tissues 
even for a given biomarker. The most commonly reported scoring system is 
based on the intensity of staining (weak, moderate and strong) (185, 234, 240, 
271), a variety of scoring systems exists for the diagnostic biomarkers. Along 
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with staining intensity some researchers have also taken into account the 
proportions of positive cells to assess the level of expression of biomarkers in 
PDAC (159, 177, 237). Moreover, the researchers have divided the proportions of 
positive cells into various categorical groups (241, 253). Others have generated a 
quick score (233, 270), the sum score of both staining intensity, the proportion 
of cells (165) and an immunoreactive score (264) (for detail refer to Table 3.4 
and 3.7). However, no consensus based immunostaining scoring system appears 
to be present for the evaluation of these diagnostic IHC based biomarkers. 
Interestingly, none of the included papers has used “Histoscore” which is an 
established and validated scoring system covering both the staining intensity and 
proportion of positive cells. 
After scoring, a cut-off for positivity of a marker is a step ahead of finally 
calculating the sensitivity and specificity of the biomarker. Unfortunately, like 
the scoring of tissues there is no standardized cut-off for positivity. A binary 
categorisation of positive and negative staining for diagnosis is the most 
frequently reported cut-off (217, 236, 248, 266); nonetheless researchers have 
used a variety of cut-offs for classifying a tissue as either positive or negative. 
Similar to scoring of immunostaining, the cut-offs are based on intensity (172, 
217, 234, 255) or proportions of positive cells (171, 232, 239) or a combination 
of both (159, 235, 240). 
The current review demonstrates weaknesses in the reporting of IHC 
biomarkers for diagnostic purposes. The standardisation of scoring of 
immunostaining is of the utmost importance. A consensus based standardisation 
of scoring by the larger IHC research community might enable us to establish a 
uniform standard of scoring for reporting diagnostic IHC biomarkers. In addition, 
the IHC cut-off for positivity in tissue sections and cytology samples requires a 
uniform interpretative threshold for assigning the case into the positive or 
negative category. The standardisation of a uniform scoring method and cut-off 
could directly reflect on the clinical utility of IHC based diagnostic biomarkers. 
The strengths and limitations of our meta-analysis are as follows: The 
strengths include a comprehensive search strategy, the first meta-analysis 
specifically designed to identify diagnostic IHC biomarkers, the quantification 
and ranking in different statistical models and identifying issues related to 
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scoring and cut-offs. The limitations include the weakness of primary studies; 
failure to use bivariate REM for all biomarkers; and failure to demonstrate any 
significant correlation with covariates that could potentially influence the 
diagnostic accuracy due to the limited number of articles for biomarkers. It is 
worth mentioning that some markers out of the ones reported in only one article 
are promising but they cannot be quantified and ranked in the statistical model.  
Conclusion: meta-analyses on prognostic IHC biomarkers for PDAC have been 
published (284, 285). However, to my knowledge this is the first meta-analysis 
specifically designed to identify potential diagnostic IHC biomarkers for PDAC. 
The main findings from the review and meta-analysis are presented as follows. 
Firstly, high ranking potential candidates such as KOC, S100P, maspin, 
mesothelin and MUC1 were identified for potential clinical validation studies. 
Secondly, deficiencies in the reporting of diagnostic IHC biomarkers studies were 
outlined and suggestions made for future IHC biomarker studies. Thirdly, issues 
with the microscopic assessment of immunostaining and cut-offs were described 
and a need for standardised scoring system and reliable cut-off was suggested. 
Fourthly, the evidence of diagnostic accuracy of biomarkers for PDAC is 
promising for some of the biomarkers. However, none of the widely studied 
biomarker is completely sensitive to identify the disease at any stage of 
presentation. Similarly, none is exclusively specific to exclude PDAC. Therefore, 
a panel of highly sensitive and specific biomarkers is suggested. All these factors 
influence the translation of biomarkers to clinical practice and are some of the 
main reasons why we have a compendium of biomarkers (229, 230) but none is 
yet used in clinical practice to improve diagnosis of PDAC. 
Therefore, a panel of better biomarkers in a sufficiently powered study with 
high methodological quality could help us to achieve appropriate 
sensitivity/specificity that could possibly be applied as an adjunct to cytology.  
Based on the available evidence, we might suggest that a panel of KOC, maspin, 
mesothelin, S100P and MUC1 could be validated by IHC in resection specimen 
and cytology samples. Afterwards, prospective diagnostic cohort studies to 
assess their diagnostic significance for possible clinical application are 
recommended.  Finally, this systematic review and meta‐analysis could serve as 
a reference approach for integrating the information and then prioritising the 
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investigation of candidate diagnostic biomarkers. Moreover, the “meta‐analysis” 
could also serve as a prototype for quantifying and ranking diagnostic biomarkers 
in statistical models for other tumours.  
What this study adds: This study identified biomarkers for future validation 
studies. It also emphasised the importance of good quality validation studies, a 
uniform scoring system, a standardised and reliable cut-off and panel approach 
for potentially diagnostic biomarkers. 
What next: In the next two chapters, 4 and 5, I will now discuss the validation 
of identified biomarkers KOC, S100P, maspin, mesothelin and MUC1 in resection 
specimens from patients with PDAC. I will use Histoscore as potential optimal 
scoring systems and various diagnostic cut-offs. Afterwards in chapter 6 I will 
investigate cut-offs for observer agreement. 
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Table 3.1: Characteristics of 64 included studies 
 Reference Biomarkers Year Country Resection 
Specimens 
(RS)/Cytology 
PDAC vs. NP 
OR CP OR 
Both 
Study 
Design 
1.  Abe et al HMGI(Y) 2000 Japan/Italy RS Both Case 
control 
2.  Agarwal et al 14 3-3 σ, CEACAM 6, Fascin, 
Maspin, Mesothelin 
2008 USA Both Both Cohort 
3.  Akashi et al RCAS 1 2003 Japan RS CP Case 
control 
4.  Ali et al SMAD4 2007 USA Cytology NP Cohort 
5.  Argani et al (a) Mesothelin 2001 USA RS NP Cohort 
6.  Argani et al (b) PSCA 2001 USA RS NP Cohort 
7.  Awadallah et al B7-H4, P53 2008 USA Both Both Cohort 
8.  Baruch et al Mesothelin 2007 USA Cytology  NP Cohort 
9.  Bhardwaj et al Maspin, MUC4, p53 2007 USA RS CP Case 
control 
10.  Boltze et al Fas L 2002 Germany RS Both Case 
control 
11.  Cao et al Maspin 2007 USA RS NP Cohort 
12.  Chhieng et al MUC1 2003 USA Cytology CP Cohort 
13.  Chu et al CDX2, CK7, CK17, CK20, 
MUC2 
2005 USA RS NA Cohort 
14.  Deng et al S100P 2008 USA Cytology Both Cohort 
15.  Duxbury et al CEACAM 6 2005 USA RS NP Cohort 
16.  Erhuma CD10 2007 Germany RS CP Case 
control 
17.  Giorgadze et al MUC1, MUC5AC, MUC6 2006 USA Cytology CP Cohort 
18.  Glass et al Mesothelin 2011 USA RS CP Case 
control 
19.  Haglund et al CA19-9 1986 Finland RS Both Case 
control 
20.  Hassan et al Mesothelin 2005 USA RS Both Case 
control 
21.  Hosoda et al CDX2, Chromogranin A, 
CK7, Synaptophysin 
2010 Japan Both NA Cohort 
22.  Hosoda et al BCl10 2013 Japan Both NA Cohort 
23.  Ishimaru et al P53 1996 Japan Cytology CP Cohort 
24.  Jhala et al Mesothelin, MUC4 2006 USA Both Both Cohort 
25.  Karanjawala et al Annexin A8, Claudin 18 2008 USA RS Both Cohort 
26.  Kosarac et al S100P, XIAP 2011 USA Both Both Cohort 
27.  Koshiba et al COX2 1999 Japan RS Both Cohort 
28.  La Rosa et al Amylase, BCL10, CEH, 
Lipase, Trypsin 
2009 Italy RS NA Cohort 
29.  Lee et al P53 1993 Australia Cytology Both Cohort 
30.  Li et al P53 2002 China Cytology CP Cohort 
31.  Ligato et al KOC, S100A4 2008 USA Cytology Both Cohort 
32.  Lim et al Maspin 2004 Korea RS NP Cohort 
33.  Lin et al pVHL, S100A4, S100A6, 
S100P 
2008 USA RS NP Cohort 
34.  Lu et al Fascin 2004 China/Switzerland RS NP Cohort 
35.  Maass et al Maspin 2001 Germany RS NP Cohort 
36.  Maitra et al (a) Fascin, HSP47 2002 USA RS NP Cohort 
37.  Maitra et al (b) COX2 2002 USA RS NP Cohort 
38.  McCarthy et al Mesothelin, PSCA 2003 USA/Nederland Cytology Both Cohort 
39.  Nash et al Maspin 2007 USA RS CP Case 
control 
40.  Niijima et al COX2 2002 Japan RS Both Case 
control 
41.  Oh et al Maspin 2002 Korea RS NA Cohort 
42.  Ohucida et al S100A6 2005 Japan RS NP Cohort 
43.  Okami et al COX 2 1999 Japan RS NP Cohort 
44.  Ordonez et al Mesothelin 2003 USA RS NP Cohort 
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Table 3.1: Characteristics of 64 included studies 
 Reference Biomarkers Year Country Resection 
Specimens 
(RS)/Cytology 
PDAC vs. NP 
OR CP OR 
Both 
Study 
Design 
45.  Rosty et al S100A4 2002 USA RS Both Cohort 
46.  Satomura CA19-9, CA-50 1991 Japan RS Both Case 
control 
47.  Shimoyama et al ICAM1 1997 Japan RS NP Case 
control 
48.  Stewart et al P53 2000 UK Cytology CP Cohort 
49.  Strickland et al CEACAM 6 2009 USA/UK RS NP Cohort 
50.  Sun et al Bcl2 2002 China RS Both Case 
control 
51.  Swartz et al MUC4 2002 USA RS NP Cohort 
52.  Tanaka et al Claudin 18 2011 Japan RS NP Cohort 
53.  Toll et al KOC 2009 USA Both CP Cohort 
54.  Villanacci et al P53 2009 Italy Cytology CP Cohort 
55.  Wachter et al KOC 2011 Switzerland RS Both Cohort 
56.  Wang et al MUC1, MUC5AC 2007 China Cytology CP Cohort 
57.  Wang et al HPK1 2009 USA RS NP Case 
control 
58.  Wen-bin et al Claudin 4, PSCA 2008 China RS Both Case 
control 
59.  Wente et al CXCL16 2008 Germany RS Both Case 
control 
60.  Xie et al PAP 2003 Japan RS Both Cohort 
61.  Yantiss et al KOC 2005 USA RS Both Cohort 
62.  Yantiss et al KOC 2008 USA Cytology CP Cohort 
63.  Zapata et al CA 19-9, CK19, SMAD4 2007 USA Cyotlogy NP Cohort 
64.  Zhao et al KOC 2007 USA Cytology Benign Case 
control 
Note: *NA=data not available 
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Table 3.2: Bivariate summary estimates of various markers in resection specimens 
No Biomarkers % Sensitivity (95% CI) % Specificity (95% CI) Studies Specimens 
Markers differentiating PDAC vs Normal Pancreas 
1.  Maspin 91.7 (91.6-91.7) 97.5 (97.3-97.8) 4 684 
2.  KOC (IMP3) 85.2 (44.0-97.7) 97.8 (59.5-99.9) 3 162 
3.  Mesothelin 92.2 (67.2-98.6) 93.8 (74.6-98.8) 4 231 
4.  Fascin 82.8 (57.1-94.6) 95.8 (65.2-99.7) 3 194 
5.  COX2 88.3 (60.1-97.4) 88.9 (31.6-99.3) 3 162 
6.  S100P 100 (94.9-100) 100 (94.9-100) 2 140 
7.  Claudin18 83.2 (78.7-87.1) 98.5 (96.1-99.6) 2 583 
8.  S100A6 98.9 (93.9-100) 80.6 (71.4-87.9) 2 187 
9.  S100A4 83.8 (75.8-89.9) 90.0 (82.8-94.9) 2 227 
10.  PSCA 74.6 (66.5-81.7) 95.7 (88.0-99.1) 2 208 
11.  CEACAM6 91.2 (85.4-95.2) 72.3 (57.4-84.4) 2 194 
Markers differentiating  PDAC vs Chronic Pancreatitis 
1.  KOC 86.7 (79.6-91.5) 97.6 (87.0-99.6) 3 199 
2.  Mesothelin 81.0 (70.1-88.6) 90.4 (74.1-96.8) 4 190 
3.  Maspin 85.2 (71.3-92.9) 67.9 (12.1-97.0) 3 237 
4.  MUC4 82.0 (73.6-88.6) 93.1 (83.3-98.1) 2 169 
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Table 3.3: Bivariate summary estimates of various markers in cytology specimens 
No Biomarkers % Sensitivity (95% CI) % Specificity (95% CI) Studies Specimens 
Markers differentiating PDAC vs Normal Pancreas 
1.  KOC (IMP3) 85.3 (68.9-95.0) 100 (85.2-100) 2 57 
2.  SMAD4  80.0 (71.9-86.6)    100 (96.5-100)    2 230 
Markers differentiating PDAC vs Chronic Pancreatitis 
1.  KOC 84.1 (62.2-94.5) 92.1 (68.3-98.5) 3 77 
2.  Mesothelin 63.8 (57.0-74.5) 92.1 (88.0-99.1) 4 191 
3.  MUC1 82.5 (59.3-93.8) 77.3 (58.0-89.3) 3 122 
4.  p53 66.2 (52.7-77.5) 86.3 (73.9-94.4) 6 291 
5.  S100P 90.9 (80.0-97.0) 90.9 (70.8-98.9)    2 77 
6.  MUC5AC 87.3 (77.3-94.0)    58.8 (32.9-81.6)    2 88 
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Table 3.4: Outcome of studies evaluating candidate biomarkers in more than one study  
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
CEACAM 6 Duxbury et al 2005 89 0 (<5% cells positive with no or weak staining), 
1(weak), 2(moderate), 3(strong). 
>5% with weak staining Cytoplasmic, Membranous NA* Sensitivity 92% 
Insufficient data for 
specificity 
CEACAM 6 Agarwal et al 2008 61 0, 1(faint), 2(definite), 3(intense), 4 (very 
intense). 
No threshold (any staining) 
Positive/negative 
Cytoplasmic NA 75%/82% (NP) 
75%/28% (CP) 
CEACAM 6 Strickland et al 2009 151 0-3+ and proportion of cells positive. ≥10% positivity Cytoplasmic, Membranous NA 96%/70% 
Claudin 18 Karanjawala et al 2008 168 Percentage of cells positive 
Diffuse= >80% cells with 2 or 3staining. 
0-3 staining 
Only cores having ≥30% of 
carcinoma were scored. 
Positive/negative 
Cytoplasmic, Membranous NA 96%/96% (NP & CP) 
Claudin 18 Tanaka et al 2011 156 Only cores having ≥30% of carcinoma were 
scored 
0, weak(1+, 1%-25%cells), , strong(3+, >80% 
cells) 
 
Positive/negative Cytoplasmic NA 70% /100% (NP) 
COX2  Okami et al 1999 43 0-3 scale Positive/negative Cytoplasm NA 100%/100% (NP) 
COX2 Koshiba et al 1999 50 0, 1(1%-33%), 2(34%-66%), 3 (67%-100%) 
0-3 staining intensity 
Score=Intensity* proportion 
Score >4 positive Cytoplasm, nuclear 
membrane 
NA 72% sensitivity 
Data for specificity is not 
available 
COX2 Niijima 2001 26 300 epithelial cells in major ductal lesions 
Negative (<10%), +(10-30%), ++(30-50%), 
+++(>50%) 
 ≥10% cells Cytoplasm NA 80%/100% (NP) 
80%/100% (CP) 
COX2 Maitra 2002 36 Automated image analysis 
Score= intensity*percentage of cells positive 
Cut-off= >20% of cells 
positive 
 
Cytoplasm NA 77%/60% (NP) 
Fascin Maitra 2002  57 Focal (1-25%), Diffuse (26-100%) 
0-4 Intensity 
Positive and negative 
staining. 
 
Cytoplasmic granular NA 95%/94% (NP) 
Fascin Lu et al 2004 21 Positive/negative Positive/negative Cytoplasm NA 62%/100% 
Fascin Agarwal et al 2008 61 0, 1(faint), 2(definite), 3(intense), 4(very 
intense). 
No threshold (any staining) 
Positive/negative. 
Cytoplasmic NA 84%/100% (NP) 
84%/62% (CP) 
KOC (IMP3) 
 
Yantiss et al 2005 45 0%, <25%, 25–49%, 50–79%, 80–100% 
0-3+ 
>25% positive cells with 2+ 
staining 
Cytoplasm NA 95%/100% (NP) 
95%/100% (CP) 
KOC Zhao et al 2007 48 0-3+ Positive/negative Cytoplasm and/or 
membrane 
88%/100% (benign) NA 
KOC Ligato et al 2008 44 0, Focal (>5%<25% cells), diffuse (>25% cells) 
0-3+ 
>5% cells with 1+ staining Cytoplasm 92%/95% (both) NA 
KOC (IMP3) Yantiss et al 2008 25 0-3+ staining intensity* 
 
Positive/negative Cytoplasm 92%/100% (CP) NA 
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        Table 3.4: Outcome of studies evaluating candidate biomarkers in more than one study 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
KOC Toll et al 2009 21 0-3+ >75% positive cells with 3+ 
staining 
Cytoplasm 71%/100% (CP and 
benign ductal 
epithelium)  
79%/100% (CP and benign 
ductal epithelium) 
KOC (IMP3) Wachter et al 2011 45 RS 0, 1+(10% weak), 2+(10% moderate), 3+(>10% 
strong) 
≥10% positive cells with 2+ 
staining 
Cytoplasm 88%/100% (NP) 
88%/95% (CP) 
85%/98% (NP) 
85%/98% (CP) 
Maspin Maass et al 2001 27 0-3+ 1+ staining Cytoplasm NA 96%/100% (NP) 
Maspin Oh et al 2002 38  Quick Score. 0, 1(<1/100tumor cells), 2(1/100-
1/10), 3(1/10-1/3), 4(1/3-2/3), 5(>2/3) 
0-3+ 
Quick score of ≤5 Cytoplasmic and/or nuclear NA 100% sensitivity 
Maspin Lim et al 2004 72  Quick Score. 0, 1(<1/100tumor cells), 2(1/100-
1/10), 3(1/10-1/3), 4(1/3-2/3), 5(>2/3) 
0-3+ 
Quick Score ≤5 Cytoplasmic and/or nuclear NA 100%/100% 
Maspin Cao et al 2007 223 Negative (<5%), focal (5%-50%), diffuse (>50%) ≥5% positive cells Cytoplasmic and/or nuclear NA 94%/100% 
Maspin Nash et al 2007 96 0-3+ ≥5% positive cells and 2+ 
staining 
Nuclear and/or Cytoplasmic 
staining 
NA 74%/96% (CP) 
Maspin Bhardwaj et al 2007 93 Intensity=0, 1(weak), 2(strong)  
Extent= <5%, 5%-50%, >50% 
≥5% cells Cytoplasmic and Nuclear  NA 90%/67% (CP) 
Maspin Agarwal et al 2008 61 RS 
 
0, 1(faint), 2(definite), 3(intense), 4(very 
intense). 
No threshold (any staining) 
Positive/negative 
Cytoplasmic NA 88%/55% (NP) 
88%/16% (CP) 
Mesothelin Argani et al 2001 60 Focal (1-25%), Diffuse (26-100%) 
0-4 Intensity 
Positive and negative 
staining. 
 
Granular Cytoplasmic NA 100%/86% (NP) 
Mesothelin Ordonez et al 2003 14 ±<1%, +1 (1-25%), +2 (26-50%), +3 (51-75%), 
+4 (>75%) 
Positive/negative 
 
Cytoplasmic, membranous NA 86%/100% (NP) 
Mesothelin McCarthy et al 2003 30 Positive (strong, diffuse Cytoplasmic staining) 
Negative (no labelling over background) 
Positive/negative Cytoplasmic 68%/91% (non-
neoplastic cases) 
NA 
Mesothelin Hassan et al 2005 53 Negative (<1% staining), Focal (1-25%), 
extensively positive (>25%) 
0-3+ staining intensity 
≥1% cells Apical membranous and 
Cytoplasm 
NA 100%/100% (NP) 
100%/94% (CP) 
Mesothelin Jhala et al 2006 40 (RS) 
65 FNA 
0-4+ and percentage of cells >5% cells and moderate 
staining 
Cytoplasm 62%/100% (CP) 80%/90% (CP) 
Mesothelin Baruch et al 2007 28 <10%, 10%-50%, >50% 
0-3 intensity 
Positive/negative 
 
Cytoplasmic and/or 
membranous 
68%/90% (Non-
neoplastic Pancreatic 
tissue) 
NA 
Mesothelin Agarwal et al 2008 61 RS 
27 EUS-FNA 
56 Direct 
smears 
0, 1(faint), 2(definite), 3(intense), 4(very 
intense). 
No threshold (any staining) 
Positive/negative 
Cytoplasmic 68%/100% (EUS-FNA, 
Benign) 
69%/96% (Direct 
smears, Benign) 
84%/100% (NP & CP) 
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            Table 3.4: Outcome of studies evaluating candidate biomarkers in more than one study 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
Mesothelin Glass et al 2011 25 0(0%-4% cells), 1(5%-15%), 2(16%-50%), 
3(51%-100%) 
0-3+ staining intensity 
≥5% cells Cytoplasm and apical 
staining 
NA 78%/100% (CP) 
MUC1 Chhieng et al 2003 35 Any proportion of cells positive regardless of 
intensity 
Any proportion of cells 
positive regardless of 
intensity 
Membranous and 
cytoplasmic  
96%/94% (Reactive 
changes) 
NA 
MUC1 Giorgadze et al 2006 67 Any proportion of cells positive regardless of 
intensity 
Any proportion of cells 
positive regardless of 
intensity 
Membranous and 
cytoplasmic 
83%/40% (NP) 
83%/100% (CP) 
83%/0% (NP) 
83%/66% (CP) 
MUC1 Wang et al 2007 56 Negative (<5%), Positive (>5%) >5% positive cells Cytomembranous and 
cytoplasmic 
78%/75% (CP & Benign) NA 
MUC4 Swartz et al 2002 40 Focal (1-50%) 
Strong (>50%) 
Positive/negative 
 
Cytoplasm NA 89%/100% (NP) 
MUC4 Jhala et al 2006 40 (RS) 
65 FNA 
0-4+ and percentage of cells >5% cells and moderate 
staining 
Cytoplasm 91%/100% (CP) 89%/99% (CP) 
MUC4 Bhardwaj et al 2007 93 Intensity=0, 1(weak), 2(strong)  
Extent= <5%, 5%-50%, >50% 
≥5% cells Cytoplasmic and 
membranous  
NA 77%/78% (CP) 
MUC5AC Giorgadze et al 2006 67 Any proportion of cells positive regardless of 
intensity 
Any proportion of cells 
positive regardless of 
intensity 
Membranous and 
cytoplasmic 
97%/50% (CP) 100%/66% (CP) 
MUC5AC Wang et al 2007 56 Negative (<5%), Positive (>5%) >5% positive cells Membranous and 
cytoplasmic 
80%/56% (CP & Benign) NA 
p53 Lee et al 1993 71 0-3 staining intensity Positive/negative 
 
Nuclear 65%/100% (NP) 
65%/81% (CP) 
NA 
p53 Ishimaru 1996 28 Any degree of nuclear staining Positive/negative Nuclear 90%/100% (CP) NA 
p53 Stewart et al 2000 161 Nuclear staining observed at (×250) Positive/negative Nuclear 53%/100% (NP) 
53%/98% (CP) 
NA 
p53 Li et al 2002 22 One or more brown colour nuclei was 
considered positive 
Positive/negative Nuclear 59%/100% (CP) NA 
p53 Bhardwaj et al 2007 93 Intensity=0, 1(weak), 2(strong)  
Extent= <5%, 5%-50%, >50% 
≥5% cells Nuclear  NA 60%/88% (CP) 
p53 Awadallah et al 2008 15 Staining= 0, 1(very light), 2(moderate to 
strong). Proportion of cells 0% (score0), 1%-
50% (score1), >50%-100% (score2) 
Sum score= Proportion+staining (range 0-4) 
Positive/negative Nuclear 50%/80% (benign) 83% sensitivity insufficient 
data to calculate specificity 
p53 Villanacci et al 2009 24 Any degree of nuclear staining Positive/negative Nuclear 87%/78% (CP) NA 
PSCA Argani et al 2001 60 Focal (1-25%), Diffuse (26-100%) 
0-4 Intensity 
Positive and negative 
staining. 
Cytoplasmic NA 60%/98% (NP) 
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        Table 3.4: Outcome of studies evaluating candidate biomarkers in more than one study 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
PSCA McCarthy et al 2003 30 Positive (strong, diffuse Cytoplasmic staining) 
Negative (no labelling over background) 
Positive/negative Cytoplasmic 84%/91% (non-
neoplastic cases) 
NA 
PSCA Wen-bin et al 2008 
 
100 Postive/negative Positive/ negative Cytoplasm NA 80%/80% (NP) 
80%/67% (CP) 
S100A4 Rosty et al 2002 66 Focal (1-25%), Diffuse (26-100%) Positive and negative 
staining 
 
Cytoplasmic and nuclear NA 93%/100% (NP) 
93%/100% (CP) 
S100A4 Lin et al 2008 56 0 (<10%), +1 (11-25%), +2 (26-50%), +3 (50%-
75%), +4 (≥75%) 
 
>10% cells positive 
 
Nuclear OR nuclear and 
cytoplasmic was considered 
positive 
NA 73%/80% (NP) 
S100A4 Ligato et al 2008 44  0, Focal (>5%<25% cells), diffuse (>25% cells) 
0-3+ 
>5% positive cells with 1+ 
staining 
Nuclear 79%/95% (Both NP and 
CP) 
NA 
S100A6 Ohucida et al 2005 75 0, 1(<20%), 2(20%-75%), 3(>75%) 
0-3 intensity 
Final score= intensity*proportion [0, Weak(1-
3), Moderate (4-6), strong (>6) 
Positive/negative Nuclear and cytoplasmic 
staining 
NA 100%/81% (NP) 
S100A6 Lin et al 2008 56 0 (<10%), +1 (11-25%), +2 (26-50%), +3 (50%-
75%), +4 (≥75%) 
 
>10% cells positive 
 
Nuclear OR nuclear and 
cytoplasmic was considered 
positive 
NA 98%/80% (NP) 
S100P Lin et al 2008 56 0 (<10%), +1 (11-25%), +2 (26-50%), +3 (50%-
75%), +4 (≥75%) 
 
>10% of cells positive Nuclear OR nuclear and 
cytoplasmic was considered 
positive 
NA 100%/100% (NP) 
S100P Deng et al 2008 52 0, +1(<25%), +2(26-50%), +3 (51-75%), +4 
(>75%) 
0-3 staining 
 
Positive/Negative 
 
Nuclear OR nuclear and 
cytoplasmic was considered 
positive 
100%/93% (Benign or 
reactive) 
All 6 suspicious cases by 
cytology stained for 
S100P and finally 
diagnosed as 
Adenocacrcinoma 
NA 
S100P Kosarac et al 2011 14 RS 
31 EUS-FNA 
Negative (<10%), +1(10%-25%), +2(26%-75%), 
+3(>75%) 
0-3 Intensity 
≥10% positive cells with +1 
staining intensity. 
 
Nuclear OR nuclear and 
cytoplasmic was considered 
positive 
78%/88% (benign) 100%/100% (non-
neoplastic including CP) 
SMAD4 Zapata et al 2007 25 Negative, Low positive (moderate staining), 
high positive (strong intense) 
Positive/negative Nuclear 80%/100% (NP) NA 
SMAD4 Ali et al 2007 100 Negative, 1+( Low intensity positivity, 2+ (high 
intensity positivity) 
Positive/negative Nuclear 80%/100% (NP)  
Note: *NA= not available 
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Table 3.5: Immunohistochemistry details of all biomarkers progressing to meta-analysis. 
Protein Assayed Study Primary Antibody Antibody Dilution Antigen retrieval 
CEACAM6  Agarwal 2008 Santa Cruz 1:200 NA* 
CEACAM6 Strickland 2009 In house anti‐CEACAM6 Monoclonal  10 μg/ml NA 
Claudin 18   Karajawala 2008 Rabbit monoclonal, clone ZMD 395, 
Invitrogen 
1:1000 HIER, pH 6.0 
Claudin 18 Tanaka 2011 ZMD395, Zymed 1:1000 NA 
COX2  Okami 1999 Rabbit polyclonal, Immuno-Biological 
Laboratories, Co. 
5 µg/ml HIER 
COX2 Niijima 2001 Polyclonal antibodies, Santa Cruz  1:100 NA 
COX2 Maitra (a) 2002 Santa Cruz 1:100 HIER, pH 6.0 
Fascin Lu 2002 M3567, DAKO 1:50 NA 
Fascin Maitra (b) 2002  Mouse monoclonal, 55K-2, DAKO 1:500 HIER, pH 6.0 
Fascin Agarwal 2008 DAKO 1:1000 NA 
KOC Yantiss 2005 Mouse anti‐L523S/KOC antibody 2µg/ml HIER, pH 6.0 
KOC Yantiss 2008 Mouse Monoclonal, L523S, Corixa 
Corporation 
2 µg/ml HIER, pH 6.0 
KOC Ligato 2008 Monoclonal, L523S, clone 69.1, DAKO NA NA 
KOC Toll 2009 Monoclonal, KOC/L523S, clone 69.1, DAKO 1:500 HIER, pH 9.5 
KOC Wachter 2011 Mouse monoclonal, clone 69.1, DAKO 1:500 HIER, pH 6.0 
Maspin Maass 2001 Monoclonal, BD Biosciences PharMingen 1:50 HIER, pH 6.0 
Maspin Lim 2004 Monoclonal, BD Biosciences Pharmingen 1:3,000 HIER, pH 6.0 
Maspin Nash 2007 Monoclonal, clone G167‐70,  PharMingen 1:800 HIER, pH 6.1 
Maspin Cao 2007 Monoclonal, BD Biosciences Pharmingen 1:50 HIER, pH 6.0 
Maspin Bhardwaj 2007 Monoclonal, BD Biosciences Pharmingen 1:800 HIER, pH 6.1 
Maspin Agarwal 2008 Novocastra  1:20 NA 
Mesothelin Argani (a) 2001 Mouse monoclonal, clone 5B2, Novocastra 1:20 HIER, Sodium citrate 
buffer 
Mesothelin McCarthy 2003 Mouse monoclonal, clone 5B2, Novocastra 1:20 HIER, Sodium citrate 
buffer 
Mesothelin Ordonez 2003 Mouse monoclonal, clone 5B2; 
Novocastra. 
1:30 HIER, Tris‐EDTA buffer, 
pH 8.0 
Mesothelin Hassan 2005 Mouse monoclonal,  5B2 1:20 HIER, pH 6.0 
Mesothelin Jhala 2006 5B2 (MESO1), Lab Vision 1:20 HIER 
Mesothelin Baruch 2007 Novocastra 1:30 NA 
Mesothelin Agarwal 2008 NovaCastra 1:10 NA 
Mesothelin Glass 2011 Clone, 5B2 Vector 1:15 NA 
MUC1 Chhieng 2003 Clone DF3, Novocastra  1:200 HIER, pH 6.0 
MUC1 Giorgadze 2005 Mouse monoclonal, clone Ma695, 
Novocastra 
1:75 HIER, pH 6.0 
MUC1 Wang 2007 Mouse monoclonal, clone Mh1, Labvision 1:100 HIER, pH 6.0 
MUC4 Swartz 2002 Mouse monoclonal, clone 8G7 1:3,0000 HIER, pH 6.0 
MUC4 Jhala 2006 8G7, S.K.B. 1:3,000 HIER 
MUC4 Bhardwaj 2007 Zymed Laboratories 1:200 HIER, pH 6.1 
MUC5AC Giorgadze 2005 Clone CLH2, Novocastra 1:100 NA 
MUC5AC Wang 2007 Clone 45M1, Labvision 1:100 NA 
p53 Lee 1993 Polyclonal rabbit, NCL‐p53‐CMl 
Novocastra 
N/A NA 
p53 Ishimaru 1999 Mouse monoclonal, Novocastra 1:30 NA 
p53 Li 2002 The En Vision method, Shanghai Zhong Da 
Corporation 
NA NA 
P53 Stewart 2002 Mouse monoclonal, DO-7, DAKO 1:2,000 HIER, EDTA at pH 8 
P53 Bhardwaj 2007 DAKO 1:50 HIER, pH 6.1 
p53 Villanacci 2009 Mouse monoclonal, clone DO‐7, Thermo 
Scientific. 
1:50 HIER 
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Table3.5: Immunohistochemistry details of all biomarkers progressing to meta- analysis. 
Protein Assayed Study Primary Antibody Antibody Dilution Antigen retrieval 
P53 Awadallah 2008 Monoclonal, DO‐7, DAKO 1 µg/mL NA 
PSCA Argani (b) 2001 Mouse monoclonal, Clone 1G8, obtained 
from R. E. R. 
1:200 HIER, Sodium citrate 
buffer 
PSCA  McCarthy 2003 Monoclonal, clone 1G8, obtained from, 
Department Of Urology, University of 
California, Los Angeles, CA. 
1:200 HIER, Sodium citrate 
buffer 
PSCA Wen-bin 2008 
(Article in 
Chinese) 
N/A N/A N/A 
S100A4 Rosty 2002 Rabbit polyclonal, DAKO 2 µg/ml HIER, pH 6.0 
S100A4 Ligato 2008 Polyclonal, DAKO NA NA 
S100A4 Lin 2008 Rabbit polyclonal, Neo Markers 1:200 HIER, pH 6.0 
S100A6 Ohucida 2005 Mouse monoclonal, Sigma N/A NA 
S100A6 Lin 2008 Mouse monoclonal, Clone: CACY-100, 
Sigma-Aldrich 
1:1000 Proteinase K 
S100P Lin 2008 Mouse monoclonal, Clone 16, BD 
Biosciences Pharmingen 
1:100 Proteinase K 
S100P Deng 2008 Mouse monoclonal, BD Biosciences 
Pharmingen 
1:100 Proteinase K 
S100P Kosarac 2010 Monoclonal, clone 16/S100P, BD 
Biosciences Pharmingen 
1:100 NA 
SMAD4 Zapata 2007 Novacastra 1:40 HIER, pH 6.0 
SMAD4 Ali 2007 Novacastra 1:40 HIER, pH 6.0 
Note: *NA= not available 
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Table 3.6: QUADAS tool for assessing the methodological qualities of included studies. 
Note: *Reference standard is a test that correctly diagnoses the pancreatic cancer (Histopathology 
or death from pancreatic cancer). **Index tests are the IHC biomarkers. Note: Item 6 has been 
added purposefully to QUADAS tool (Both QUADAS and Cochrane database suggest adding items 
necessary for a particular question). 
No Item Description 
1 Representative 
spectrum and selection 
criteria? 
Yes, if the paper fulfils the following criteria: the selection of 
patients had been consecutive; the male to female ratio and 
the age distribution of patients; and the number of samples 
with pancreatic cancer and non-neoplastic disease reported. 
2 Acceptable reference 
standard*?  
Yes, if histopathology and/or death from pancreatic cancer was 
used as a reference standard. 
3 Partial verification 
avoided?  
Yes, if all the samples included in the paper received verification 
by either histopathology and/or death from pancreatic cancer. 
4 Differential verification 
avoided?  
Yes if the same reference standard (either histopathology OR 
death from pancreatic cancer but not both) was used for all 
samples included in the paper. 
5 Incorporation avoided?  Yes, if the reference standard was not part of the index test**. 
6 Details of index test? Yes, if the details of immunohistochemistry (Antigen retrieval 
method, Primary antibody (clone) and antibody concentration) 
have been discussed in sufficient details to allow replication of 
test. 
7 Reference standard 
results blinded?  
Yes, if the histopathology results for pancreatic cancer and non-
neoplastic tissue were interpreted without knowledge of the 
results of the index test. 
8 Index test results 
blinded?  
Yes, if the index test results were interpreted without 
knowledge of the histopathology results for pancreatic cancer 
and non- neoplastic tissue. 
9 Uninterpretable results 
reported?  
Yes, if uninterpretable or intermediate test results were 
reported. In addition, we would call it “Yes”, if there was no 
uninterpretable or intermediate test result. 
10 Withdrawals explained? Yes, if withdrawals from the study were explained or there was 
no withdrawal from the included participants. 
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Table 3.7: Outcome of studies evaluating candidate biomarkers with reasonable sensitivity and/or specificity reported in one study 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
14 3-3 σ Agarwal et al 2008 61 RS 
27 EUS-FNA 
56 Direct 
smears 
0, 1(faint), 2(definite), 3(intense), 4(very 
intense). 
No threshold (any staining) 
Positive/negative 
membranous 100%/80% (EUS-FNA, 
Benign) 
96%/78% (Direct 
smears, Benign) 
88%/100% (NP & CP) 
Annexin A8 Karanjawala et al 2008 154 Percentage of cells positive 
Focal staining 
Diffuse= >80% cells with 2 or 3, staining 0-3 
Only cores having ≥30% of 
carcinoma were scored. 
Focal or diffuse positive. 
Nuclear, Cytoplasmic NA 98%/88% (NP & CP) 
Bcl2 Sun et al 2002 150 0 (<10%), Positive (≥10%) ≥10% of cells positive Cytomembrane and /or 
cytoplasmic 
NA 72%/95% (NP) 
72%/90% (CP) 
B7-H4 Awadallah et al 2008 25 Staining= 0, 1(very light), 2(moderate to 
strong). Proportion of cells 0% (score0), 1%-
50% (score1), >50%-100% (score2) 
Sum score= Proportion+staining (range 0-4) 
Positive/negative Membranous/ cytoplasmic 90%/80% (CP) 92% sensitivity, insufficient 
data to calculate specificity 
CK 19 Zapata et al 2007 25 Negative, Low positive (moderate staining), 
high positive (strong intense) 
Positive/negative Cytoplasm 100%/100% (NP) NA 
Claudin 4 Wen-bin et al 2008 100 Positive/negative Positive/ negative Not Available  88%/70% (NP) 
88%/67% (CP) 
CXCL16 Wente et al 2008 31 0-3+ staining Positive/negative Cytomembranous  85%/45% (NP) 
85%/0% (CP) 
Fas-L Boltze et al 2002 126 0-3+ staining intensity 
0, 1(<10%cells), 2(10%-50%cells), 3(51%-
80%cells), 4(>80%cells) 
Immunoreactive score (0 to 12) = 
Intensity×Proportion of cells 
. 
Cut-off= Score>2 
Cytoplasm NA 100%/100% (NP) 
100%/90% (CP) 
HMGI(Y) Abe et al 2000 21 1000 cells in 3 random fields. 
 
Positivity= ≥20% of cells Nuclear NA 100%/100% (NP) 
100%/100% (CP) 
 
HSP 47 Maitra 2002 57 Focal (1-25%), Diffuse (26-100%) 
0-4 Intensity 
Positive and negative 
staining. 
 
PDAC desmoplastic stroma 
vs. stroma of non-neoplastic 
pancreatic parenchyma. 
NA 100%/88% (NP) 
ICAM1 Shimoyama et al 1997 19 0-3 staining 
0, 1(<33%), 2(34%-66%), 3(<67%) 
Positive/negative 
 
Cytoplasm NA* 100%/100% (NP) 
PAP Xie et al 2003 87 0(<10%), 1(10%-30%), 2(30%-50%), 3(>50%). Cut-Off= 2 Cytoplasm NA 79%/100% (NP) 
79%/81% (CP) 
RCAS 1 Akashi et al 2003 25 <5%= negative, >5%=positive Cut-Off= >5% cells positive Cytoplasm NA 100%/60% (CP) 
XIAP Kosarac et al 2011 14 RS 
31 EUS-FNA 
0-3 Intensity 
Negative (<10%), +1(10%-25%), +2(26%-75%), 
+3(>75%) 
≥10% positive cells with +1 
intensity, 
 
Granular Cytoplasmic 83%/50% (benign) 100%/100% (non-
neoplastic including CP) 
Note: *NA= not applicable  
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Table 3.8: Outcome of studies evaluating negative biomarkers for PDAC (biomarkers expressed in normal ducts but not in PDAC)  
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
Amylase La Rosa et al 2009 14 Weak (1+) & <50% of tumour cells; intense 
(3+) & diffuse reaction; moderate (2+) 
showing features between scores 1+ and 3+. 
Positive/Negative N/A  0%/no data to calculate 
specificity but positive in 
normal acini. 
BCL10 La Rosa et al 2009 14 Weak (1+) & <50% of tumour cells; intense 
(3+) & diffuse reaction; moderate (2+) 
showing features between scores 1+ and 3+. 
Positive/Negative Granular Cytoplasm  0%/ no data to calculate 
specificity but authors 
state and diagram shows 
positivity of acinar cells of 
normal 
pancrease, while ductal 
and islet cells were 
negative. 
BCL10 Hosoda et al 2013 23 (RS), 18 
(EUS-FNA) 
4-tiered scoring system: negative; 1+, faint 
and focal staining (<50% of the total area); 
2+, faint and diffuse staining (>50% of the 
total area) or strong but focal staining (< 
50% of the total area); and 3+, strong and 
diffuse staining (>50% of the total area).  
 
Tumour cells showing 
moderate or greater 
intensity in 50% of the area 
(2+, or 3+). 
Granular Cytoplasm 0%/ no data to calculate 
specificity 
0%/ no data to calculate 
specificity but authors 
state and diagram shows 
positivity of acinar cells of 
normal 
pancrease, while ductal 
and islet cells were 
negative. 
CDX2 Hosoda et al 2010 25 0: 0–5%, faint staining; 1+: 6–75%, variable 
staining intensity; and 2+: 76–100%, mostly 
strong staining. 
2+ Nuclear 4% /no data to calculate 
specificity but authors 
state and diagram shows 
the expression of CDX2 
in normal cells 
0% /no data to calculate 
specificity but authors 
state and diagram shows 
the expression of CDX2 in 
normal ducts 
CEH (carboxyl 
ester 
hydrolase) 
La Rosa et al 2009 14 Weak (1+) & <50% of tumour cells; intense 
(3+) & diffuse reaction; moderate (2+) 
showing features between scores 1+ and 3+. 
Positive/Negative N/A  0%/no data to calculate 
specificity but positive in 
normal acini. 
 
 
Chromogranin 
A 
Hosoda et al 2010 25 0: 0–5%, faint staining; 1+: 6–75%, variable 
staining intensity; and 2+: 76–100%, mostly 
strong staining. 
2+ Cytoplasmic 4%/ no data to calculate 
specificity  
0% /no data to calculate 
specificity  
HPK1  Wang et al 2009 79 Negative= No or only weak focal staining 
(<5% of cells); Positive= Strong staining (≥5% 
of the cells. 
Strong cytoplasmic staining 
for HPK1 (≥5% of the cells) 
Cytoplasmic  4%/0%  
(PDAC vs Benign 
pancreatic tissue) 
Lipase La Rosa et al 2009 14 Weak (1+) & <50% of tumour cells; intense 
(3+) & diffuse reaction; moderate (2+) 
showing features between scores 1+ and 3+. 
Positive/Negative N/A  0%/no data to calculate 
specificity but positive in 
normal acini. 
MUC2 Chu et al 2005 46 Proportion of positive cells >5% Positive cells Cytoplasmic and 
membranous 
 2% /no data to calculate 
specificity. 
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          Table 3.8: Outcome of studies evaluating negative biomarkers for PDAC (biomarkers expressed in normal ducts but not in PDAC) 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
Synaptophysin Hosoda et al 2010 25 0: 0–5%, faint staining; 1+: 6–75%, variable 
staining intensity; and 2+: 76–100%, mostly 
strong staining. 
2+ NA* 0%/no data to calculate 
specificity  
0% /no data to calculate 
specificity  
Trypsin La Rosa et al 2009 14 Weak (1+) & <50% of tumour cells; intense 
(3+) & diffuse reaction; moderate (2+) 
showing features between scores 1+ and 3+. 
Positive/Negative Cytoplasm  0%/no data to calculate 
specificity but positive in 
normal acini. 
von Hippel-
Lindau gene 
product (pVHL) 
Lin et al 2008 56 0 (<10%), +1 (11-25%), +2 (26-50%), +3 
(50%-75%), +4 (≥75%) 
 
>10% positive cells Granular 
cytoplasmic/membranous 
staining 
 0% /0%  
Note: *NA= not available 
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Table 3.9: Outcome of studies evaluating biomarkers with low sensitivity and/or specificity 
Markers Reference Sample Size Scoring of tissue Threshold for positivity Staining pattern  Cytology 
Sensitivity/ Specificity 
Resection Specimens 
Sensitivity/ Specificity 
CA19-9 Satomura et al 1991 80 (-); <1/3 epithelial cells stained, (+); >1/3 but 
<2/3 of the epithelial cells stained, (+ +); 
>2/3 epithelial cells stained, (+ + +). 
<1/3 epithelial cells stained, 
(+) 
Apical and cytoplasmic   83% /24% (NP) 
83% /24% (CP) 
 
CA19-9 Haglund et al 1986 112 Positive/negative Positive/negative Apical and cytoplasmic  80% / 21% (NP) 
80% / 4% (CP) 
 
 
CA-50 Satomura 1991 80 (-); <1/3 epithelial cells stained, (+); >1/3 but 
<2/3 of the epithelial cells stained, (+ +); 
>2/3 epithelial cells stained, (+ + +). 
<1/3 epithelial cells stained, 
(+) 
Apical and cytoplasmic  98%/ 8% (NP) 
98%/ 4% (CP) 
 
CD10 Erhuma et al 2007 30 Proportion of positive cells. >25% stained cells. Membranous and 
cytoplasmic 
 25% /50% (CP) 
CDX2 Chu et al 2005 46 Proportion of positive cells >5% Positive cells Cytoplasmic and 
membranous 
 21% / no data to calculate 
specificity. 
CK7  Hosoda et al 2010 25 0: 0–5%, faint staining; 1+: 6–75%, variable 
staining intensity; and 2+: 76–100%, mostly 
strong staining. 
2+ Cytoplasmic 92%/no data to calculate 
specificity but author 
state and diagram shows 
the expression of CK7 in 
normal cells 
88% /no data to calculate 
specificity but authors 
state and diagram shows 
the expression of CK7 in 
normal ducts 
CK7 Chu et al 2005 46 Proportion of positive cells. >5% Positive cells Cytoplasmic and 
membranous 
 98%/no data to calculate 
specificity. 
CK 17 Chu et al 2005 46 Proportion of positive cells. >5% Positive cells Cytoplasmic and 
membranous 
 83% / no data to calculate 
specificity. 
CK20 Chu et al 2005 46 Proportion of positive cells. >5% Positive cells Cytoplasmic and 
membranous 
 46% / no data to calculate 
specificity. 
MUC6 Giorgadze et al 2006 67 Any proportion of cells positive regardless of 
intensity 
Any proportion of cells 
positive regardless of 
intensity 
Membranous and 
cytoplasmic 
35%/0% (NP) 
35%/0% (CP) 
37%/60% (NP) 
37%/100% (CP) 
Note: *NA= not available 
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Figure 3.1: Prisma flow chart of selection of papers for systematic review and meta-
analysis. 
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Figure 3.2: Coupled Forest plots of sensitivity and specificity of included studies for various 
markers in resection specimens arranged by biomarkers. 
Figure Legend:  The squares represent the sensitivity and specificity for a given candidate 
biomarker, the black line its confidence interval. Studies are grouped by the type of biomarkers. 
Cut-Off values based on proportion of positive cells (1= 1%-9%, 2= 10%-24%, 3= 25%-49%, 4= 
≥50%) for biomarkers are also shown in the Forest plot. Some papers reported sensitivity & 
specificity data for more than one biomarker and/or for more than one scenario and they were 
included more than once in Forest plot.  
Abbreviations: PDAC, Pancreatic ductal adenocarcinoma; NP, Normal Pancreatic duct; CP, 
Chronic Pancreatitis; TP, true positive; FP, false positive; FN,  false negative; TN, true negative. 
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Figure 3.3: Combined SROC curves of various biomarkers studied in resection specimens. 
Figure Legend:  Each SROC curve consists of a summary line of diagnostic accuracy resulting 
from various studies for a biomarker and individual study points around the summary line. In 
addition, SROC curves from various biomarkers have been compared in a combined SROC curve 
for each scenario  A) PDAC vs normal pancreas- five biomarkers (maspin, mesothelin, KOC, fascin 
and COX2) each reported in at least 3 studies B) PDAC vs normal pancreas- six biomarkers 
(S100P, claudin18, S100A6, S100A4, PSCA and CEACAM6) each reported in 2 studies C) PDAC 
vs chronic pancreatitis-three biomarkers (KOC, mesothelin and maspin) each reported in at least 3 
studies D) PDAC vs chronic pancreatitis-One biomarker (MUC4) reported in 2 studies. 
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Figure 3.4: Coupled Forest plots of sensitivity and specificity of included studies for 
various markers in cytology specimens arranged by biomarkers.  
Figure Legend:  The squares represent the sensitivity and specificity for a given candidate 
biomarker, the black line its confidence interval. Studies are grouped by the type of biomarkers. 
Cut-Off values based on proportion of positive cells (1= 1%-9%, 2= 10%-24%, 3= 25%-49%, 4= 
≥50%) for biomarkers are also shown in the Forest plot. Some papers reported sensitivity & 
specificity data for more than one biomarker and/or for more than one scenario and they were 
included more than once in Forest plot.  
Abbreviations: PDAC, Pancreatic ductal adenocarcinoma; NP, Normal Pancreatic duct; CP, 
Chronic Pancreatitis; TP, true positive; FP, false positive; FN, false negative; TN, true negative. 
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Figure 3.5: Combined SROC curves of various biomarkers studied in cytology specimens. 
Figure legend: Each SROC curve consists of a summary line of diagnostic accuracy resulting from 
various studies for a biomarker and individual study points around the summary line. In addition, 
SROC curves from various biomarkers have been compared in a combined SROC curve for each 
scenario A) PDAC vs normal pancreas-Two biomarkers (KOC and SMAD4) each reported in 2 
studies B) PDAC vs chronic pancreatitis-Four biomarkers (KOC, mesothelin, MUC1 and p53) each 
reported in at least 3 studies C) PDAC vs chronic pancreatitis-Two biomarkers (S100P and 
MUC5AC) each reported in 2 studies. 
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Figure 3.6: Methodological quality graph: review authors' judgements about each 
methodological quality item presented as percentages across all included studies. 
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Figure 3.7: Methodological quality summary: review authors' judgements about each 
methodological quality item for each included study. 
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4 Expression of KOC, S100P, mesothelin, and 
MUC1 in pancreatico-biliary adenocarcinomas: 
development and utility of a potential diagnostic 
immunohistochemistry panel.  
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4.1 Chapter Summary 
Pancreatico-biliary adenocarcinomas (PBA) have a poor prognosis. Diagnosis is 
usually achieved by imaging and/or endoscopy with confirmatory cytology. 
Cytological interpretation can be difficult especially in the setting of chronic 
pancreatitis/cholangitis. Immunohistochemistry (IHC) biomarkers could act as an 
adjunct to cytology to improve the diagnosis. Thus, we performed a meta-
analysis of diagnostic IHC biomarkers for PDAC and selected KOC, S100P, 
mesothelin and MUC1 for further validation in PBA resection specimens. 
Tissue microarrays (TMAs) containing tumour and normal cores in a ratio of 3:2, 
from 99 surgically resected PBA patients, were used. IHC was performed on the 
TMAs using an automated platform using antibodies against KOC, S100P, 
mesothelin and MUC1. Tissue cores were scored for staining intensity and the 
proportion of tissue stained using a Histoscore method (range, 0–300). Sensitivity 
and specificity for individual biomarkers, as well as biomarker panels, were 
determined with different cut-offs for positivity and compared by summary 
receiver operating characteristic (ROC) curves. 
The expression of all four biomarkers was high in PBA versus normal ducts, with 
a mean Histoscore of 150 vs. 0.4 for KOC, 165 vs. 0.3 for S100P, 115 vs. 0.5 for 
mesothelin and 200 vs. 14 for MUC1 (p<0.0001 for all comparisons). Five cut-offs 
were carefully chosen for sensitivity/specificity analysis. Four of these cut-offs, 
namely 5%, 10% or 20% positive cells and Histoscore 20 were identified using ROC 
curve analysis and the fifth cut-off was moderate-strong staining intensity. Using 
20% positive cells as a cut-off achieved higher sensitivity/specificity values: KOC 
84%/100%; S100P 83%/100%; mesothelin 88%/92%; and MUC1 89%/63%. Analysis 
of a panel of KOC, S100P and mesothelin achieved 100% sensitivity and 99% 
specificity if at least 2 biomarkers were positive at the 10% cut-off; and 100% 
sensitivity and specificity at the 20% cut-off. 
We examined biomarkers using various cut-offs to identify a suitable panel and 
cut-off based on diagnostic accuracy. A biomarker panel of KOC, S100P and 
mesothelin with at least 2 biomarkers positive was found to be a good panel with 
both 10% and 20% cut-offs in resection specimens from patients with PBA. 
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4.2 Introduction 
Adenocarcinomas of the head of the pancreas and extra-hepatic 
cholangiocarcinomas (CCC) present similarly most often with jaundice, pain or 
weight loss (286). Morphological similarities in addition to generally poor 
prognosis for both diseases enable PDAC to be grouped with extra-hepatic CCC to 
form so-called pancreatico-biliary adenocarcinomas (PBA). 
Diagnosis of PBA relies upon a combination of radiological and cytology or 
pathology findings (22, 287-289). Confirmatory tissue diagnosis is necessary 
before chemotherapy or radiotherapy treatment, however a biopsy specimen is 
not always required for resection when the suspicion of cancer is high; as 
generally, the resection will provide therapeutic benefit, and substantially 
delaying surgery to confirm a diagnosis may deny potentially curative treatment 
(28, 58, 59, 61, 113, 288). Cytological samples obtained at EUS-FNA and ERCP 
with brushing requires the distinction of malignant PB epithelial cells from 
reactive pancreatic and bile duct cells as well as other gastrointestinal 
contaminants. This task requires tremendous expertise and can be difficult 
(102).  
We performed a meta-analysis of potential PDAC IHC diagnostic biomarkers (290) 
aiming to generate a list of biomarkers assessed in either surgical or cytology 
specimens, where PDAC was compared with normal pancreas and/or chronic 
pancreatitis. Meta-analytical results showed KOC, S100P, mesothelin and MUC1 
to be high-ranking candidates. These biomarkers have not entered into routine 
clinical practice partly because they were investigated in separate studies with 
relatively small sample sizes and without uniform and clinically appropriate 
thresholds for positivity.  
We sought to investigate the utility of these four candidate biomarkers in the 
characterisation of PBA, including both PDAC and CCC. CCC has been included 
because it often enters the clinical and pathological differential diagnosis; and 
its positive biomarkers are generally shared with PDAC (237, 276, 291, 292).  
The following is a brief description of the biomarkers investigated here; found in 
previous chapter. KOC (K homology domain containing protein overexpressed in 
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cancer) is a promising biomarker investigated in several different neoplasms. It 
is also called IMP3 (Insulin like growth factor mRNA binding protein). It is 
expressed in the developing epithelium and placenta during embryogenesis but 
the expression is limited in the adult tissues (293). IMP3 has been shown to 
promote proliferation in leukemia cells, pointing to its role in regulating cellular 
proliferation (294). It is overexpressed in different malignancies including 
pancreatic, lung, breast, colon and endometrial carcinomas (180, 295-298). 
S100P first identified from placenta, belongs to the S100 family of calcium 
binding proteins (299). S100P expression is associated with cell proliferation, 
survival and invasiveness (300). S100P is overexpressed in pancreatic, lung, 
breast, gastric and colorectal cancer (159, 177, 301). 
Mesothelin is a glycoprotein that is attached to the cell membrane by a 
glycosylphosphatidyl-inositol anchor. It is a differentiation antigen and in normal 
human tissues is expressed only in mesothelial cells lining pericardium, pleura 
and peritoneum (302). The precise biological function of mesothelin is largely 
unknown but it may play an important role in cellular proliferation and tumour 
progression (303). Mesothelin is overexpressed in several malignancies including 
mesotheliomas, pancreatic, lung and ovarian carcinoma (236, 238, 304). 
MUC 1 (Mucin 1; also known as PEM) is a transmembrane glycoprotein with a 
heavily glycosylated extracellular domain. It is normally expressed in the 
epithelial cells of breast, esophagus, stomach, duodenum, pancreas, uterus and 
lung tissue (305). Tumour associated MUC1 is different from MUC1 expressed in 
normal cells. MUC1 is aberrantly glycosylated and overexpressed in a range of 
epithelial tumours. MUC1 mediates the production of growth factors that 
promote cellular proliferation and survival (306). MUC1 is overexpressed in a 
variety of tumours including pancreatic, ampullary, gastric, esophageal and 
breast (170, 176, 307-310). 
4.2.1 Aims  
Having identified better biomarkers from the meta-analysis, the aims of this 
chapter were as follows: to validate biomarkers by IHC and to assess the 
diagnostic accuracy (sensitivity and specificity) of identified biomarkers singly 
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and in panels in a local pancreatico-biliary resection cohort; to investigate and 
find appropriate diagnostic cut-offs resulting in suitable diagnostic sensitivity 
and specificity for the categorisation of PBA versus normal. These aims should 
help us in determining a clinically useful diagnostic biomarker or panel of 
biomarkers with a robust cut-off for positivity that could potentially be taken 
forward for validation in PBA cytology samples. 
KOC, mesothelin, S100P and MUC1 were investigated in one cohort (SD TMAs) 
and the results are presented in this chapter. Due to loss of tissue cores in SD 
TMAs, maspin was investigated in another cohort (NBJ TMAs) and the results are 
presented in next chapter (chapter 5). However, both cohorts originate from the 
same surgical and pathology departments. 
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4.3 Results 
IHC was performed on an automated platform for KOC, mesothelin, S100P and 
MUC1. Three tissue microarrays (TMAs) from patients with PBA were used for 
IHC. The TMAs are composed of both tumour and normal cores in a ratio of 3:2. 
After staining, TMAs were scanned and uploaded in a digital microscope (Distiller 
2.2) for scoring the immunostaining. The scoring was performed manually using a 
scoring sheet and in a blinded fashion to the final diagnosis (tumour or normal). 
All scoring of immunostaining was performed by the author (AA) and a consensus 
was reached on difficult cores with a consultant histopathologist (KAO).  
A semiquantitative “Histoscore” with a range (0-300) taking into account both 
staining intensity and the proportion of positive cells was used for evaluating 
protein expression. Various cut-offs were then established from Histoscores and 
further analysis of sensitivity and specificity was then performed. 
The results are subdivided into four main categories: expression of biomarkers in 
tumour and normal tissue using “positivity” (proportion of positive cells) and 
“Histoscore” (both intensity and proportion); comparing the expression of 
biomarkers in PDAC and CCC; establishing cut-offs from receiver operating 
characteristics (ROC) curves; and calculating sensitivity and specificity based on 
various cut-offs singly and as a panel of biomarkers. I hypothesised that by 
combining various biomarkers in panels we would be able to determine the 
combination of biomarkers that would deliver the best diagnostic sensitivity and 
specificity. 
4.3.1 Expression of all biomarkers was epithelial and was higher 
in tumour than normal tissue 
For each marker assessed in the PB TMAs, IHC staining was seen only in epithelial 
cells.  As expected, KOC expression was observed in the cytoplasm; S100P was 
expressed in the cytoplasm and nucleus, while mesothelin and MUC1 expression 
was cytoplasmic and membranous (Figure 4.1). In general, moderate to strong 
intensity of staining for KOC, mesothelin, S100P and MUC1 in PBA was observed. 
Moreover, for all four biomarkers, significantly higher expression in tumour 
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versus normal tissue (non-neoplastic ducts or pancreatic acinar tissue) was 
observed as expected (Table 4.1, p<0.0001, Independent sample t test).  
4.3.2 The percentage positivity in tumour is similar for all 
biomarkers but Histoscores show variation in expression 
levels 
When scored simply as the percentage of positive staining cells, similar results 
for all four biomarkers in tumour tissue were observed. As shown in Table 4.1 
and Figure 4.2, the mean percentage of positive carcinoma cells in tumour cores 
was 74% for KOC, 75% for S100P, 73% for mesothelin and 75% for MUC1. It was 
important to quantify not only the extent of biomarker expression, but also the 
level of expression. By employing the Histoscore scoring method, which takes 
into account both the staining intensity and the extent of expression across the 
tissue, we were able to perform a more comprehensive analysis of our 
biomarkers. Utilizing this method revealed variance of expression of the 
different biomarkers. As shown in Table 4.1 and Figure 4.3, the mean tumour 
Histoscore for MUC1 was 193, while for S100P, KOC and mesothelin, the mean 
tumour Histoscores were 165, 150 and 115 respectively. 
A biomarker highly expressed in tumour tissue is a better candidate for 
diagnostic purposes as it achieves better sensitivity values especially in samples 
with less tissue such as cytology samples. All four biomarkers investigated in this 
project are highly expressed in adenocarcinoma and thus they are better 
diagnostic candidates. Next, I assessed the expression of biomarkers in normal 
ducts and pancreatic acini to evaluate biomarker specificity. 
4.3.3 Expression of all biomarkers in normal tissue was very low 
except MUC1 
Although one biomarker, MUC1, was expressed in normal ducts as evidenced by 
the mean percentage positivity of 18% of normal cells in normal duct cores, the 
expression of the other three biomarkers was very low in normal pancreatico-
biliary ducts (Table 4.1, Figure 4.2 & 4.3). Thus, in a mixed population of 
tumour and normal cells, only positive staining would need to be taken into 
account for diagnostic purposes, as positivity is essentially associated only with 
tumour cells. Furthermore, there were no significant differences in biomarker 
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expression between normal ducts only and normal ducts and acini together 
(Table 4.2). Again this means that in a mixed population of tumour and normal 
cells, only positive staining needs to be taken into account and is essentially 
associated only with tumour cells. Thus, IHC staining using these markers could 
greatly facilitate interpretation of cytology samples. The cytology samples from 
patients with PDAC are composed of adenocarcinoma cells, normal ductal and 
acinar epithelial cells and gastro-intestinal contaminants amongst other 
inflammatory and degenerating cells. 
A biomarker with very low expression in normal tissue is a better candidate for 
diagnostic purposes due to high specificity and not classifying the benign disease 
process as malignant. Thus KOC, mesothelin and S100P are more specific 
candidates for PBA than MUC1 for diagnostic purposes. The expression of all 
three biomarkers is limited to adenocarcinoma cells with very low expression in 
benign tissue. These biomarkers might therefore have optimum diagnostic 
sensitivity and specificity. I next analysed the expression of these biomarkers in 
PDAC compared to CCC and then calculated the sensitivity and specificity of 
biomarkers. 
4.3.4 Expression of all biomarkers was similar in PDAC and CCC 
Biomarkers expression was also assessed in PDAC compared to CCC. Generally, 
the expression of all four biomarkers is comparable between PDAC and CCC and 
this is supported by the lack of any statistically significant difference in the 
mean expression of biomarkers between these two tumour types (p>0.05, 
independent sample t test). The mean positivity in PDAC compared to CCC for 
KOC, S100P, mesothelin and MUC1 is 74% vs. 60%, 75% vs. 80%, 72% vs. 75% and 
76% vs. 72% respectively.  In addition, the mean Histoscore in PDAC compared to 
CCC for KOC, S100P, mesothelin and MUC1 is 155 vs. 131, 160 vs. 180, 120 vs. 
135 and 195 vs. 198 respectively (Table 4.3).  
Therefore, for sensitivity and specificity analyses PDAC and CCC were grouped as 
pancreatico-biliary adenocarcinomas (PBA). Next I assessed the sensitivity and 
specificity of biomarkers using various cut-offs calculated with the help of 
receiver operating characteristics (ROC) curve analyses. 
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4.3.5 Cut-offs were established using ROC curve analysis 
The sensitivity and specificity of these four biomarkers were evaluated using five 
cut-offs (thresholds) for positivity as follows: 5% positive cells of any staining 
intensity (5% cut-off); 10% positive cells of any staining intensity (10% cut-off); 
20% positive cells of any staining intensity (20% cut-off); moderate or strong 
staining of any cells (+2/+3 cut-off); and Histoscore equal to and more than 20 
(HS20). Three of these cut-offs were based on percentage of positive cells and 
identified by ROC curve analysis. The sensitivity of each biomarker was plotted 
against (1 − specificity), and ROC curves with coordinates were generated for all 
four biomarkers. The area under the curve was 0.93 (0.88-0.97, 95% CI) for KOC, 
0.92 (0.85-0.99, 95% CI) for S100P, 0.95 (0.92-0.99, 95% CI) for mesothelin, and 
0.87 (0.81-0.93, 95% CI) for MUC1.  
Based on the percentage of positive cells in the tumour compared with normal 
cores, ROC curve analysis allowed us to assess potential cut-offs, from 5% 
positive cells to 95% positive cells, with their corresponding sensitivity and 
specificity values for all four biomarkers (Table 4.4, Figure 4.4). Three suitable 
cut-offs; 5%, 10% or 20% of positive cells of any staining intensity, were selected 
based on their sensitivity and specificity values. The fourth cut-off was based on 
moderate to strong staining intensity (+2/+3 staining) in any of the cells. This 
was selected as moderate to strong staining was expected to be easily 
interpreted by pathologists. Interestingly, cases with +2/+3 staining for all four 
biomarkers have more than 20% cells positive for each of the four biomarkers. 
Indeed patients with +2/+3 staining are represented only 5 cases with less than 
50% of cells positive for MUC1, 2 cases in which KOC was expressed in fewer than 
50% of cells, and only 1 case each for mesothelin and S100P staining with less 
than 50% positivity. The fifth cut-off was based on Histoscore value of 20 (HS20), 
and was determined from ROC curve analysis (Figure 4.5). 
4.3.6 KOC, S100P and mesothelin were good candidate 
biomarkers based on sensitivity and specificity values 
There are two approaches to utilising cut-offs to calculate sensitivity and 
specificity values. One is to score the biomarker expression as a continuous 
variable in tumour and normal tissue for example each patient receive a 
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Histoscore (range, 0-300) and percentage positivity (0%-100%). Then identify 
appropriate cut-offs from the scoring results using ROC curves that achieve 
optimum diagnostic sensitivity and specificity for the biomarker. The other is to 
select cut-off(s) at the start of scoring the tissue for example selecting 10% 
positive cells as cut-off, then ask the scorer to categorise the tissue as a binary 
variable i.e. positive or negative for staining based on 10% positive cells. The 
former approach to cut-off identification was used for all subsequent sensitivity 
and specificity analysis in this chapter and chapter 5. The latter approach of cut-
offs was used in chapter 6 to validate the cut-offs identified in the current 
chapter for observer agreement. As an example, a 10% cut-off for PDAC would 
mean the presence of at least 10% positively stained cells for a biomarker in the 
ductal epithelium. Thus a tissue with more than 10% positive cells in ductal 
epithelium will be categorised as tumour based on biomarker staining. On the 
contrary, staining in less than 10% positive cells in ductal epithelium will be 
categorised as being benign or a normal condition. 
The sensitivities and specificities of all four biomarkers were calculated using 
the five cut-offs namely 5%, 10%, 20%, +2/+3 and HS20. KOC expression appears 
to show reasonably high sensitivity and specificity for all cut-offs except for the 
cut-off based on +2/+3 staining, which resulted in low sensitivity of only 67%. 
The 20% cut-off achieves marginally better sensitivity (84%) and specificity 
(100%) values compared with other cut-offs for KOC (Figure 4.6A). S100P appears 
to have similar sensitivity and specificity values for all five cut-offs with the 20% 
cut-off again achieving better combination of specificity and sensitivity, with 
values of 83% sensitivity and 100% specificity (Figure 4.6B). Applying the five 
cuts-offs to the analysis of mesothelin expression resulted in significantly 
different sensitivity and specificity values, however, the best combination was 
again achieved using the 20% cut-off, with 88% sensitivity and 92% specificity 
(Figure 4.6C). Although the sensitivity of MUC1 is high for all cut-offs, its 
specificity is too low with a range of 18%-63% for various cut-offs (Figure 4.6D). 
Thus MUC1 might not be a good diagnostic candidate. 
In summary KOC, meosthelin and S100P achieved reasonable combinations of 
sensitivity and specificity due to their high expression in tumour tissue but very 
low expression in normal tissue. The sensitivity of MUC1 is high due to 
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overexpression in tumour but its specificity is low and hence it is not a suitable 
candidate for diagnostic purposes comparing PBA with benign tissue. KOC, 
mesothelin and S100P are highly specific biomarkers but their sensitivity of 
detecting malignancy is not perfect. Thus as a single candidate biomarker they 
might miss malignancy and could potentially lead to false negative diagnosis. 
One way of improving the diagnostic sensitivity is to use panel of biomarkers. 
Hence in the next section I will present panels of biomarkers to determine a 
highly sensitive and specific panel for future validation. 
4.3.7 A biomarker panel of KOC, S100P and mesothelin with at 
least 2 biomarkers positive was found to be a good working 
panel 
Due to the biological variability between individual tumours it is unlikely that 
one biomarker will stain all tumours. A panel approach using biomarker 
combinations can thus be an adequate diagnostic solution. I next wanted to 
assess the sensitivity and specificity achieved using panels of biomarkers. The 
10% and 20% cut-offs were selected for this investigation. These two cut-offs 
achieve good combination of sensitivity and specificity in the single biomarker 
analysis as shown in the previous section (section 4.3.6 and Figure 4.6).  
The sensitivity and specificity was assessed when one biomarker in a panel is 
positive. For example for a 10% cut-off, a positivity of 10% epithelial cells for 
one or more biomarker in a panel is sufficient to categorise the patient into 
tumour category. Using this approach four panels of biomarkers were tested as 
shown in Table 4.5. These panels were: a panel comprising all four biomarkers; a 
panel of three biomarkers (KOC, S100P and mesothelin); and two panels of two 
biomarkers (KOC and mesothelin, KOC and S100P). A panel of KOC and S100P 
achieved better combinations of sensitivity/specificity values of 98%/96% for the 
10% cut-off and 99%/99% for the 20% cut-off. In addition, these panels were 
compared by combined SROC curve, using both the 10% cut-off (Figure 4.7A) and 
20% cut-offs (Figure 4.7B). The combined SROC curve showed that a panel of 
KOC and S100P is superior to the other panels for both 10% and 20% cut-offs.  
Lastly, one biomarker panel comprising KOC, S100P and mesothelin was tested 
for sensitivity and specificity when at least two biomarkers in the panel are 
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positive. For example for a 10% cut-off, a positivity of 10% epithelial cells for 
two or more biomarkers in a panel will be sufficient to categorise the patient 
into tumour category. Analysis of this panel achieved 100% sensitivity and 99% 
specificity for 10% cut-off; and 100% sensitivity and specificity for 20% cut-off 
(Table 4.5). Taken together, our results show that a panel of KOC, mesothelin 
and S100P could be used to improve the diagnosis of PBA in difficult to diagnose 
cases. 
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4.4 Discussion: 
Four potentially diagnostic biomarkers, KOC, S100P, mesothelin and MUC1, 
were investigated in a relatively large cohort of PB patients (n=99). The 
expression levels of KOC, S100P and mesothelin were high in tumour tissue 
compared with normal tissue. The diagnostic accuracy (sensitivity and 
specificity) of KOC and S100P individually was greater than that of mesothelin 
and MUC1. A panel of KOC, S100P and mesothelin with at least two biomarkers 
positive achieved optimal diagnostic accuracy in the differentiation of 
adenocarcinoma from normal tissue. 
IHC biomarkers have been investigated to improve the diagnosis of PBA but 
none is yet routinely used. They have been investigated in both the surgical 
and cytological cohorts for potentially improving the diagnosis of PBA (159, 217, 
233, 234, 237, 240, 253). There are six significant reasons delaying the clinical 
translation of diagnostic biomarkers in PBA and probably in other cancers 
(outlined in detail in chapter 1). These reasons and our approach to address 
them are outlined below.  
First, a plethora of research exists on diagnostic IHC biomarkers coming from 
the bench assessed in pilot studies. There are many excellent papers but fewer 
validation studies for biomarkers that have shown promising results. Clearly, 
validation is important for future clinical application. Therefore, we performed 
a meta-analysis on diagnostic IHC biomarkers for PDAC (290), to review, quantify 
and assess the performance of already existing biomarkers and to try and 
identify superior candidate biomarkers. 
The biomarkers derived from the meta-analysis in PDAC were applied in our 
study to both PDAC and CCC samples. Separate meta-analysis was not performed 
for CCC, because there are relatively few published papers on biomarkers in CCC 
(approximately 20-fold fewer than for PDAC; PubMed search in June 2014, 
unpublished data).  However, those papers which are available for CCC suggest 
that the biomarker expression profile is similar to PDAC.  To our knowledge, all 
of the known positive biomarkers for PDAC (versus corresponding normal tissue), 
including MUC1, P53, CK17, mesothelin, fascin, MUC4, 14-3-3σ and prostate stem 
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cell antigen, show similar IHC expression in CCC (versus corresponding normal 
tissue) (237, 276, 291, 292). 
For these reasons, we focused on PDAC for the identification of potential 
diagnostic biomarkers then tested the resulting candidates in TMAs containing 
tissue from both PDAC and CCC using IHC. From our meta-analysis, we selected 
KOC (217, 240, 241, 253), S100P (159, 166, 177), mesothelin (172, 236, 255) and 
MUC1 (170, 188, 276) for investigation. We found that expression of these 
biomarkers was similar in PDAC and CCC (Table 4.3): our results therefore agree 
with the previous literature (237, 276, 291, 292). 
Second, the sample size for studies investigating diagnostic biomarkers for PDAC 
is relatively small (median sample size, n=48 from 57 articles). Moreover, 
matched normal tissue for most of the carcinoma case was not always available, 
leading to even smaller sample sizes for calculating biomarker specificity. 
Therefore, statistical power is relatively low and subsequently potentially useful 
biomarkers may be ignored. Our relatively larger sample size of 99 PBA cases 
(n=99 adenocarcinomas and n=99 matched normal tissue for each case; total 
n=198) provided a solid platform for investigating these diagnostic IHC 
biomarkers. 
Third, the lack of a standardised scoring system and absence of a uniform cut-
off (threshold) for the interpretation of IHC remains problematic. Thus, 
researchers use a variety of traditional and novel scoring systems and diverse 
cut-offs, making the adoption of scoring systems and cut-offs potentially 
challenging for pathologists (159, 165, 172, 232, 234, 236, 237, 240, 264). We 
systematically chose cut-offs from ROC curve analysis to fully explore the 
diagnostic potential of all four biomarkers. These cut-offs provide an opportunity 
for the pathologists to select the best threshold that is more clinically applicable 
and has the potential to be routinely used in pathology. Three of these cut-offs 
are based on the proportion of positive cells (5%, 10% and 20%) with staining of 
any intensity. The fourth cut-off is based on any proportion of cells exhibiting 
moderate and strong staining intensity, and the fifth cut-off is based on a 
Histoscore of 20. Notably, the 20% cut-off and Histoscore 20 provide reasonable 
sensitivity and specificity values for PBA diagnosis. A higher Histoscore value 
could potentially lead to more false negatives in tumour cases, therefore, a low 
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cut-off value of 20 was chosen. Clearly, this cut-off will remove the probability 
of false negative and should increase the diagnostic confidence of pathologists 
for higher Histoscore values. For example, a Histoscore value of 200 for a 
biomarker in a suspicious case might help the pathologist to diagnose a tumour 
with confidence and with a much higher specificity. 
Fourth, most of the IHC diagnostic biomarkers have been investigated 
individually (177, 234, 241, 252, 254), with few studies reporting the utility of 
biomarker panels. (172, 253). We carefully selected candidate biomarkers 
reported in different studies (KOC, mesothelin, S100P and MUC1) for 
investigation in a single experimental setting. Investigation of these biomarkers 
in a single cohort gave us the opportunity to compare biomarkers, and then 
further explore their diagnostic accuracy in a panel. Expectation from an ideal 
diagnostic biomarker is its ability to identify the diseased population (sensitivity) 
and exclude the normal population (specificity) in 100% cases. However, no 
single biomarker is 100% perfect; therefore these biomarkers were investigated 
in various combinations, to select an optimum panel for potential clinical 
application. For example, the individual sensitivity/specificity of KOC and S100P 
at a cut-off of 20% positive cells was 84%/100% and 83%/100% respectively. 
However, using a panel of KOC and S100P improved sensitivity to 99% without 
compromising the specificity (99%).  
Furthermore, using a panel of KOC, S100P and mesothelin with at least two 
positive biomarkers achieved almost 100% sensitivity and specificity for both 10% 
and 20% cut-offs. This approach would assign a patient into the tumour positive 
category if two or more biomarkers are positive, possibly giving more assurance 
to the pathologist before assigning the patient into positive category. Moreover, 
a combination of KOC, S100P and mesothelin antibodies should stain all major 
cellular compartments (cell membrane, nucleus and cytoplasm). Clinically, a 
cytology sample comprises a mixed population of cells and this panel will stain 
malignant cells more intensely making the interpretation of IHC convenient for 
the pathologist. The possible additional advantage of KOC is that it is not 
expressed in the contaminating gastrointestinal epithelial cells that are usually 
present in cytological samples (217, 271). Our data also confirm the lack of 
expression of KOC in normal duodenum. Taken together, our results reinforce 
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the reported sensitivity/specificity values for KOC, S100P and mesothelin (159, 
172, 240, 271) and further explores their utility as a panel. 
Fifth, is that different research groups use different IHC experimental 
conditions, primary antibodies, clones, antigen retrieval, antibody dilutions and 
manual/automated platforms that could potentially lead to a diverse range of 
sensitivity and specificity values for biomarkers (171, 172, 232, 233, 238, 249). 
We thoroughly searched the literature for IHC parameters for KOC, S100P, 
mesothelin and MUC1. Those IHC parameters that achieved superior diagnostic 
accuracy were selected and further optimised in our histology laboratory before 
staining our cohort. 
Sixth, an important requirement for biomarker translation to the clinic is 
independent validation with the aim of improving already existing diagnosis. 
Purposeful validation in surgical and cytological tissue from PBA cohorts and 
subsequent prospective clinical study on cytological samples is deficient. 
Therefore, as an important step for potential clinical translation we investigated 
KOC, S100P, mesothelin and MUC1 in a surgical cohort of PBA patients with 
promising results for KOC, S100P and mesothelin as a biomarker panel.  
The next step forward is to possibly investigate these biomarkers in a 
retrospective study and then in a prospective cohort of cytology samples. This 
chapter systematically attempted to answer all six major reasons hindering the 
clinical translation of diagnostic IHC biomarkers for pancreatic cancer. It also 
provides future direction and work packages to be performed before these 
diagnostic biomarkers can be used in day-to-day pathology practice.  
The strengths and limitations are: The strengths include relatively large sample 
size, using semi-quantitative Histoscores for scoring, using multiple cut-offs for 
biomarkers and panel approaches. The main limitation of this project is the use 
of a separate TMA set for maspin. 
Conclusion: Our results demonstrate that a biomarker panel of KOC, S100P and 
mesothelin is capable of categorising PB malignancy with high diagnostic 
accuracy in resection specimens. We plan to investigate this panel in archival 
cytological samples. As an adjunct to cytology, this panel has the potential to 
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augment the categorisation for challenging diagnostic cases in routine clinical 
practice.To our knowledge, this is the first study of PB literature that identified 
cut-offs systematically for diagnostic purposes and used stringent panels to 
identify an optimum biomarker panel. 
What this adds: This study validated the biomarkers identified in meta-analysis. 
Histoscore was used as a scoring system and five potential diagnostic cut-offs 
were investigated. Biomarkers showed similar expression in PDAC and CCC. 
Biomarkers were validated singly and in panels for PBA diagnosis. 
What Next: I will now investigate maspin as a potential diagnostic biomarker in 
the next chapter, which will be followed by investigation of cut-offs for observer 
agreement and finally investigation of panel of biomarkers in cytology samples. 
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Table 4.1: Summary statistics of KOC, S100P, mesothelin and MUC1 expression comparing 
PBA with normal tissue. 
Biomarkers Pancreaticobiliary 
Adenocarcinoma 
Normal 
tissue 
P value 
KOC 
Positivity* Mean 74% 0.4% <0.0001 
Median 100% 0%   
Histoscore Mean 150 0.5 <0.0001 
Median 180 0   
S100P 
Positivity Mean 75% 0.30% <0.0001 
Median 100% 0%   
Histoscore Mean 165 0.3 <0.0001 
  Median 180 0   
Mesothelin 
Positivity Mean 73% 4% <0.0001 
Median 90% 0%   
Histoscore Mean 115 4 <0.0001 
Median 110 0   
MUC1 
Positivity Mean 75% 18% <0.0001 
  Median 90% 10%   
Histoscore Mean 193 48 <0.0001 
  Median 200 30   
Note: *Positivity (percentage of positive cells with any staining intensity in tumour and normal 
tissue); P value (shows the statistical significance of the difference in expression of a biomarker in 
tumour vs. normal tissue); Positivity range (0%-100%), Histoscore range (0-300). 
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Table 4.2: Summary statistics of KOC, S100P, mesothelin and MUC1 expression comparing 
normal ducts with normal ducts & acini together 
Biomarkers Normal ducts Normal ducts & acini 
KOC 
Positivity* 
 
Mean 0.2% 0.4% 
Median 0% 0% 
Histoscore 
 
Mean 0.4 0.5 
Median 0 0 
S100P 
Positivity Mean 0.3% 0.3% 
Median 0% 0% 
Histoscore Mean 0.3 0.3 
 Median 0 0 
Mesothelin 
Positivity Mean 5% 4% 
Median 0% 0% 
Histoscore Mean 5 4 
Median 0 0 
MUC1 
Positivity Mean 16% 18% 
Median 5% 10% 
Histoscore Mean 37 48 
Median 14 30 
Note: *Positivity (percentage of positive cells of any staining intensity in tumour and normal tissue); 
Positivity range (0%-100%), Histoscore range (0-300). 
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Table 4.3: Summary statistics of KOC, S100P, mesothelin and MUC1 expression comparing 
PDAC with CCC 
Biomarkers  Pancreatic ductal 
adenocarcinoma 
Cholangiocarcinoma P value 
KOC 
Positivity* 
 
Mean 74% 60% 0.09 
Median 100% 90%  
Histoscore 
 
Mean 155 131 0.33 
Median 180 120  
S100P 
Positivity 
 
Mean 75% 80% 0.38 
Median 100% 100%  
Histoscore 
 
Mean 160 180 0.15 
Median 150 190  
Mesothelin 
Positivity 
 
Mean 72% 75% 0.65 
Median 90% 90%  
Histoscore 
 
Mean 120 135 0.37 
Median 105 140  
MUC1 
Positivity 
 
Mean 76% 72% 0.58 
Median 90% 100%  
Histoscore 
 
Mean 195 198 0.91 
Median 220 260  
Note: *Positivity (percentage of positive cells with any staining intensity in tumour tissue); P value, 
independent sample t test (shows the statistical significance of the difference in expression of these 
biomarkers in pancreatic ductal adenocarcinoma vs. cholangiocarcinoma); Positivity range (0%-
100%), Histoscore range (0-300).  
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Table 4.4: Cut-offs resulting from ROC curve analysis based on the percentage of positive cells in tumour and normal cases for KOC, S100P, mesothelin 
and MUC1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: * These cut-offs are based on percentage positivity [percentage of positive cells (0%-100%) of any staining intensity (weak, moderate and strong) in tumour and 
normal tissues]. 
Cut-offs* KOC S100P Mesothelin MUC1 
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
5% 87 96 86 97 95 77 92 18 
10% 87 98 86 97 94 88 90 35 
20% 84 100 83 100 88 92 89 63 
35% 81 100 80 100 82 97 87 85 
45% 77 100 80 100 79 97 84 90 
55% 72 100 78 100 73 100 77 93 
65% 71 100 71 100 70 100 71 95 
70% 70 100 66 100 67 100 70 96 
80% 68 100 59 100 56 100 65 96 
90% 63 100 56 100 53 100 53 98 
95% 56 100 54 100 42 100 40 98 
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Table 4.5: Panels of biomarkers used for sensitivity and specificity analyses, using 10% and 
20% positive cells as cut-offs for positivity 
10% positive cells as cut-off 
Panels  Sensitivity Specificity 
   
KOC, S100P, Mesothelin, MUC1 100% 40% 
KOC, S100P, Mesothelin 100% 88% 
KOC, Mesothelin 97% 87% 
KOC, S100P  98% 96% 
KOC, S100P, Mesothelin*  100% 99% 
20% positive cells as cut-off 
Panels Sensitivity Specificity 
   
KOC, S100P, Mesothelin, MUC1 100% 65% 
KOC, S100P, Mesothelin 99% 94% 
KOC, Mesothelin 96% 93% 
KOC, S100P  99% 99% 
KOC, S100P, Mesothelin* 100% 100% 
Note: * At least 2 biomarkers required to be positive in this panel. In the rest of the panels only one 
biomarker was required to be positive in a panel. 
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Figure 4.1: Immunostaining of KOC, S100P, mesothelin and MUC1. 
 
Figure Legend: Representative images of staining of all four biomarkers in normal tissue (normal 
pancreatic tissue) and range of staining intensities (weak, moderate and strong) in tumour tissue 
from tissue microarray cores. The staining for all biomarkers is epithelial. The staining for KOC is 
cytoplasmic, staining for S100P is cytoplasmic and/or nuclear, staining for mesothelin and MUC1 is 
cytoplasmic and/or membranous. Normal ducts and acini and negative for KOC. S100P and 
mesothelin but some staining in normal acini is present for MUC1. 
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Figure 4.2: Boxplots comparing the expression of biomarkers (KOC, mesothelin, S100P and 
MUC1) in PBA compared to normal tissue based on percentage of positively stained cells 
(0%-100%) 
Symbols explained: Red Circles are individual data symbol. Green triangles are median data 
symbols. 
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Figure 4.3: Boxplots comparing the expression of biomarkers (KOC, mesothelin, S100P and 
MUC1) in PBA compared to normal tissue based on Histoscores (0-300) 
Symbols explained: Red Circles are individual data symbols. Green triangles are median data 
symbols. 
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Figure 4.4: Receiver operating characteristics (ROC) curves for biomarkers based on 
positive percentage of cells 
Figure Legend: ROC curves based on percentage of positive cells (0%-100%) for any staining 
intensity  (weak, moderate or strong), in tumour and normal cases, for four biomarkers (A) KOC, 
(B) S100P, C) mesothelin and D) MUC1. 
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Figure 4.5:  Receiver operating characteristics (ROC) curves for biomarkers based on 
Histoscore 
Figure Legend: ROC curves based on Histoscore (0-300), in tumour and normal cases, for four 
biomarkers (A) KOC, (B) S100P, (C) mesothelin and (D) MUC1. 
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Figure 4.6: Sensitivity and specificity analysis based on five cut-offs for biomarkers. 
Figure Legend: Sensitivity and specificity analysis of biomarkers for the diagnosis of pancreatico-
biliary adenocarcinoma compared to normal tissue, based on five cut-offs for positivity: 5% positive 
cells of any staining intensity; 10% positive cells of any staining intensity; 20% positive cells of any 
staining intensity; 2 OR 3 intensity i.e. moderate or strong staining of cells; and Histoscore 20.  
Analysis is presented for A) KOC, B) S100P, C) mesothelin and D) MUC1. 
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Figure 4.7: Combined Summary ROC curves for comparing panels of biomarkers. 
Figure Legend: *Combined Summary ROC curves for 10% (A) and 20% (B) cut-offs if only one 
biomarker was required to be positive in a panel. Four panels of biomarkers were compared. Panel 
1 - KOC, S100P, Mesothelin and MUC1; Panel 2 - KOC, S100P, Mesothelin; Panel 3 - KOC, 
S100P; Panel 4 - KOC, Mesothelin. 
*Summary ROC curves plot sensitivity against specificity and draw a summary line depicting 
combined sensitivity and specificity of a panel. Combined Summary ROC curves compare different 
panels to show the most “accurate” panel. The summary line at the top left corner shows the 
biomarker which is most accurate compared to others lying lower and further to the right. This 
enables the most accurate panel to be identified.  
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5 Expression of maspin in pancreatico-biliary 
adenocarcinomas as a potential diagnostic 
immunohistochemistry biomarker 
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5.1 Chapter Summary 
Maspin as a potential diagnostic biomarker was also identified from our meta-
analysis and is investigated in this chapter. The aim was to independently 
validate the diagnostic significance of maspin in our cohort and to assess its 
suitability for diagnostic panel investigation in cytology. 
Tissue microarrays containing tumour and normal cores in a ratio of 6:2, from 
137 surgically resected PBA patients, were used for immunohistochemistry (IHC). 
IHC was performed on an automated platform using an antibody against maspin. 
Tissue cores were scored for staining intensity and the proportion of tissue 
stained using a Histoscore method (range, 0–300). Sensitivity and specificity was 
determined with different cut-offs for positivity and compared by summary 
receiver operating characteristic (ROC) curve. 
The expression of maspin was high in PBA versus normal ducts, with a mean 
Histoscore of 215 vs. 0.4 (p<.0001). Five cut-offs were carefully chosen for 
sensitivity/specificity analysis namely 5%, 10% or 20% positive cells, +2/+3 and 
Histoscore 20. Using 20% positive cells as a cut-off achieved 96% sensitivity and 
99% specificity for maspin.  
We examined the potential diagnostic utility of maspin using various cut-offs and 
found that maspin achieves optimum diagnostic sensitivity and specificity in 
resection specimens from patients with PBA. The high specificity (98%-100%) 
might enable maspin to be used as a potential candidate in a diagnostic panel 
with other biomarkers. 
 
 
 
 
 
Chapter 5  183 
 
   
5.2 Introduction 
Five candidate biomarkers KOC, S100P, mesothelin, MUC1 and maspin were 
identified from the meta-analysis. The first four were investigated using ‘SD 
TMAs’ and the results are presented in chapter 4. In this chapter I will now 
discuss maspin as a potential diagnostic biomarker for pancreatico-biliary 
adenocarcinomas (PBA). ‘NBJ TMAs’ were used instead of ‘SD TMAs’ for 
investigating maspin expression, because a significant loss of tissue cores in the 
later sections of ‘SD TMAs’ was noticed and thus considered inappropriate for 
biomarker studies. The loss of tissue cores was due to the intervening use of the 
TMA resource for biomarker studies by other researchers. 
Maspin (mammary serine protease inhibitor) was first identified in normal 
mammary epithelial cells and has been characterised as a tumour suppressor in 
many cancer types (311). The anti-tumour effects of maspin are related to 
inhibiting cell invasion, promoting apoptosis and inhibiting angiogenesis (234, 
312). Experimental data suggest the role of maspin as a tumour suppressor but 
clinical data have conflicting results regarding its prognostic significance in 
different tumour types (311, 313). Maspin expression is associated with a 
favourable prognosis in lung, prostate and colorectal cancer, while in pancreatic 
and breast cancer it predicts poor prognosis (232, 314-317). These conflicting 
results can partly be explained by the distinct subcellular localisation 
(cytoplasm, nuclear or both) of maspin (313). 
5.2.1 Aims 
The aims of this chapter are as follows: to validate maspin by IHC and to assess 
the diagnostic accuracy (sensitivity and specificity) in the local pancreatico-
biliary resection cohort and; to investigate and identify appropriate diagnostic 
cut-offs resulting in good sensitivity and specificity for the distinction of PBA 
from normal. These two aims will help us in determining the suitability of 
maspin as a candidate diagnostic biomarker and its potential role in the panel of 
biomarkers identified in the previous chapter.  
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5.3 Results 
5.3.1 Expression of maspin was epithelial and was higher in 
tumour than normal tissue 
IHC staining was seen only in epithelial cells.  As expected, maspin expression 
was observed in the cytoplasm and nucleus but only cytoplasmic staining was 
scored for diagnostic purposes (Figure 5.1). Generally, staining intensity was 
moderate to strong and significantly higher expression in tumour versus normal 
tissue (non-neoplastic ducts or pancreatic acinar tissue) was observed (Table 
5.1, p<0.0001, Independent sample t-test).  
The mean percentage of positive carcinoma cells in tumour cores was 90% for 
maspin (Table 5.1 and Figure 5.2). By employing a Histoscore scoring method, 
the mean tumour Histoscore for maspin was 215 (Table 5.1 and Figure 5.3). The 
mean expression of maspin (90% positivity and 215 histoscore) is higher than the 
biomarkers studied in the previous chapter.  
As discussed early in this thesis an ideal diagnostic biomarker should be highly 
expressed in the tumour tissue compared to normal and maspin appears to have 
a very high expression in PBA. This makes maspin a desirable diagnostic 
candidate for investigation in cytology. 
5.3.2 Expression of maspin in normal tissue was very low 
The expression of maspin was very low in normal tissue as shown by the mean 
percentage of positive cells (0.4%) and mean Histoscore (0.4) in normal tissue 
(Table 5.1, Figure 5.2). Thus, in a mixed population of tumour and normal cells, 
only positive staining would need to be taken into account for diagnostic 
purposes, as positivity is essentially associated only with tumour cells. 
Furthermore, there were no significant differences in biomarker expression 
between normal ducts only and normal ducts and acini together (Table 5.2). 
Again this means that in a mixed population of tumour and normal cells, only 
positive staining needs to be taken into account and is essentially associated 
only with tumour cells. 
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An ideal diagnostic biomarker should have very low expression in normal tissue 
compared to tumour and maspin appears to have very low expression in normal 
tissue. This makes maspin a desirable diagnostic candidate for investigation in 
cytology. Thus, IHC staining using maspin could greatly facilitate interpretation 
of cytology samples with indeterminate or difficult diagnosis.  
5.3.3 Expression of maspin was similar in PDAC and 
cholangiocarcinomas (CCC) 
Maspin expression was also assessed in PDAC compared to CCC as shown in Table 
5.3. The expression of maspin is comparable between PDAC and 
cholangiocarcinoma and this is supported by no statistically significant 
difference in the mean expression of biomarkers between these two tumour 
types (p>0.05, independent sample t-test). The mean positivity in PDAC 
compared to CCC for maspin is 90% vs. 92% and the mean Histoscore is 215 vs. 
220. 
Therefore, for sensitivity and specificity analyses PDAC and CCC were grouped as 
pancreatico-biliary adenocarcinomas (PBA). Next I assessed the sensitivity and 
specificity of biomarkers using various cut-offs calculated with the help of 
receiver operating characteristics (ROC) curve analysis. 
5.3.4 Cut-offs were established using ROC curve analysis 
The sensitivity and specificity of maspin was evaluated using five cut-offs 
(thresholds) for positivity as follows: 5% positive cells of any staining intensity 
(5% cut-off); 10% positive cells of any staining intensity (10% cut-off); 20% 
positive cells of any staining intensity (20% cut-off); moderate or strong staining 
of any cells (+2/+3); and Histoscore equal to or more than 20 (HS20). Three of 
these cut-offs were based on percentage of positive cells and identified by ROC 
curve analysis. The sensitivity of maspin was plotted against (1 – specificity), and 
corresponding ROC curves with coordinates were generated. The area under the 
curve for maspin was 0.99 (0.97-1.00, 95% CI).  
Based on percentage of positive cells in the tumour compared with normal 
cores, ROC curve analysis allowed us to assess potential cut-offs, from 5% 
positive cells to 95% positive cells, with their corresponding sensitivity and 
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specificity values for maspin (Table 5.4, Figure 5.4). Three optimal cut-offs; 5%; 
10% or 20% of positive cells of any staining intensity were selected based on their 
sensitivity and specificity values. The fourth cut-off was based on moderate to 
strong staining intensity (+2/+3 staining) in any of the cells. Interestingly, cases 
with +2/+3 staining for maspin have more than 20% cells positive. Indeed 
patients with +2/+3 staining have only 2 cases with less than 50% of cells positive 
for maspin. The fifth cut-off was based on a Histoscore value of 20 (HS20), and 
was selected from ROC curve analysis (Figure 5.5). 
5.3.5 Maspin achieves optimum sensitivity and specificity for all 
five cut-offs 
The sensitivities and specificities of maspin were calculated using five cut-offs, 
as shown in Figure 5.6. Maspin expression appears to show reasonably high 
sensitivity and specificity for all cut-offs including the cut-off based on +2/+3 
staining, which resulted in sensitivity of 91% and 100% specificity. The 20% 
positive cells cut-off achieves marginally better sensitivity (96%) and specificity 
(99%) values compared with other cut-offs. The sensitivity and specificity values 
achieved for maspin across all cut-offs are high and are better than the 
biomarkers investigated in the previous chapters for some cut-offs. For example 
for +2/+3 cut-off the sensitivity of KOC is 67%, mesothelin is 55%, S100P is 81% 
but for maspin it is 91%. Maspin might potentially be used along with the 
biomarkers validated in previous chapter due to its high specificity and 
sensitivity. 
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5.4 Discussion 
Maspin was investigated in a relatively large cohort of PB patients (n=137). 
The expression level of maspin is high in tumour tissue compared to normal 
tissue. The diagnostic accuracy (sensitivity and specificity) of maspin is high and 
is comparable to the biomarkers investigated in the previous chapter. Maspin as 
a diagnostic biomarker for improving the diagnosis of PDAC has been investigated 
in surgical (164, 167) and cytology specimens (167, 171, 235) but like other 
biomarkers further clinical translation has not yet occurred.  
Let us apply the six main reasons delaying clinical translation of biomarkers 
in PDAC (discussed in chapter 1) to maspin and our approach to address 
them. First, maspin has been previously investigated and the diagnostic 
evidence of maspin was identified in the meta-analysis. It was identified as a 
high ranking candidate and hence it was investigated in our surgical and cytology 
cohort. Second, the sample size of ‘NBJ TMAs’ used for maspin staining is very 
good compared to published diagnostic IHC literature for PBA (164, 167, 171, 
237). Third, the cut-offs determined in the previous chapters namely 5%, 10%, 
20%, +2/+3 and HS20 were identified by ROC curve analysis for maspin. These 
cut-offs were then validated for maspin with largely similar diagnostic patterns 
to the other biomarkers. The use of 5% cut-off for maspin has been reported 
(171, 232) but other cut-offs are novel for maspin in PBA literature. Fourth, 
maspin has been investigated singly in this chapter but it is highly specific (99% 
for 20% cut-off) and sensitive (96% for 20% cut-off). Therefore, hypothetically it 
can enter into the panel of biomarkers identified in the previous chapter as a 
potential candidate in future validation studies. Fifth, the optimum IHC 
conditions from the literature were identified and then optimised in our 
laboratory as outlined in chapter 2 (section 2.2.4.2). The IHC conditions that we 
finally used to stain the TMAs achieved optimum staining in tumour tissue but 
very less staining in the normal tissue. Sixth, maspin was independently 
validated in this chapter as a diagnostic IHC biomarker and could potentially be 
used with other biomarkers as a panel in further validation studies. Therefore, a 
panel comprising of KOC, mesothelin, S100P and maspin might potentially be 
used for investigation and validation in cytology samples. Finally, the expression 
of maspin was similar in PDAC and CCC (Table 5.3): our results therefore agree 
with the previous literature (237, 276, 291, 292). 
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Conclusion: Our results demonstrate that maspin is capable of categorising PB 
malignancy with high diagnostic accuracy in resection specimens. We plan to 
investigate maspin along-with KOC, S100P and mesothelin (from chapter 4) as a 
panel in archival cytology samples. As part of a future plan, this panel will then 
be investigated in prospectively collected cytology samples. As an adjunct to 
cytology, this panel has the potential to augment the categorisation for 
challenging diagnostic cases in routine clinical practice.  
What this study adds: This study independently validated maspin identified in 
the meta-analysis in a surgical cohort of patients with PBA. Histoscore was used 
as a scoring system and high diagnostic sensitivity and specificity was observed 
for all five potential diagnostic cut-offs. Maspin showed similar expression in 
PDAC and CCC.  
What Next: We now have identified a potential panel of markers, namely KOC, 
S100P, mesothelin and maspin for investigation in cytology samples. Diagnostic 
cut-offs identified through ROC curve analysis achieved very good sensitivity and 
specificity for the diagnosis of PBA. However, the question of how good these 
cut-offs are in achieving observer agreement between pathologists is still to be 
answered. The project thus evolved and a need to investigate observer 
variations for cut-offs emerged. Therefore, in the next chapter diagnostic cut-
offs will be investigated for observer agreement between practising pathologists. 
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Table 5.1: Summary statistics of maspin expression comparing PBA with normal tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: *Positivity (percentage of positive cells of any staining intensity in tumour and normal tissue); 
P value (Shows the statistical significance of the difference in expression of maspin in tumour vs. 
normal tissue); Positivity range (0%-100%), Histoscore range (0-300). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers Pancreaticobiliary 
Adenocarcinoma 
Normal tissue P value 
Maspin 
Positivity* 
 
Mean 90% 0.4% <0.0001 
Median 100% 0%  
Histoscore 
 
Mean 215 0.4 <0.0001 
Median 240 0  
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Table 5.2: Summary statistics of maspin expression comparing PBA with normal ducts and 
normal ducts & acini together 
Biomarkers Normal ducts Normal ducts & acini 
Maspin 
Positivity* 
 
Mean 0.4% 0.4% 
Median 0% 0% 
Histoscore 
 
Mean 0.4 0.4 
Median 0 0 
Note: *Positivity (percentage of positive cells of any staining intensity in tumour and normal tissue); 
Positivity range (0%-100%), Histoscore range (0-300). 
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Table 5.3: Summary statistics of maspin expression comparing PDAC with CCC 
Biomarkers  Pancreatic ductal 
adenocarcinoma 
Cholangiocarcinoma P value 
Maspin 
Positivity* 
 
Mean 90% 92% 0.18 
Median 100% 100%  
Histoscore 
 
Mean 215 220 0.53 
Median 235 240  
Note: *Positivity (percentage of positive cells with any staining intensity in tumour tissue); P value, 
independent sample t test (shows the statistical significance of the difference in expression of 
maspin in pancreatic ductal adenocarcinoma vs. cholangiocarcinoma); Positivity range (0%-100%), 
Histoscore range (0-300).  
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Table 5.4: Cut-offs resulting from ROC curve analysis based on the percentage of positive 
cells in tumour and normal cases for maspin. 
Cut-offs* 
Maspin 
Sensitivity Specificity 
5% 98 95 
10% 98 98 
20% 96 99 
35% 95 100 
45% 94 100 
55% 92 100 
65% 91 100 
70% 90 100 
80% 85 100 
90% 74 100 
95% 65 100 
Note: * These cut-offs are based on percentage positivity [percentage of positive cells (0%-100%) 
of any staining intensity (weak, moderate and strong) in tumour and normal tissues]. 
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Figure 5.1: Maspin immunostaining 
Figure Legend: Representative images of staining for maspin in normal tissue and range of 
staining intensities (weak, moderate and strong) in tumour tissue from tissue microarray cores. The 
staining is epithelial and is both cytoplasmic and nuclear (but for diagnostic purposes only 
cytoplasmic staining was considered. Normal ducts and acini are negative for maspin but varying 
proportion of positivity is noticed in tumour tissue. 
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Figure 5.2: Boxplots comparing the expression of maspin in PBA compared to normal 
tissue based on percentage of positively stained cells (0%-100%) 
Symbols explained: Red Circles are individual data symbol. Green triangle is median data symbol 
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Figure 5.3: Boxplots comparing the expression of maspin in PBA compared to normal 
tissue based on histoscores (0-300) 
 
Symbols explained: Red Circles are individual data symbol. Green triangle is median data symbol 
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Figure 5.4: Receiver operating characteristics (ROC) curves for maspin based on positive 
percentage of cells 
 
Figure Legend: ROC curves based on percentage of positive cells (0%-100%) for any staining 
intensity (weak, moderate or strong), in tumour and normal cases, for maspin. 
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Figure 5.5: Receiver operating characteristic (ROC) curves for maspin based on Histoscores 
 
Figure Legend: ROC curves based on Histoscore (0-300), in tumour and normal cases, for 
maspin. 
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Figure 5.6: Sensitivity and specificity analysis of maspin based on five cut-offs  
 
Figure Legend: Sensitivity and specificity analysis of maspin for the diagnosis of pancreatico-
biliary adenocarcinoma compared to normal tissue, based on five cut-offs for positivity: 5% positive 
cells of any staining intensity; 10% positive cells of any staining intensity; 20% positive cells of any 
staining intensity; 2 OR 3 intensity i.e. moderate or strong staining of cells; and Histoscore 20.   
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6 Investigating various thresholds as 
immunohistochemistry cut-offs for observer 
agreement 
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6.1 Chapter Summary 
Clinical translation of immunohistochemistry (IHC) biomarkers requires a reliable 
and reproducible cut-off for interpretation of immunostaining. Most of the IHC 
biomarker research focuses on the clinical relevance (diagnostic or prognostic 
utility) of cut-offs with less emphasis on observer agreement using these cut-
offs. We identified three cut-offs from our TMA work and literature namely, 10% 
positive epithelial cells (10% hereafter), 20% positive epithelial cells (20% 
hereafter) and moderate to strong staining intensity (+2/+3 hereafter) for 
investigating observer agreement. The aim was to establish consensus based cut-
off(s) that could potentially be used by pathologists. 
A series of 36 IHC images of microarray cores for four IHC biomarkers with 
variable staining intensity and percentage of positive cells was used for 
investigating inter- and intra-observer agreement. Seven pathologists 
participated in the study and they scored the immunostaining of each image for 
the three cut-offs. Kappa statistic was used to assess the strength of agreement 
for each cut-off.  
The inter-observer agreement between all seven pathologists using the three 
cut-offs was reasonably good. A good agreement was observed for experienced 
pathologists using 10% cut-offs and the agreement was statistically higher than 
junior pathologists (p=0.02). In addition, the mean intra-observer agreement for 
all seven pathologists using the three cut-offs was reasonably good. For all three 
cut-offs a positive correlation was observed with perceived ease of 
interpretations (p<0.0001 for 10% cut-off, p=0.001 for +2/+3 cut-off and p=0.004 
for 20% cut-off). Finally, cytoplasmic only staining achieved higher agreement 
using all three cut-offs than cytoplasmic/nuclear staining and 
cytoplasmic/membranous staining. 
All three cut-offs investigated achieve reasonable strength of agreement 
modestly decreasing inter and intra-observer variability in IHC interpretation but 
10% is slightly better than 20% and +2/+3 cut-offs. These cut-offs have previously 
been used in cancer pathology and we have provided evidence that they are 
reproducible between practising pathologists. 
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6.2 Introduction 
The use of immunohistochemistry (IHC) biomarkers for clinical decision making is 
an important research field with a significant translational potential. A 
multitude of biomarkers for a variety of cancers is available for clinical 
translation and an enormous literature exists on novel biomarker discovery, but 
only a minority is used for patient care. Amongst other reasons, one barrier for 
clinical translation of biomarkers is the lack of a standardised cut-off or 
threshold for interpretation of IHC (189, 190). 
Evaluation of immunostaining is important in translational studies assessing 
biomarker expression for diagnostic, prognostic or predictive purposes.  
Biomarker expression reported in the literature is usually on a continuous or 
ordinal scale but for meaningful clinical use it is usually dichotomised and a cut-
off is established for assigning a patient into either positive/negative category or 
high/low expression category  (318). In addition, for some biomarkers two or 
more categories may be required for example the use of the ‘Allred score’ for 
estrogen receptor positivity (161). For clinical translation two issues revolve 
around a standardised cut-off for IHC biomarkers. One is the identification of an 
appropriate cut-off that provides suitable sensitivity/specificity for diagnostic 
biomarkers and stratifies patients based on survival and response to treatment 
for prognostic and predictive biomarkers respectively. The other issue is to 
assess the inter- and intra-observer agreement in the interpretation of cut-off. 
The former can be addressed using a receiver operating characteristics (ROC) 
curve that could help to identify an appropriate cut-off (189, 319). The latter 
issue can be answered by assessing the level of agreement between practising 
pathologists (320-322).  
There is no standardized cut-off for diagnostic IHC biomarkers. Most of the 
reported cut-offs are purposive that best fit cancer or normal groups. These cut-
offs are based on the intensity of staining or percentage of positive cells or 
combination of both intensity and percentage in terms of immunoreactive 
scores, H scores and “quick” scores (264, 270, 321, 323-325). Two widely used 
cut-offs reported in the literature for IHC diagnostic biomarkers are 
positive/negative staining (e.g. p16/Ki-67 staining for the diagnosis of cervical 
intra-epithelial neoplasia III) and 10% positive cells (e.g. CEACAM6 differentiating 
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PDAC from non-neoplastic pancreas) (326-330). Other reported cut-offs are: 5% 
positive epithelial cells for maspin (differentiating PDAC from chronic 
pancreatitis) (171); more than 20% positive epithelial cells for HMGI(Y) 
(differentiating PDAC from non-neoplastic pancreas) (265); and more than 30% 
cells with uniform, intense membranous staining of invasive tumour cells for 
human epidermal growth factor receptor 2 (HER2) (positive HER2 staining in 
breast cancer) (331). 
These scoring systems and cut-offs have been adopted for research purposes and 
some of them are in clinical practice but studies looking at their reproducibility 
between pathologists are minimal. A cut-off should both be clinically relevant 
and easily interpretable by pathologists. There is a tendency to focus more on 
the clinical relevance of the cut-off for a biomarker with less focus on the level 
of agreement between pathologists when they use it for scoring purposes (320, 
332). Inter- and intra-observer variation of a cut-off is infrequently analysed 
despite the fact that it is recognised as a potential barrier to clinical translation. 
We selected three cut-offs for investigation based on our TMA work and 
literature. These cut-offs are 10% positive epithelial cells (10% hereafter), 20% 
positive epithelial cells (20% hereafter) and moderate to strong staining intensity 
with any proportion of positive cells (+2/+3 hereafter) (156, 210, 322, 326, 329, 
333-335). These cut-offs are clinically relevant achieving appropriate diagnostic 
and prognostic utility and we postulated that they are easily interpretable and 
reproducible amongst pathologists. 
6.2.1 Aims 
We have now recognized from the systematic review (chapter 3) that a variety 
of cut-offs exist and there is a lack of standard cut-offs for diagnostic IHC 
biomarkers investigated in PDAC. This project thus evolved and a need for a 
standardised cut-off for IHC biomarkers was appreciated. A standard cut-off has 
two main components. One is the ability to categorise patients into distinct 
groups and the second is providing evidence of observer agreement. The former, 
i.e. the ability of these cut-offs (10%, 20% and +2/+3) in the diagnosis of 
adenocarcinoma and excluding normal was assessed in chapters 4 and 5. The 
latter, i.e. observer agreement, is addressed in the current chapter. The aims 
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therefore were: to investigate the cut-offs (10%, 20% and +2/+3) for inter and 
intra-observer agreements; and to explore the factors influencing agreement 
between pathologists for IHC cut-offs. 
6.3 Results 
Seven practising pathologists (3 experienced and 4 junior) participated in this 
study and they were coded as A, B, C, D, E, F and G. A series of 36 IHC images 
from four biomarkers was carefully selected. A scoring sheet was provided to the 
pathologists with instructions to score images for the three cut-offs namely 10%, 
20% and +2/+3. Inter-observer agreement of IHC interpretation was assessed in 
one session which was followed after three weeks by a second similar session for 
evaluating intra-observer agreement. All seven pathologists thus scored all 36 
images for the three cut-offs in each of the two sessions. Taken together, 1512 
evaluations were made in both sessions by the pathologists. The average time 
for interpretation of an image was roughly 30-45 seconds. The strength of 
agreement was assessed using kappa (κ) scores (Table 6.1) which are based on 
the Landis and Koch model (226). The κ score between 0.21-0.40 is regarded as 
‘fair’ agreement, κ score between 0.41-0.60 is regarded as ‘moderate’ 
agreement, κ score between 0.61-0.80 is regarded as ‘substantial agreement’ 
and κ score between 0.81-1.00 is regarded as ‘almost perfect’ agreement (226). 
Results are divided into four parts: inter-observer agreement; perceived ease of 
scoring; intra-observer agreement; and staining of the different cellular 
compartments. The inter-observer part is further subdivided based on the 
pairwise comparison of pathologists into: all seven pathologists; experienced 
pathologists versus junior pathologists.  
6.3.1 Inter-observer agreement 
The aim was to determine the level of agreement between the pathologists for 
the three cut-offs and to assess whether one cut-off achieves better agreement 
than the others. 
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6.3.1.1 The inter-observer agreement between all seven pathologists is 
reasonably good for all three cut-offs 
This analysis was carried out from the scoring results of all seven pathologists. 
Pairwise comparisons of the interpretation of immunostaining among 
pathologists were used to generate κ scores. As an example, the κ score inter-
observer agreement between pathologist A and B using the 10% cut-off was 0.80 
(substantial agreement, P<0.001) (Table 6.2). Subsequently, 21 such inter-
observer (AB, AC, AD and so on…) κ scores were generated for each of the three 
cut-offs. Finally a mean inter-observer κ score for each cut-off was used as a 
measure of strength of agreement between pathologists (Table 6.2). 
The mean inter-observer κ scores were 0.64, 0.59 and 0.62 for 10%, 20% and 
+2/+3 cut-offs respectively (Table 6.2). The mean κ score agreement for 10% 
and +2/+3 cut-offs is in the ‘substantial’ agreement category and for 20% cut-off 
it is the ‘moderate’ agreement category. However, the κ score agreements 
between the three cut-offs were not statistically different from each other 
(Figure 6.1). 
Figure 6.2 shows examples of IHC images used in this study. Images with low 
observer agreement have either weak staining intensity or the proportion of 
positively stained cells is lower compared to images with high level agreement. 
In fact, tissues with both strong staining intensity and a higher percentage of 
positive cells have higher agreement regardless of the biomarker and staining 
pattern. 
In summary, the inter-observer agreements between all seven pathologists for 
the three cut-offs were reasonably good. In addition, the agreements for the 
cut-offs were not statistically different from each other. A good observer 
agreement using these cut-offs might facilitate their use for IHC biomarkers. 
Next I compared the agreements of experienced and junior pathologists. 
6.3.1.2 Experienced pathologists have statistically higher agreement for 
10% cut-off than junior pathologists 
The aim of this analysis was to compare the level of agreement amongst 
experienced pathologists with that of junior pathologists. 
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The mean inter-observer κ scores for experienced pathologists were 0.81, 0.70 
and 0.55 for 10%, 20% and +2/+3 cut-offs respectively (Table 6.3A). The mean 
inter-observer κ scores for junior pathologists were 0.61, 0.60 and 0.73 for 10%, 
20% and +2/+3 cut-offs respectively (Table 6.3B). The agreement on 10% cut-off 
is statistically higher for the experienced pathologists than the junior 
pathologists (P=0.02, Mann-Whitney U test). However, no statistically significant 
difference between experienced and junior pathologists was observed for 20% 
and +2/+3 cut-offs. 
In summary, a higher level of agreement was observed for experienced 
pathologists using 10% cut-off and this was statistically higher than junior 
pathologists.  
6.3.2 A positive correlation was observed between all three cut-
offs and the perceived ease of scoring 
In order to determine the perceived ease of scoring using the three cut-offs, the 
pathologists were asked to categorise each individual core as easy or challenging 
to score on the scoring sheet. A positive correlation was observed between all 
three cut-offs and perceived ease of scoring (p<.0001). However, in a 
multivariate analysis the 10% cut-off (β=0.41, p<0.001) was more easily scored as 
compared to +2/+3 cut-off (β=0.38, p=0.001) or the 20% cut-off (β=0.34, 
p=0.004) (Table 6.4).  
Interestingly, the pattern emerging from this correlation, that 10% is relatively 
more easily scored, followed by +2/+3 and 20%, supports the mean inter- and 
intra-observer κ scores for these cut-offs (Table 6.2 and Table 6.5). 
6.3.3 Intra-observer agreements 
The aim was to investigate the intra-observer reproducibility of these cut-offs 
and to determine if the reproducibility of one cut-off was better.  
6.3.3.1 The intra-observer agreement for all three cut-offs was high 
confirming the reproducibility of cut-offs 
A pairwise comparison of the scoring and then re-scoring of the IHC images by 
the same pathologist was made at two sessions three weeks apart. Kappa scores 
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were generated for all seven pathologists (A-A, B-B, C-C, D-D, E-E, F-F and G-G) 
using the three cut-offs (Table 6.5). As an example, the κ score intra-observer 
agreement for pathologist A using the 10% cut-off was 0.76 (‘substantial’ 
agreement, P<0.001) (Table 6.5). Subsequently, seven such intra-observer 
agreements (AA, BB, CC, DD, EE, FF and GG) were generated for each cut-off. A 
mean intra-observer κ score for each cut-off was then used as a measure of 
strength of agreement (Table 6.5). 
The mean intra-observer κ scores were 0.71, 0.60 and 0.73 for 10%, 20% and 
+2/+3 cut-offs respectively (Table 6.5). The κ score agreement for 10% and 
+2/+3 cut-offs is in the ‘substantial’ agreement category and for 20% cut-off it is 
the ‘moderate’ agreement category. However, the κ score agreements between 
all seven pathologists for the three cut-offs were not statistically different 
(Figure 6.3).  
In summary, the intra-observer agreements for the three cut-offs were 
reasonably good. In addition, the agreements for the three cut-offs were not 
statistically different from each other. Thus a good intra-observer agreement 
confirms the reproducibility of these cut-offs by pathologists and again this 
supports their use for IHC biomarkers. 
The inter- and intra-observer agreements follow the same pattern i.e. 
‘substantial’ agreement for 10% and +2/+3 and ‘moderate’ agreement for 20% 
cut-off. 
6.3.4 Scoring of different cellular compartments 
The aim was to determine if the pathologists tend to have more agreement for a 
particular staining pattern (cytoplasmic, nuclear and membranous). Depending 
on the staining pattern in the images studied, three patterns emerged: 
cytoplasmic only staining, cytoplasmic and/or nuclear staining (CN), and 
cytoplasmic and/or membranous staining (CM). Therefore, for each cut-off, 
three scenarios were identified i.e. cytoplasmic only staining compared to CN, 
cytoplasmic only staining compared to CM and CN compared to CM.  
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6.3.4.1 Cytoplasmic only staining achieved higher agreement using all three 
cut-offs than the other staining patterns 
The level of agreement on different staining patterns (cytoplasmic only, CN and 
CM) was analysed for the three cut-offs. Overall, the mean κ scores for 
cytoplasmic only staining were higher than the other staining patterns. More 
specifically, a statistically higher agreement for cytoplasmic only staining was 
observed in the following scenarios: cytoplasmic compared to CN category using 
+2/+3 cut-off; and cytoplasmic compared to CM category using 20% and +2/+3 
cut-offs.  
Moreover, a statistically higher agreement for CN staining was observed in the 
following scenarios: CN compared to CM category using 20% and +2/+3 cut-offs. 
No statistically significant difference between different staining patterns was 
observed for 10% cut-off (Table 6.6). 
In summary, there is more agreement for cytoplasmic only staining followed by 
CN and CM. Clearly, this suggests that cytoplasmic only staining is easier to 
interpret than cytoplasmic staining mixed with nuclear or membranous staining. 
Finally 10% cut-off is easy to interpret regardless of the staining compartment of 
cell. 
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6.4 Discussion 
Three IHC cut-offs, namely 10%, 20% and +2/+3 were assessed for observer 
agreement between pathologists. All cut-offs showed good inter- and intra-
observer agreement between pathologists. Similarly, all three cut-offs showed 
high correlation with perceived ease of scoring. Finally, the observer agreement 
for cytoplasmic only staining is higher than cytoplasmic/nuclear staining and 
cytoplasmic/membranous staining. 
Establishing a cut-off for biomarker assessment is an essential pre-requisite 
for clinical translation. A wide range of cut-offs have been used for diagnostic, 
prognostic and predictive IHC biomarkers in research and clinical settings. The 
purpose of a cut-off for a diagnostic biomarker is to assign patients into positive 
or negative categories with reasonable sensitivity without compromising 
specificity (336). Based on the expression level for a candidate biomarker in 
cancer and normal tissue, a cut-off is established. A good diagnostic cut-off has 
a low probability of false positivity. This removes the possibility of assigning 
normal population to the diseased group. Similarly, it has a low probability of 
false negativity to avoid missing the diseased group (336). The purpose of a cut-
off for a prognostic biomarker is to divide the population into categories of 
longer and shorter survival for the outcome. In research settings a cut-off based 
on percentage of positive tumour cells is mostly used (337, 338). Similarly, the 
aim of a cut-off for predictive biomarkers is to stratify patients into likely 
responders and non-responders to treatment and intervention (339).  
IHC cut-offs used for prognostic and predictive biomarkers have been 
investigated for observer agreement but such studies are limited for 
diagnostic biomarkers. The cut-offs of 10% and 30% positive cells with strong 
membranous staining for HER2 have been investigated for reproducibility 
amongst pathologists (322). In addition, for estrogen receptor (ER) and 
progesterone receptor (PR), the continuous H-score (range 0-300) and 
categorical scores (negative: H-score<1, positive: H-score ≥1) have been 
investigated for inter-observer agreement (321). These cut-offs for HER2, PR and 
ER are clinically important and are used in day-to-day practice by pathologists.  
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Clinically relevant cut-offs are important for biomarker evaluation but the intra- 
and inter-observer agreements for cut-offs between pathologists may be 
required to fully explore their clinical utility. We sought to investigate three cut-
offs i.e. 10%, 20% and +2/+3 with the hope that if evidence of their scoring 
reproducibility is provided, they could potentially help the clinical translation of 
IHC biomarkers. Interestingly, the purpose of cut-offs differ for different 
biomarkers but these three cut-offs have been used for diagnostic (S100P, pVHL, 
KIT, HMGI(Y), CK20, P53, Ki-67) (156, 166, 265, 329, 335), prognostic (Ki-67, 
p53) and predictive (APAF-1, EGFR) biomarkers (340-343). Therefore, providing 
the strength of agreement between pathologists for these three cut-offs has 
significant clinical potential. 
Inter-observer agreement between pathologists was used to elucidate the 
reliability of cut-offs. A ‘substantial’ agreement was observed with overall 
mean κ scores of 0.64 and 0.62 for 10% and +2/+3 cut-offs respectively, whereas 
‘moderate’ agreement with a κ score of 0.59 was observed for 20% cut-off. In a 
study comparing the 10% positivity with 30% positivity for HER2, the mean κ 
scores for inter-observer agreement were 0.49 for 10% positive cells and 0.54 for 
30% positive cells (322). Clearly, the κ scores generated for the three cut-offs 
under investigation in our project are comparable to the k scores for HER2 which 
is already in clinical practice as a predictive biomarker. Moreover, studies 
looking at the inter-observer reproducibility in histopathology and the IHC 
literature have shown that κ scores more than 0.60 (substantial agreement) are 
regarded as a good level of agreement. In comparison, κ scores less than 0.40 
(fair agreement) are regarded as an unacceptably low level of agreements for 
diagnostic purposes (344-348). 
Intra-observer agreement of the scoring and then re-scoring of the same 
image was used to assess reproducibility of the cut-offs. Again a pattern 
similar to inter-observer agreement emerged with ‘substantial’ agreements for 
the 10% and +2/+3 cut-offs and ‘moderate’ agreement for 20% cut-off. However, 
the intra-observer agreements (0.71, 0.60 and 0.73) in the present study are 
higher than inter-observer agreements (0.64, 0.59 and 0.62) for the three cut-
offs. This finding agrees with the previous literature that the intra-observer 
agreement is more than the inter-observer agreement. For example the intra-
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observer agreement (k=0.85) is better than the inter-observer agreement 
(k=0.80) for PDX-1 IHC staining intensity in prostate cancer (349). In addition, 
the intra-observer agreement (k=0.78) is better than the inter-observer 
agreement (k=0.65) for evaluation of focal cortical dysplasia categories (350).  
Taking 10% positive cells as a cut-off has been used for a variety of IHC 
biomarkers in different cancer types. These include S100P and XIAP in the 
differentiation of pancreatic cancer from non-neoplastic pancreatic tissue, and 
for a panel of napsin-A, Thyroid transcription factor 1, Cytokeratin 5, and P63 in 
differentiating adenocarcinoma from squamous cell carcinoma of the lung (157, 
158). Moreover, 10% cut-off is prognostic in breast cancer for a panel of Ki67 and 
p53, predictive of event-free survival in stage II colon cancer for VEGF and is 
predictive in rectal tumours treated with preoperative, high-dose-rate 
brachytherapy for APAF-1 (341, 343, 351).  The use of a 10% cut-off in other 
areas of pathology means that the more experienced pathologists in the present 
study will have already had experience in applying this cut-off, which is a 
possible explanation for why they have a higher agreement than junior 
pathologists. Studies have attempted to show the reproducibility of the 10% cut-
off and the κ scores achieved in the current study (0.64, substantial agreement) 
is similar to the k scores (0.57-0.77, moderate to substantial) in the reported 
literature (341, 352-354).  
The 20% positive staining cut-off has also been used for a variety of IHC 
biomarkers. These include EGFR as a predictive biomarker in non-small cell lung 
cancer (390), Ki-67 as a prognostic biomarker in breast carcinoma (355) and NF-
E2 in the differentiation of essential thrombocythemia from primary 
myelofibrosis (342, 356). However, studies investigating the variation in 
interpretation of this cut-off between pathologists are very limited. The current 
study investigated the 20% cut-off for observer agreement and our results 
suggested a good level of agreement.  
Moderate to strong staining intensity and any percentage of positive cells 
(+2/+3) as a cut-off has also been for IHC biomarkers.  These include CK20, 
P53, CK5/6, CD138, and Her2/Neu in the diagnosis of urothelial carcinoma in situ 
(382) and the use of claudin-4 to distinguish adenocarcinoma from malignant 
mesothelioma in effusion cytology (156, 357, 358). However, once again studies 
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observing the variation in interpretation of this cut-off between pathologists are 
very limited. Our results demonstrate that this cut-off is also reliable, 
reproducible and easy to score and it can be ranked second to 10% cut-off from 
the current study. Separating moderate staining from weak staining can 
sometime be difficult. Using only strong staining gives a high level of agreement 
but for diagnostic purposes if moderate staining is ignored the sensitivity will 
substantially drop for markers stained less intensely compared to biomarkers 
with high expression. 
The observer agreement was also assessed using staining in different cellular 
compartments. Staining in only cytoplasmic compartment achieved higher 
agreements than other staining patterns. The k score (0.62) from membranous 
and/or cytoplasmic staining for 10% cut-off in the current study is comparable to 
the k score (0.49) for 10% cells with membranous staining in HER2 (322).  
The sample size was good and seven pathologists participated in the present 
study. This number is comparable to the IHC biomarker and histopathology 
literature (4 to 7 participants) where observer agreement was investigated (283, 
349, 359, 360). In addition, the participants in the current study were practising 
pathologists with variable levels of experience as compared to studies where 
either physicians (with no formal pathology experience) (349) or researchers 
with experience in IHC were recruited (283). Thus the results of this study 
provide good evidence on the use of cut-offs for IHC biomarkers. 
The strengths and limitations are: The strengths of this project include: the 
participation by seven practising pathologists in two sessions; and investigation 
of three different cut-offs for the same image making this study time-effective 
and a broad study in the PDAC IHC literature for observer agreement. The 
limitations include: the relatively fewer number of images due to the time 
constraints imposed by the clinical work of the pathologists; and all pathologists 
were from the same institution; the aim was to carry out the study with all of 
the pathologists present at one session and this was achieved for the inter-
observer part but for the intra-observer part we had to arrange an extra session. 
The other potential limitation might be that the images were shown as a 
PowerPoint presentation on screen rather than using a standard microscope.  
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Conclusion: In a day-to-day clinical practice pathologists need a scoring system 
and a cut-off that is reproducible and easy to use (189, 322).  A wide range of 
cut-offs have been used for IHC biomarkers and they are becoming more 
important. We selected 10%, 20% and +2/+3 cut-offs that have good clinical 
potential from the already existing cut-offs. These three cut-offs are reliable 
and reproducible achieving a reasonably good agreement level between 
pathologists (when compared with the literature). They could facilitate 
translational biomarker studies and could potentially be used by scientists who 
are not trained pathologist but are involved in investigating potential IHC 
biomarkers. Further studies are required to assess these cut-offs with 
pathologists from different institutions and using a larger sample of images.  
What this study adds: This is a wide study in PDAC biomarker research 
investigating cut-offs with implications for clinical practice. The translational 
significance of this work is providing a reasonable base for studies investigating 
biomarkers. A biomarker achieving diagnostic, prognostic and/or predictive 
significance with any of the three cut-offs might have a good translational 
potential as it might be easily interpreted by pathologists. 
What next: We have validated biomarkers in surgical specimens, determined 
cut-offs achieving better diagnostic sensitivity and specificity and we have 
validated cut-offs for observer agreement. The next step is to investigate the 
previously investigated biomarkers (KOC, maspin, mesothelin and S100P) as a 
panel in archival cytology samples using the identified and validated cut-offs. 
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Table 6.1: Explanation of the categories of k scores with colour codes 
0.01-0.20 Slight   
0.21-0.40 Fair   
0.41-0.60 Moderate   
0.61-0.80 Substantial   
0.81-1 Almost Perfect   
Note: These colour codes will be used for all subsequent figures and tables. 
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Table 6.2: Pairwise k scores of inter-observer agreements between pathologists for the 
three cut-offs. 
Note: Comparison of pairwise k scores with colour codes between pathologists (A-G) in the 
evaluation of immunohistochemistry using 10%, 20% and +2/+3 cut-offs. 21 inter-observer pairwise 
k scores (AB, AC, AD and so on……) were generated for all three cut-offs and are shown with 
mean k score and 95% CI separately for each cut-off. 
            10% Cut-Off 
Observers 
O
b
se
rv
e
rs
 
  A B C D E F G 
A   0.8 0.82 0.62 0.47 0.72 0.89 
B     0.82 0.62 0.47 0.53 0.89 
C       0.48 0.36 0.58 0.72 
D         0.48 0.55 0.72 
E           0.74 0.54 
F             0.6 
G               
  Mean k score   0.64 (95% CI, 0.57-0.70) 
             20% Cut-Off 
Observers 
O
b
se
rv
e
rs
 
  A B C D E F G 
A   0.85 0.57 0.64 0.54 0.49 0.92 
B     0.7 0.53 0.43 0.38 0.77 
C       0.64 0.42 0.48 0.51 
D         0.62 0.82 0.56 
E           0.71 0.46 
F             0.42 
G               
 
Mean k score 0.59 (95% CI, 0.52-0.66) 
           +2/+3 Cut-Off 
Observers 
O
b
se
rv
e
rs
 
  A B C D E F G 
A   0.75 0.42 0.6 0.55 0.46 0.65 
B     0.48 0.54 0.49 0.52 0.59 
C       0.55 0.61 0.72 0.61 
D         0.58 0.6 0.7 
E           0.88 0.88 
F             0.77 
G               
  Mean k score 0.62 (95% CI, 0.56-0.67) 
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Table 6.3: Pairwise k scores of inter-observer agreements between experienced and junior pathologists for the three cut-offs. 
 
Table 6.3: A, Comparison of 
pairwise K scores with colour 
codes between experienced 
pathologists (A-C) in the 
evaluation of 
immunohistochemistry using 10%, 
20% and +2/+3 cut-offs. Three 
inter-observer pairwise k scores 
(AB, AC and BC) were generated 
and are shown with mean k score 
and 95% CI separately for each 
cut-off.  
B, Comparison of pairwise K 
scores with colour codes between 
junior pathologists (D-G) in the 
evaluation of 
immunohistochemistry using 10%, 
20% and +2/+3 cut-offs. Six inter-
observer pairwise k scores (DE, 
DF, DG, EF, EG and FG) were 
generated and are shown with 
mean k score and 95% CI 
separately for each cut-off. 
A 
    
B 
    Experienced pathologists 
 
Junior pathologists 
10% Cut-Off 
 
10% Cut-Off 
 Observers   
Observers 
O
b
se
rv
e
rs
   A B C 
O
b
se
rv
e
rs
   D E F G 
A   0.80 0.82 
 
D   0.48 0.55 0.72 
B   
 
0.82 
 
E   
 
0.74 0.54 
        
 
F   
  
0.60 
        
 
G         
 Mean K score 0.81 (Range: 0.80-0.82) 
 
 Mean k score 0.61 (Range: 0.48-0.74) 
20% Cut-Off 
 
20% Cut-Off 
Observers  Observers 
O
b
se
rv
e
rs
   A B C 
 
O
b
se
rv
e
rs
   D E F G 
A   0.85 0.57 
 
D   0.62 0.82 0.56 
B   
 
0.70 
 
E   
 
0.71 0.46 
        
 
F   
  
0.42 
        
 
G         
 Mean K score 0.71 (Range: 0.57-0.85) 
 
 Mean k score 0.60 (Range: 0.42-0.82) 
+2/+3 Cut-Off 
 
+2/+3 Cut-Off 
Observers  Observers 
O
b
se
rv
e
rs
   A B C 
 
O
b
se
rv
e
rs
   D E F G 
A   0.75 0.42 
 
D   0.58 0.60 0.7 
B   
 
0.48 
 
E   
 
0.88 0.88 
        
 
F   
  
0.77 
        
 
G         
 Mean K score 0.55 (Range: 0.42-0.75) 
 
 Mean k score 0.73 (Range: 0.58-0.88) 
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Table 6.4: Multivariable linear regression for 10%, 20% and +2/+3 cut-offs as predictor 
variables and perceived ease of interpretation as dependent variable. 
Variables Unstandardized 
Coefficients 
Standardized 
Coefficients 
P value 
B Std. Error Beta 
(Constant) -5.67 1.07   <0.001 
10% Cut-off 0.71 0.16 0.41 <0.001 
+2/+3 Cut-off .46 0.12 0.38 0.001 
20% Cut-off 0.51 0.16 0.34 0.004 
Note: The 10%, 20% and +2/+3 are predictor variables i.e. they are variables that are predicting an 
outcome (the ease of interpretation). In this regression model ease of interpretation is a dependent 
variable i.e. a variable which “depends” on the predictor variable. The standardised beta 
coefficients were used as an estimate of association between predictor and dependent variable. 
The higher the beta coefficient the higher is the p-value significance and the stronger is the 
association between predictor and dependent variables. Beta coefficient in this model is highest 
(0.41) for 10% cut-off, followed by +2/+3 (0.38) and 20% (0.34). However, the p-value for all three 
cut-offs is significant showing a positive association with ease of interpretation. 
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Table 6.5: Pairwise k scores of intra-observer agreements for pathologists for the three cut-
offs. 
                                               K Scores 
Codes 10% P value 20% P value +2/+3 P value 
A-A 0.76 0.000 0.74 0.000 0.80 0.000 
B-B 0.89 0.000 0.68 0.000 0.72 0.000 
C-C 0.84 0.000 0.59 0.000 0.50 0.003 
D-D 0.43 0.002 0.55 0.001 0.59 0.000 
E-E 0.68 0.000 0.59 0.000 0.88 0.000 
F-F 0.47 0.003 0.51 0.002 0.94 0.000 
G-G 0.87 0.000 0.53 0.001 0.68 0.000 
Mean 
(95% CI) 
0.71  
(0.53-0.88) 
  
0.60  
(0.52-0.68) 
  
0.73  
(0.59-0.87) 
  
Note: Pairwise k scores showing intra-observer reproducibility from scoring re-scoring (for example 
A-A) of all seven pathologists (A-G) in the evaluation of Immunohistochemistry using 10%, 20% 
and +2/+3 cut-offs. 
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Table 6.6: Mean k scores with p values for staining of different cellular compartments. 
 
C vs. CN C vs. CM CN vs. CM 
Cut-Offs mean p value* mean p value mean p value 
10% 0.77 vs. o.71 0.380 0.77 vs. 0.64 0.150 0.71 vs. 0.64 0.500 
20% 0.75 vs. 0.63 0.100 0.75 vs. 0.40 <0.001 0.63 vs. 0.40 0.009 
+2/+3 0.81 vs. 0.58 0.001 0.81 vs. 0.40 <0.001 0.58 vs. 0.40 0.010 
Note: *Paired sample t test 
Abbreviations: C (cytoplasmic staining), CM (cytoplasmic and membranous staining) and CN 
(cytoplasmic and nuclear staining). 
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Figure 6.1: Boxplots showing the distribution of inter-observer k scores for 10%, 20% and 
+2/+3 cut-offs. 
 
Figure Legend: For each cut-off 21 pairwise inter-observer k scores are shown in boxplots. As 
evident from boxplots the k scores for 10% cut-off appear higher than 20% and +2/+3 cut-0ffs. To 
investigate whether the k scores of one cut-off is statistically higher than the others, paired sample t 
test was used to compare the three cut-offs. Three possible comparisons can be made: 10% vs. 
20%; 10% vs. +2/+3 and 20% vs. +2/+3. However, no statistically significant difference in the k 
scores was observed between the three cut-offs as shown by the p values. 
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Figure 6.2: Representative images of high and low inter-observer agreement between all 
pathologists for 10%, 20% and +2/+3 cut-offs. 
 
Figure legend: The high (left column grid) and low (right column grid) inter-observer agreement of 
IHC interpretation is shown for the three cut-offs. The staining for the three cut-offs was recorded 
only in the tumour epithelium. The high level agreement is attributed to the strong staining intensity 
and higher proportion of positive cells as illustrated in left column grid. All pathologists agreed on 
the images in the left column grid for all three cut-offs. However, there were differences in the 
number of pathologists agreeing on the images in the right column grid. For 10% cut-off (right 
upper image) 4/7 pathologists agreed, for 20% cut-off (right middle image) 5/7 pathologists agreed 
and for the +2/+3 cut-off (right lower image) 3/7 pathologists agreed. 
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Figure 6.3: Boxplots showing the distribution of intra-observer k scores for 10%, 20% and 
+2/+3 cut-offs. 
 
Figure Legend: For each cut-off seven pairwise intra-observer k scores are shown in boxplots. As 
evident from boxplots the k scores for 10% cut-off appear higher than 20% and +2/+3 cut-0ffs. To 
investigate whether the k scores of one cut-off is statistically higher than the others, Wilcoxon 
signed ranked test was used to compare the three cut-offs. Three possible comparisons can be 
made: 10% vs. 20%; 10% vs. +2/+3 and 20% vs. +2/+3. However, no statistically significant 
difference in the k scores was observed between the three cut-offs as shown by the p values. 
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7 A panel of KOC, maspin and mesothelin is a 
good working immunohistochemistry panel for 
PDAC diagnosis from cytology samples 
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7.1 Chapter Summary 
Pre-treatment diagnosis of PDAC involves imaging followed by endoscopy with 
cytology. Diagnostic confirmation is important for patient management and is 
achieved from interpretation of cytology samples. However, cytology is not 
perfect and can be difficult, especially in chronic pancreatitis. 
Immunohistochemical (IHC) biomarkers could help but none is yet routinely 
used. IHC biomarkers validated in pancreatico-biliary (PB) TMAs (discussed in 
chapters 4 and 5) were used to stain the archival cytology samples in a pilot 
study. The aim was to generate a diagnostic panel that could potentially help as 
an adjunct to cytology in difficult to diagnose cases. 
A cytology resource was generated from fresh Whipple’s resections for the 
optimisation of IHC antibodies. Optimised antibodies for IHC were then used on 
archival cytology samples from 11 patients with PDAC and 10 patients with 
benign diagnoses. IHC was performed on an automated platform using antibodies 
against KOC, maspin and mesothelin. Tissue cores were scored for staining 
intensity and the proportion of tissue stained using the Histoscore method 
(range, 0-300). Sensitivity and specificity for individual biomarkers, as well as 
biomarker panels, were determined with different cut-offs for positivity and 
compared using summary receiver operating characteristic (ROC) curves. 
The expression of all three biomarkers was high in PDAC cytology as compared to 
benign cytology with a mean Histoscore of 168 vs. 0 for KOC, 50 vs. 1.5 for 
maspin and 73 vs. 0.5 for mesothelin (p<.001). Five cut-offs, namely 5%, 10% or 
20% positive cells, moderate-strong staining intensity and Histoscore 20 were 
carefully chosen for sensitivity/specificity analysis. Using 10% positive cells as a 
cut-off achieved higher sensitivity/specificity values: KOC 92%/100%; maspin 
54%/100% and mesothelin 72%/100%. Analysis of a panel of KOC, S100P and 
mesothelin achieved 82% sensitivity and 100% specificity if at least 2 biomarkers 
were positive for the 10% cut-off; and 72% sensitivity and 100% specificity for the 
20% cut-off. 
A biomarker panel of KOC, maspin and mesothelin was found to be good panel 
with the 10% cut-off achieving high sensitivity and specificity in PDAC compared 
to benign diagnoses from cytology samples. 
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7.2 Introduction 
Pre-treatment diagnosis is important for the management of patients with PDAC 
and is achieved from cytology samples. The difficulty of morphologic assessment 
of cytology samples to distinguish PDAC from non-neoplastic pancreas and the 
potential role of IHC biomarkers to improve the cytology diagnosis has been 
discussed in detail in chapter 1. 
A systematic approach was adopted to address the unmet clinical need in the 
diagnosis of PDAC from cytology samples. A systematic review and meta-analysis 
was performed and five candidate diagnostic IHC biomarkers were selected for 
validation in our local cohort of resection specimens from patients with PBA. Of 
the five biomarkers tested, four appear to be specific and sensitive in tissue 
samples: KOC, maspin, S100P and mesothelin. These four candidate biomarkers 
will now be investigated in archival cytology samples to elucidate their 
diagnostic potential for clinical translation. 
7.2.1 Aims  
The aims of this chapter were as follows: to assess the sensitivity and specificity 
of biomarkers singly and in panels in archival cytology samples (PDAC and benign 
samples); and to assess the suitability of ‘needling’ cytology samples for IHC 
optimisation. This should enable us in determining a clinically useful diagnostic 
biomarker or panel of biomarkers that could potentially be applied in difficult to 
diagnose cytology cases. 
7.3 Results 
IHC on cytology samples was performed utilising an automated IHC platform for 
KOC, mesothelin, maspin and S100P. After immunostaining the scoring of 
cytology samples was performed using a standard light microscope. The scoring 
of cytology samples was performed by a pathologist (SB) and all subsequent 
sensitivity and specificity analyses are based on this scoring. A categorical 
scoring using 10% positive cells as a cut-off was performed by the same 
pathologist (SB) and by the author (AA) for inter-observer agreement. The 
scoring of cytology samples was performed blind to the final diagnosis.  
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The results of this chapter are divided into two main parts: the use of ‘needling’ 
cytology samples for antibody optimisation; and assessing the diagnostic 
sensitivity and specificity of biomarkers in the archival cytology samples from 
patients with PDAC and benign cytology. 
7.3.1 The use of ‘needling’ cytology samples for antibody 
optimisation  
A resource of normal (pancreatic, duodenal) and malignant (PDAC) cytology, in 
the form of “cell blocks”, from Whipple’s resections was developed. These 
samples were called ‘needling’ cytology samples. The purpose of this resource 
was four-fold: to stain these samples with same IHC parameters used for staining 
TMAs; to further optimise IHC for cytology samples to achieve potentially better 
staining; to observe biomarker expression in malignant and normal (pancreatic, 
duodenal) cytology samples; and to use these samples as positive controls for 
staining the archival cytology samples.  
The ‘needling’ samples were first stained with ‘IHC parameters optimised for 
TMAs’ and then with the ‘IHC parameters optimised for cytology’. 
7.3.1.1 Staining the ‘needling’ samples with ‘IHC parameters optimised for 
TMAs’ 
Ten ‘needling’ samples obtained from five Whipple specimens (5 samples from 
tumour and 5 from adjacent normal pancreas) were used for IHC staining for 
each biomarker (KOC, S100P, maspin and mesothelin). The corresponding tissue 
sections of these cytology samples were also used to compare IHC staining in cell 
and tissue specimens. The ‘IHC parameters optimised for TMAs’ were used for 
this IHC run (shown in Table 2.4, Chapter 2). The staining achieved is presented 
for the four biomarkers.  
PDAC ‘needling’ and tumour staining in corresponding tissue sections: The 
staining for KOC was cytoplasmic and present in 2 out of 5 PDAC ‘needling’ 
samples with Histoscore of 60 and 10 for the two samples. Overall the staining 
was weak in intensity and patchy. The staining in all five corresponding PDAC 
tissue sections was present as expected and was weak to strong in intensity and 
diffuse in PDAC (Figure 7.1).  
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The staining for mesothelin was cytoplasmic and membranous and for diagnostic 
purposes the presence of either cytoplasmic or membranous or both types of 
staining was considered. The staining was present in 2 out of 5 PDAC ‘needling’ 
samples with Histoscore of 80 and 70 for the two samples. Overall the staining 
was weak in intensity and diffuse. The staining in all five corresponding PDAC 
tissue sections was present as expected and was weak to strong in intensity and 
diffuse in PDAC (Figure 7.1).  
The staining for maspin was cytoplasmic and nuclear but for diagnostic purposes 
only cytoplasmic staining was considered. The staining was present in 3 out of 5 
PDAC ‘needling’ samples with Histoscores of 300, 60 and 90 for the three 
samples. Overall, the staining was weak to strong in intensity and diffuse but a 
significant amount of background staining was observed. The staining in all five 
corresponding PDAC tissue sections was present as expected and was moderate 
to strong in intensity and diffuse in PDAC (Figure 7.1).  
No staining for S100P was observed in any of the PDAC ‘needling’ samples. 
However, the staining in all five corresponding PDAC tissue sections was present 
as expected and was moderate to strong in intensity and diffuse in PDAC (Figure 
7.1). 
Normal pancreatic ‘needling’ and normal pancreas in corresponding 
resection specimens: For all four biomarkers, staining was absent from the 
normal pancreatic ‘needling’ samples and from normal tissues in tissue sections.  
In summary, the purpose of this IHC phase was to verify the ‘IHC parameters 
optimised for TMAs’ using cytology samples. It appeared that the staining for 
maspin was good (but with a high background staining), staining for KOC and 
mesothelin was weak in intensity and less percentage of neoplastic cells showed 
positive staining and S100P showed no staining. Thus all four biomarkers might 
require further optimisation. The staining achieved in TMA sections has not fully 
reflected in cytology samples. The next section thus explains the optimisation of 
biomarkers for cytology specimens. 
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7.3.1.2 Optimising the IHC parameters for four antibodies to achieve better 
staining using ‘needling’ cytology samples 
IHC staining can sometimes be challenging to achieve due to technical issues. 
The available evidence on IHC parameters for these antibodies was reviewed in 
the PDAC cytology literature (shown in Table 2.2, Chapter 2). In assessing the 
PDAC IHC literature for these biomarkers, we identified other options used in 
two IHC parameters i.e. antigen retrieval and primary antibody dilutions. Hence 
these two parameters were reviewed.  
The purpose of this IHC run on ‘needling’ samples was to optimise antibodies 
with the hope of achieving better staining. The aim for KOC and mesothelin was 
to achieve better staining in terms of both intensity and the proportion of 
positive cells. The aim for maspin was to reduce the background signal and the 
aim for S100P was to achieve any staining. 
For each antibody two sets of five PDAC ‘needling’ samples were used to 
compare different IHC parameters. One set was used for staining the samples 
with ‘IHC parameters optimised for TMAs’ and the second set was used to vary 
antigen retrieval buffer for KOC and mesothelin, to vary antigen retrieval 
method for S100P and to vary antibody dilution for maspin. These were called 
‘IHC parameters optimised for cytology’. The details of these parameters are 
outlined in Tables 2.4, 2.5 and 2.6 in chapter 2.  
Comparing the staining achieved for various IHC parameters using ‘needling’ 
cytology samples: The issue of weak staining for KOC and mesothelin was 
addressed by changing the pH of antigen retrieval buffer solution.  
For KOC, an improvement in IHC staining was observed with a mean Histoscore 
of 250 compared to 30 in malignant cells of all ‘needling’ samples for ‘IHC 
parameters optimised for cytology’ compared to ‘IHC parameters optimised for 
TMAs’.  
Similarly, for mesothelin, an improvement in IHC staining was observed with a 
mean Histoscore of 160 compared to 65 in malignant cells of all ‘needling’ 
samples. Thus by changing only one IHC parameter a significant improvement in 
staining was achieved for KOC and mesothelin (Figure 7.2).  
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For maspin, the issue of significant background staining was addressed by 
doubling the dilution of primary antibody. The mean Histoscore was 135 for ‘IHC 
parameters optimised for cytology’ compared to 150 for the ‘IHC parameters 
optimised for TMAs’. Thus the sensitivity of maspin detection was not 
significantly affected but the background signal was decreased (Figure 7.2). For 
S100P, no staining was observed with varying the IHC parameters (both antibody 
dilution and antigen retrieval). 
In summary, changing the antigen retrieval buffer for KOC and mesothelin 
significantly improved the staining in ‘needling’ samples. The background signal 
for maspin was decreased by doubling the antibody dilution without significantly 
affecting the antigen detection.  
Staining the normal pancreatic and normal duodenal ‘needling’ samples: The 
changes in IHC parameters might potentially affect the staining in normal tissue 
and hence the specificity of biomarkers. To address this issue normal pancreatic 
‘needling’ samples were stained with the ‘IHC parameters optimised for 
cytology’. Cytology samples may contain gastro-intestinal contaminants 
including normal duodenal epithelial cells and it would be of value to assess the 
biomarker expression in these cells. The normal duodenal ‘needling’ samples 
were therefore stained. Five normal pancreatic and five normal duodenal 
‘needling’ samples were used for each of the four antibodies (KOC, S100P, 
maspin and mesothelin). No or focal (<5%) staining in all normal ‘needling’ 
samples was observed for all biomarkers. Hence changing the IHC parameters did 
not affect the specificity of these biomarkers providing more confidence for 
using of changed IHC parameters for staining the archival cytology samples.  
The analysis of PDAC and normal ‘needling’ samples using ‘IHC parameters 
optimised for cytology’ achieved better staining and correlated well with the 
ultimate malignant versus benign diagnoses. The handling and processing of the 
‘needling’ samples was performed as similarly as possible to how actual EUS-FNA 
cytology samples are collected and processed. We therefore considered that the 
IHC conditions that worked well on the ‘needling’ samples could be taken 
forward to stain archival cytology samples. The final optimised IHC conditions 
are summarised in Table 2.6, chapter 2. The optimisation was successful for 
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KOC, maspin and mesothelin and therefore these biomarkers will be taken 
forward for staining the archival cytology samples. 
7.3.2 Immunohistochemical diagnostic biomarkers for pancreatic 
ductal adenocarcinoma - a pilot study on cytology samples. 
The archival cytology samples were used to investigate the panel of KOC, maspin 
and mesothelin. 11 malignant cytology cell blocks (final diagnosis PDAC) and 10 
benign cytology cell blocks were retrieved from the cytology archive of Southern 
General Hospital, Glasgow, UK. The detail of the selection process of the 
samples for this pilot project is outlined chapter 2. The cellularity of these 
samples was checked using the H&E section to ensure that malignant and benign 
samples contained adequate malignant and benign cells for testing. IHC was 
performed using ‘IHC parameters optimised for cytology’. 
The objectives of this pilot study were as follows: to assess the diagnostic 
sensitivity and specificity of KOC, maspin and mesothelin singly and in panel 
using archival cytology samples; to assess the utility of five cut-offs identified in 
TMA work but especially to validate the diagnostic performance of 10%, 20% and 
+2/+3 cut-offs in cytology samples; and finally to assess the observer agreement 
for 10% cut-off by two independent observers i.e. a pathologist (SB) and the 
author (AA). 
The results of this section are subdivided into three main categories: assessing 
the expression of biomarkers in PDAC and benign cytology; using the cut-offs to 
calculate sensitivity and specificity singly and as a panel of biomarkers; and 
using the 10% cut-off as a binary categorical variable (positive/negative) to 
investigate inter-observer agreement. 
7.3.2.1 Expression of all biomarkers was epithelial and was significantly 
higher in PDAC than benign cytology 
For each marker assessed in the cytology cohort, IHC staining was seen only in 
epithelial cells.  As expected, KOC expression was observed in the cytoplasm; 
maspin was expressed in the cytoplasm and nucleus (but for diagnostic purposes 
cytoplasmic staining was scored), while mesothelin expression was cytoplasmic 
and membranous (Figure 7.3). In general, moderate to strong intensity of 
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staining was observed for KOC, while weak to strong staining was observed for 
maspin and mesothelin in malignant cytology samples. Moreover, for all three 
biomarkers significantly higher expression in malignant versus benign cytology 
was observed (Table 7.1, p<0.003, Independent sample t-test).  
7.3.2.2 Expression of KOC was higher than maspin and mesothelin in PDAC 
cytology samples as assessed by the percentage positivity and 
Histoscores 
When scored simply as the proportion of positive staining cells, the mean 
percentage of positive cells in malignant cytology samples for KOC was 66%, for 
maspin it was 33% and for mesothelin it was 36%. A more comprehensive and 
semi-quantitative analysis was performed by utilizing a Histoscore as a scoring 
system. The mean Histoscore in malignant cytology for KOC was 168, while for 
maspin and mesothelin, the mean Histoscores were 50 and 73 respectively 
(Table 7.1). 
The expression level for all three biomarkers in PDAC cytology samples was high 
making the interpretation of immunostaining easy. Next I assessed the 
expression levels of biomarkers in benign cytology samples to evaluate the 
specificity of biomarkers. 
7.3.2.3 Expression of all biomarkers in normal tissue was very low for all 
three biomarkers 
The expression of the three biomarkers was very low (mean Histoscore for KOC 
0, for maspin 1.5 and for mesothelin 0.5) in benign cytology samples (Table 7.1). 
It is therefore hoped that in a mixed population of tumour and normal cells, only 
positive staining would need to be taken into account for diagnostic purposes, as 
positivity is essentially associated only with tumour cells. Thus, IHC staining 
using these markers could facilitate the interpretation of cytology samples. The 
sensitivity and specificity of biomarkers using various cut-offs was next analysed. 
7.3.2.4 KOC is a better candidate diagnostic biomarker than maspin and 
mesothelin based on sensitivity and specificity values 
The following number of PDAC cytology cases stained positive using 10% cut-off 
for KOC, maspin and mesothelin: for KOC 10 out of 11 PDAC cases; for maspin 6 
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out of 11 PDAC cases; and for mesothelin 8 out of 11 PDAC cases (Table 7.2). All 
PDAC cases (11 out of 11) were positively stained taking all biomarkers together 
as a panel. In contrast, all benign cytology cases (10 out of 10) were negative for 
all three biomarkers (Table 7.2).  
The sensitivities and specificities of all three biomarkers were calculated using 
five cut-offs, as shown in Figure 7.4. KOC expression appears to show reasonably 
high sensitivity and specificity for all cut-offs. The 5% and 10% cut-offs achieve 
marginally better sensitivity (92%) and specificity (100%) values compared with 
other cut-offs for KOC (Figure 7.4A). Maspin appears to have similar sensitivity 
and specificity values for all cut-offs except the 5% cut-off that has low 
specificity (82%) (Figure 7.4B). Applying the five cuts-offs to the analysis of 
mesothelin expression resulted in different sensitivity and specificity values, 
however, the best combination was again achieved using the 10% cut-off, with 
72% sensitivity and 100% specificity (Figure 7.4C). 
In summary, KOC is a highly sensitive and specific biomarker for PDAC diagnosis. 
Maspin and mesothelin are highly specific biomarkers but their sensitivity in 
detecting malignancy in cytology samples is low. Now we know that these 
biomarkers are highly specific with very low expression in the normal pancreas 
but their sensitivity as a single candidate biomarker might not be clinically 
useful. To improve the sensitivity, panels of biomarkers were used. KOC, maspin 
and mesothelin were used in different panels for PDAC diagnosis in cytology 
samples as shown in the following section. 
7.3.2.5 A biomarker panel of KOC, maspin and mesothelin was found to be a 
good diagnostic panel for PDAC diagnosis from cytology 
The sensitivity and specificity of panel of biomarkers were next assessed to find 
a suitable panel for PDAC diagnosis. The 10% and 20% cut-offs were selected for 
this investigation, based on their diagnostic performance. 
Two panel approaches were used for sensitivity and specificity analysis. One 
approach categorised the patients into malignant and benign cytology if at least 
one biomarker in the panel was positive. For example for a 10% cut-off, the 
presence of 10% positive cells for one or more biomarker in a panel in the same 
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cytology sample is required to categorise the patient into a tumour category. 
Using this approach four panels of biomarkers were tested as shown in Table 7.3. 
These panels were: a panel comprising all three biomarkers; and three panels of 
two biomarkers in combination (KOC and mesothelin, KOC and maspin, maspin 
and mesothelin). A panel of all three biomarkers achieved 100% sensitivity and 
specificity for a 10% cut-off; and further achieved 90% sensitivity and 100% 
specificity for a 20% cut-off. These panels were compared by combined SROC 
curve, using both the 10% cut-off (Figure 7.5A) and 20% cut-offs (Figure 7.5B). 
The combined SROC curve showed that a panel of all three biomarkers is better 
than the other panels for both 10% and 20% cut-offs.  
The second panel approach categorised the patients into malignant and benign 
cytology if at least two biomarkers in the panel were positive. For example for a 
10% cut-off, the presence of 10% positive cells for two or more biomarkers in a 
panel in the same cytology sample is required to categorise the patient into a 
tumour category. A biomarker panel comprising all three biomarkers (KOC, 
maspin and mesothelin) was tested for sensitivity and specificity analysis using 
this approach. This panel achieved 82% sensitivity and 100% specificity for a 10% 
cut-off and 72% sensitivity and 100% specificity for a 20% cut-off (Table 7.3). 
Figure 7.6 shows immunostaining of a PDAC cytology case to demonstrate the 
importance of the panel of biomarkers. This shows that the immunostaining may 
help in confirming the diagnosis in cases where the cytologist is unsure. Taken 
together, our results show that a panel comprising all three biomarkers could be 
used to improve the diagnosis of PDAC in difficult to diagnose cases. 
7.3.2.6 The 10% cut-off achieved a high inter-observer agreement for IHC 
interpretation in cytology samples  
The 10% cut-off achieved a good combination of sensitivity and specificity for all 
three candidate biomarkers and panels in cytology samples. Therefore, I next 
analysed the inter-observer agreement for 10% cut-off as a categorical 
(positive/negative) variable. The cytology sample is called positive for 
malignancy when immunostaining is present in 10% or more cells. Conversely, 
the cytology sample is called negative for malignancy when immunostaining is 
present in less than 10% cells.  
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All malignant and benign cytology samples were scored by two observers. The 
inter-observer agreement for KOC using a 10% cut-off is in ‘almost perfect’ 
category (κ score=1.00). Similarly, the k scores using 10% cut-off for maspin and 
mesothelin are 0.92 and 0.91 respectively. Finally, the k score taking all three 
biomarkers as a panel for the 10% cut-off is 0.94 (Table 7.4).  
Although the sample size is small, there is a high level agreement on the 10% 
cut-off between observers. This suggests that if the 10% cut-off is used in PDAC 
diagnostic cytology the observer variation is minimised. The use of the 10% cut-
off is thus not only good in differentiating PDAC from benign but also achieves a 
good agreement level. 
In summary, a panel of KOC, maspin and mesothelin using 10% cut-off is a good 
panel for the diagnosis of PDAC from cytology samples. This panel could 
potentially be used in difficult to diagnose cases as an adjunct to morphologic 
interpretation of cytology. 
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7.4 Discussion 
Biomarkers could help improve the diagnostic management of patients with 
PDAC. We systematically addressed the issues delaying the translation of 
biomarkers from bench to clinic. After identification and validation in our 
surgical cohort, the utility of good biomarkers was investigated using archival 
cytology samples in a pilot study. A panel of KOC, maspin and mesothelin 
achieved high diagnostic sensitivity and specificity for PDAC diagnosis in cytology 
samples. 
Biomarker research in cytology samples can present some challenges (361) and 
the discussion is thus broadly divided into two sections. The first section will 
discuss the issues related to assay development and IHC optimisation. The 
second section will discuss the utility of diagnostic IHC biomarkers in potentially 
improving PDAC diagnosis from cytology samples.  
7.4.1 The role of ‘needling’ resource for biomarker optimisation 
Antibody optimisation is important to ensure good staining. The ‘needling’ 
samples were processed into cell blocks and sections from these cell blocks were 
used for antibody optimisation and assay development. Cell block sections 
provide a good platform for IHC (362). The sample preparation of cell blocks 
differs from surgical specimens and this might affect the transfer of IHC 
conditions from tissue to cytology for some biomarkers. Briefly, surgical 
specimens are fixed in formalin for 24-48 hours, specimens are then cut, 
processed, embedded in wax and ultimately result in paraffin blocks for 
sectioning (363). In comparison, the fine needle aspiration specimens are put in 
PreservCyt solution, spun in a centrifuge, cells/tissue fragments settle to the 
bottom of the tube, the supernatant fluid is removed and then plasma and 
thrombin are added to make clot of cells or cell pellet. The cell pellet is then 
fixed in formalin overnight and with the help of wax is processed to paraffin cell 
blocks (167). Theoretically, the target antigen in the cell block sections might 
therefore need different antigen retrieval conditions than tissue sections to 
expose some antigens for immunostaining.  
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A cytology resource from fresh Whipple resections was generated to allow 
antibody optimisation and to use as control sections. Archival cytology samples 
are precious and given the limited availability, optimisation of IHC is 
challenging. In addition, the clinicopathologic information of all patients 
undergoing cell sample collection is maintained that requires a significant 
amount of time and cost. It is therefore vital to use the archival cytology 
samples for properly worked up biomarkers. A ‘needling’ cytology resource in 
the form of FFPE cell blocks was thus generated for optimising antibodies. The 
procurement of cell samples from Whipple resections and then the processing of 
these cell specimens into cell blocks were performed in a similar manner to the 
fine needle aspiration samples (167, 364). This comparable processing will help 
in transferring the optimised IHC conditions from ‘needling’ to archival samples.  
An ideal diagnostic biomarker should have higher expression levels in the tissue 
of interest than its comparator (365, 366). In this study the tissue of interest was 
malignant cells in the PDAC cytology samples and the comparator was non-
neoplastic pancreatic epithelial cells. To achieve good staining in PDAC cytology 
and low staining in non-neoplastic cells, the IHC conditions were optimised.  
IHC optimisation is the cornerstone of assay development in IHC biomarker 
research and optimisation is sometimes necessary to achieve better staining 
(120, 122, 147). Usually the IHC conditions used for surgical specimens are used 
for cytology specimens (164, 167, 176). However, the IHC conditions of surgical 
specimens did not work well on ‘needling’ samples in the current project. 
Therefore, the IHC conditions were optimised using ‘needling’ samples to ensure 
good staining for archival cytology samples. A variety of parameters could be 
changed for optimisation of IHC and include, among others, antigen retrieval, 
antibody dilutions, incubation timing and temperature conditions (122, 146, 
194). The antigen retrieval greatly improves the immunostaining in formalin 
fixed cytology specimens (367) and the method can be varied by time, 
temperature, type of enzyme, and buffer solutions. The heat induced epitope 
retrieval (HIER) is by far the most common method employed in clinical and 
research laboratories (146). In the present study, better staining for KOC and 
mesothelin was achieved after varying the antigen retrieval buffer for HIER and 
better staining for maspin was achieved after varying the antibody dilution. The 
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utilisation of HIER is subjective and there is no consensus on the type of HIER in 
IHC laboratories. The application of various buffers, timing and temperature 
conditions are used randomly. The level of immunostaining is directly related to 
the method adopted for HIER (195, 368, 369). We have also illustrated here that 
the change in HIER buffer solution significantly enhances the staining without 
compromising specificity. The optimisation for S100P was not successful despite 
varying both the antigen retrieval and antibody dilutions in the current study. 
This might probably be related to the processing of cytology samples. Liu et al 
(167) fixed the cells after EUS-FNA in formalin for 10 minutes compared to 12 
hour formalin fixation in our cytology laboratory. 
The use of control specimens is important in IHC and they must be of 
similarly prepared material for quality assurance (361). No cytology control is 
mentioned in the literature for diagnostic biomarkers investigated in PDAC (166, 
167, 174). The PDAC ‘needling’ sample with positive staining for a biomarker 
was used as positive control and a normal ‘needling’ sample with negative 
staining for biomarker was used as negative control. As the ‘needling’ samples 
were prepared in a similar manner to the archival samples, they could serve as 
good control specimens for biomarkers.  
The diagnostic utility of worked-up biomarkers (KOC, maspin and mesothelin) on 
archival cytology samples was then evaluated.  
7.4.2 The staining of archival cytology samples and development 
of diagnostic IHC panel 
Clinical translation of diagnostic biomarkers requires careful investigation from 
assay development to microscopic assessment of biomarkers and evaluation of 
their diagnostic accuracy (138, 147). A significant number of potential 
biomarkers have been investigated in surgical pathology specimens and a variety 
of cytology preparations (cell blocks, direct smear etc) to improve the diagnosis 
of PDAC. The usefulness of KOC, maspin and mesothelin as diagnostic biomarkers 
has been investigated singly and in a panel; however, none has entered routine 
clinical practice (166, 167, 217, 235). Lack of specific and sensitive biomarkers 
make the diagnosis of PDAC challenging in atypical or indeterminate to diagnose 
cases.  
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Archival cytology samples were stained for the three biomarkers KOC, maspin 
and mesothelin. The IHC staining in cytology samples was interpreted based on 
the overall staining irrespective of the benign or malignant mixture of cells. A 
variety of scoring systems have been adopted for biomarker research in PDAC 
cytology samples (141, 165, 173, 186, 255, 271). The Histoscore is a semi-
quantitative IHC scoring system covering both staining intensity and the 
percentage of positive cells and gives a better indication of the expression level 
of the biomarker (321). Biomarkers with high expression levels in malignant 
tissue are better candidates for diagnostic purposes. Hence the cytology samples 
were scored using a Histoscore for each sample. KOC is highly expressed in 
malignant cytology samples as illustrated by the high Histoscore values 
compared to maspin and mesothelin. The expression of KOC is comparatively 
more homogenous than maspin and mesothelin in malignant cytology samples. In 
comparison, all three biomarkers have either no or focal expression in benign 
samples. 
The sensitivity and specificity of biomarkers was assessed using cut-offs 
identified in chapter 4. A special focus was on the three cut-offs i.e. 10%, 20% 
and +2/+3 which were tested for reliability and reproducibility in chapter 6. The 
three most common cut-offs used in the literature for PDAC cytology are positive 
or negative staining (255, 256, 271), 5% positive cells (175) and 10% positive cells 
(159, 186). The 10% cut-off was therefore investigated for reproducibility 
between two observers. 
The sensitivity and specificity of biomarkers in PDAC cytology is usually tested 
using only one diagnostic cut-off for categorizing patients into diagnostic groups 
(166, 167, 217, 254). Here, we report the use of multiple cut-offs for the same 
biomarker investigated in the same samples. Based on the results reported, the 
translational scientists or pathologists can then select a cut-off that is more 
appropriate to their situation. A cut-off should deliver a good combination of 
sensitivity and specificity. We know (from chapter 6) that 10%, 20% and +2/+3 
are good cut-offs, therefore, let us discuss the diagnostic ability of biomarkers 
individually utilizing these cut-offs.  
KOC, is a highly sensitive and specific biomarker across all cut-offs and the 
values are comparable to the TMA work (presented in chapters 4). The 
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sensitivity and specificity achieved in the current study is 92% and 100%. A 
sensitivity range of 71%-95% and a specificity range of 91%-100% have been 
reported for KOC in PDAC cytology literature (174, 175, 217). The specificity of 
maspin is good for all cut-offs but the sensitivity is lower compared to our TMA 
work (presented in chapter 5) and literature. The sensitivity and specificity 
achieved in the current study is 54% and 100%. The sensitivity and specificity for 
maspin reported in a PDAC cytology study is 100% and 90% (167). Finally, 
mesothelin is moderately sensitive and specific and the values are comparable 
to our TMA work except for 20% cut-off where the sensitivity is less than the 
TMAs (presented in chapters 4). The sensitivity and specificity achieved in the 
current study is 72% and 100%. A sensitivity range of 62%-69% and a specificity 
range of 91%-100% have been reported for mesothelin in PDAC cytology 
literature (164, 173, 254, 255). 
Taken together, these biomarkers could help diagnose PDAC from clinical 
cytology samples with good diagnostic accuracy for KOC followed by mesothelin 
and maspin. KOC appears to be a very good candidate for categorizing patients 
in malignant and benign groups. This also agrees with the PDAC cytology 
literature for KOC and is highly recommended for future diagnostic studies. 
Maspin and mesothelin have comparatively low sensitivity but they are highly 
specific which makes them suitable candidates for investigation as a panel. 
Lastly, these results should be interpreted with caution due to the small sample 
size of this pilot project. These biomarkers were next investigated as a panel. 
A panel of KOC, maspin and mesothelin is highly sensitive and specific for 
PDAC diagnosis from cytology. The high specificity of KOC, maspin and 
mesothelin will ensure that the combination of biomarkers will not affect the 
specificity and will improve the sensitivity. The inter- and intra-tumour 
heterogeneity of biomarker expression makes it hard for a single candidate to be 
100% sensitive (191, 192). Our results also show that none of the proposed 
biomarkers provide perfect sensitivity. Thus, a negative test result based on a 
single biomarker expression can lead to false negativity. Therefore, a panel of 
biomarkers seems more appropriate as it improves the sensitivity and the chance 
of missing malignancy is significantly reduced. Highly specific biomarkers are 
important to avoid false positivity and misclassification of disease (366, 370). 
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Clinically, this would mean that positivity is essentially limited to the condition 
of interest (malignant disease) and negative results essentially mean a benign 
etiology. 
Two different approaches were adopted in this study to determine a panel 
delivering clinically useful sensitivity and specificity. One approach categorised 
patients into malignant and benign disease if one or more biomarker in a panel 
was positive. In contrast, the second approach assigned patient into malignant 
and benign groups if two or more biomarkers were positive in the panel. Clearly, 
the second approach provides more diagnostic confidence to the cytopathologist 
reporting the sample based on biomarker expression. However, the first 
approach provides better sensitivity compared to the second approach. The 
panel of KOC, maspin, mesothelin utilising 10% cut-off and two or more positive 
biomarkers achieve good sensitivity (82%) and specificity (100%). This panel is 
recommended for further investigation in prospective samples. 
Diagnostic biomarkers have been previously investigated in cytology samples 
collected during EUS-FNA and pancreatico-biliary brushing. They have been 
investigated as single biomarkers e.g. KOC, MUC1, S100P, XIAP, mesothelin, P53 
and SMAD4 (141, 170, 174, 177, 217, 254, 258) or as panel of biomarkers (139, 
159, 165, 173, 175, 176, 188). The panel of biomarkers investigated in 
pancreatic cytology mostly compose of two biomarkers for example panels of B7-
H4 and P53 (165), S100P and XIAP (159), MUC1 and MU2 (170), KOC and S100A4 
(175) and mesothelin and 14-3-3σ (164). The sensitivity and specificity achieved 
in the current study for a panel of KOC, maspin and mesothelin is 100% and 100% 
(at least one positive marker in panel) and, 82% and 100% (at least two positive 
biomarkers in panel). This is comparable to the panel of KOC and S100A4 with a 
sensitivity and specificity of 100% and 95% (175) , panel of S100P and XIAP with 
sensitivity of 83% (specificity not given) (159). Furthermore, the specificity of 
our panel is better than the panel of mesothelin and 14-3-3σ with sensitivity and 
specificity of 96% and 75% (164).  
The panel of KOC, maspin and mesothelin has thus good translational potential. 
Neuroendocrine differentiation markers such as synaptophysin, CD56 and 
chromogranin A are clinically used for confirming the diagnosis of 
neuroendocrine tumours in pancreatic cytology (153, 154, 371). The staining of 
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PDAC cytology achieved for the biomarkers investigated in the current project 
(Figure 7.2 and Figure 7.3) is comparable to the neuroendocrine markers 
(synaptophysin and CD56) staining in pancreatic cytology (Figure1c and 1d 
(153)). The clinical translation of the proposed biomarkers might thus be easy 
for improving PDAC diagnosis from cytology samples in difficult to diagnose 
cases. 
Finally, the 10% cut-off was tested for observer agreement in PDAC cytology 
samples. From chapter 6, we know that the 10% cut-off achieves high observer 
agreement. Almost perfect (k score >0.80) agreement was observed for the 10% 
cut-off for all three biomarkers. The k score agreement generated from our work 
is comparable to (k score=0.71-0.89) (372, 373) and sometimes better (k 
score=0.44-0.54) (374, 375) than the k scores reported in the cytology literature. 
The PDAC cytology literature was searched (Pubmed, 12 August 2014) but no 
study was found assessing observer agreement for IHC markers in pancreatic 
cytology. The samples size is small and hence these results should be interpreted 
with caution, however, this study adds to our understanding of observer 
agreement in the PDAC cytology. This may open avenues for future studies 
investigating biomarkers and cut-offs in cytology samples for observer 
agreements. 
The strengths of this study are: utilising ‘needling’ cytology samples for IHC 
optimisation and as controls for cytology IHC run before staining the precious 
and finite archival samples; using Histoscore for scoring purposes providing a 
semi-quantitative expression level of biomarkers; assessing of IHC staining by an 
independent pathologist (SB) to remove the subjective bias that the author (AA) 
might introduce to this important pilot study; evaluating sensitivity and 
specificity of  biomarkers utilising consensus based cut-offs; investigating 10% 
cut-off for inter-observer agreement.  
The limitations are: the sample size is relatively small (n=21 cytology samples), 
however, the pancreatic cytology literature for biomarker studies  can be as 
small as 15 (165, 376), 21 (174), 22 (258) and 25 (217); the inability to stain 
cytology samples for S100P which will be part of our future work; lower than 
expected sensitivity achieved for maspin compared to our TMA work and 
literature; and only two observers for inter-observer agreement analysis. 
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Conclusions: A pilot project for improving PDAC diagnosis from cytology samples 
was evaluated utilising a panel of KOC, maspin and mesothelin. This panel 
appears to achieve good sensitivity and specificity in diagnosing PDAC and 
excluding benign cytology. A threshold of 10% positive cells appears to achieve 
better diagnostic accuracy for PDAC diagnosis for all biomarkers and panels. In 
addition, the inter-observer agreement for 10% cut-off is very good for all three 
biomarkers. To sum up, our data show that a panel of KOC, maspin and 
mesothelin using 10% cut-off could potentially be used as an adjunct to 
morphologic interpretation (like neuroendocrine markers) to confirm the 
diagnosis of PDAC from cytology. 
What this study adds: This study proposes the utility of a panel for biomarkers 
for improving the diagnosis of PDAC from cytology samples as an adjunct to 
cytology in difficult-to-diagnose cases. It also provides evidence of the utility of 
‘needling’ samples for IHC biomarker optimisation. 
What next: Applying the suggested panel to prospectively collected cytology 
samples and assessing the role of the panel in PDAC diagnosis from cytology 
samples. 
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Table 7.1: Summary statistics of KOC, maspin and mesothelin expression comparing PDAC 
and benign cytology samples 
Biomarkers Malignant 
cytology 
Benign 
cytology 
P value 
KOC 
Positivity* Mean 66% 0% <0.001 
Median 80% 0%  
Histoscore Mean 168 0 <0.001 
Median 175 0  
Maspin 
Positivity Mean 33% 1.2% <0.003 
Median 50% 0%  
Histoscore Mean 50 1.5 <0.003 
  Median 60 0  
Mesothelin 
Positivity Mean 36% 0.5% <0.001 
Median 20% 0%  
Histoscore Mean 73 0.5 <0.001 
Median 40 0  
Note: *Positivity (percentage of positive cells with any staining intensity in tumour and normal 
tissue); P value (shows the statistical significance of the difference in expression of a biomarker in 
tumour vs. normal tissue); Positivity range (0-100), Histoscore range (0-300). 
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Table 7.2: Distribution of staining results for biomarkers in PDAC and benign cytology 
samples 
Biomarkers PDAC Cytology  Benign Cytology 
KOC 10/11 (92%) 0/10 (0%) 
Maspin 6/11 (54%) 0/10 (0%) 
Mesothelin 8/11 (72%) 0/10 (0%) 
KOC, maspin, mesothelin 11/11 (100%) 0/10 (0%) 
Note: Data are given as number of positive cases for biomarker divided by total number of cases. 
The percentage of positive cases is shown in brackets. These results are based on 10% cut-off. A 
positive case is defined as the presence of 10% cells with positive staining in the cytology sample. 
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Table 7.3: Panels of biomarkers used for sensitivity and specificity analyses, using 10% and 
20% positive cells as cut-offs for positivity  
10% positive cells as cut-off 
Panels  Sensitivity Specificity 
KOC, Maspin, Mesothelin 100% 100% 
KOC, Mesothelin 100% 100% 
KOC, Maspin 90% 100% 
Maspin, Mesothelin  90% 100% 
KOC, Maspin, Mesothelin*  82% 100% 
20% positive cells as cut-off 
Panels Sensitivity Specificity 
KOC, Maspin, Mesothelin 90% 100% 
KOC, Mesothelin 90% 100% 
KOC, Maspin 82% 100% 
Maspin, Mesothelin  82% 100% 
KOC, Maspin, Mesothelin*  72% 100% 
Note: * At least 2 biomarkers required to be positive in this panel. In the rest of the panels only one 
biomarker was required to be positive in a panel. 
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Table 7.4: Inter-observer agreement (kappa score) for 10% cut-off between two observers (A 
and B) for KOC, maspin, mesothelin and all 3 biomarkers 
K Scores 
Biomarker-Inter-observer 10% Cut-off P-Value 
KOC-AB 1.00 0.000 
Maspin-AB 0.84 0.000 
Mesothelin-AB 0.83 0.001 
All 3 Biomarkers-AB 0.89 0.000 
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Figure 7.1: Immunostaining of KOC, maspin and mesothelin comparing the biomarker 
expression in needling cytology samples and corresponding resection specimens   
Figure Legend: The IHC staining of needling and corresponding resection specimens is shown for 
in a grid manner for KOC (cytoplasmic staining), maspin (cytoplasmic and nuclear staining), 
mesothelin (cytoplasmic and memebranous staining) and S100P (cytoplasmic and nuclear). This 
staining was achieved with ‘IHC parameters optimised for TMAs’. 
Biomarkers Needling Cytology Corresponding resection specimens 
KOC 
  
Maspin 
  
Mesothelin 
  
S100P 
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Figure 7.2: Immunostaining of KOC, maspin and mesothelin comparing the different 
optimisation parameters using ‘needling’ cytology samples 
 
Figure Legend: Comparison of the staining patterns achieved with ‘IHC parameters optimised for 
TMAs’ (A, C, E) and ‘IHC parameters optimised for cytology’ (B, D, F) for KOC, maspin and 
mesothelin. For KOC comparing the staining achieved with (A) pH 6.0 as a heat induced antigen 
retrieval buffer with staining achieved using (B) pH 9.0. For maspin comparing the staining 
achieved with (C) 1/75 primary antibody dilution with (D) 1/150. For mesothelin comparing the 
staining achieved with (E) pH 6.0 as a heat induced antigen retrieval buffer with staining achieved 
using (F) pH 8.0.  
 
 
 
 
KOC
Maspin
Mesothelin
E
DC
BA
F
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Figure 7.3: Immunostaining of KOC, Maspin and Mesothelin in benign and PDAC cytology 
samples. 
Figure Legend: Representative images of staining observed for KOC (cytoplasmic), maspin 
(cytoplasmic) and mesothelin (membranous and/or cytoplasmic) in benign compared to malignant 
PDAC cytology samples. This staining was achieved with ‘IHC parameters optimised for cytology’. 
 
 
 
 
 
 
Biomarkers Benign Cytology PDAC Cytology
KOC
Maspin
Mesothelin
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Figure 7.4: Sensitivity and specificity analysis based on five cut-offs for biomarkers 
Figure Legend: Sensitivity and specificity analysis of biomarkers for the diagnosis of PDAC 
compared to benign disease, based on five cut-offs for positivity: 5% positive cells of any staining 
intensity; 10% positive cells of any staining intensity; 20% positive cells of any staining intensity; 2 
OR 3 intensity i.e. moderate or strong staining of cells; and Histoscore 20.  Analysis is presented 
for A) KOC, B) Maspin and C) Mesothelin. 
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Figure 7.5: Combined Summary ROC curves for comparing panels of biomarkers.  
Figure Legend: *Combined Summary ROC curves for 10% (A) and 20% (B) cut-offs if only one 
biomarker was required to be positive in a panel. Four panels of biomarkers were compared. Panel 
1 - KOC, Maspin, Mesothelin; Panel 2 - KOC, Mesothelin; Panel 3 - KOC, Maspin; Panel 4 - 
Maspin, Mesothelin. 
*Summary ROC curves plot sensitivity against specificity and draw a summary line depicting 
combined sensitivity and specificity of a panel. Combined Summary ROC curves compare different 
panels to show the most “accurate” panel. The summary line at the top left corner shows the 
biomarker which is most accurate compared to others lying lower and further to the right. This 
enables the most accurate panel to be identified. 
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Figure 7.6: Hematoxylin & eosin  and IHC staining of a PDAC cytology case to demonstrate 
the utility of panel of biomarkers 
 
Figure legend: These images are showing the importance of panel of biomarkers. A) H&E staining 
of a PDAC cytology case, B) Cytoplasmic staining of KOC showing moderate-strong and diffuse 
expression C) Cytoplasmic and nuclear staining of maspin showing moderate-strong and diffuse 
expression D) Membranous staining of mesothelin showing moderate-strong and diffuse 
expression, some weak cytoplasmic staining and patchy distribution. This staining was achieved 
with ‘IHC parameters optimised for cytology’. 
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8 Overall discussion 
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8.1 Thesis summary 
This thesis presents the role of immunohistochemistry (IHC) biomarkers in 
improving the diagnosis of pancreatic ductal adenocarcinoma (PDAC) from 
cytology samples. To achieve this goal, a systematic approach was adopted to 
identify and validate biomarkers for potential clinical application.  
The identification phase involved reviewing the literature to identify already 
existing IHC biomarkers investigated in PDAC resection and cytology specimens. 
This was performed as discussed in chapter 3, with a focus on IHC biomarkers 
showing differential expression between PDAC and non-neoplastic pancreas. 
Rigorous search criteria were used to identify the most relevant articles for 
systematic review and meta-analysis. The meta-analysis helped to quantify and 
rank the performance of biomarkers.  
High ranking candidate biomarkers from the meta-analysis were then validated 
in our cohort of resection specimens from patients with pancreatico-biliary 
adenocarcinoma (PBA) in an attempt to determine a suitable candidate 
biomarker or panel of biomarkers. This was presented in chapter 4 and 5, which 
also discuss various cut-offs for a positive diagnosis based on IHC staining. The 
project evolved and a need to investigate a consensus based cut-off with high 
inter- and intra-observer agreement emerged. In chapter 6, various cut-offs for 
observer agreement between practicing pathologists were investigated. It was 
found that cut-offs from our IHC validation work on TMAs and the literature 
achieve a good level of agreement between pathologists. 
Finally, chapter 7 reports the utility of a panel of biomarkers (KOC, maspin and 
mesothelin) in archival cytology samples. This panel is a good working panel with 
a potential to improve the diagnosis of PDAC as an adjunct to cytology. Figure 
8.1 is a summarising diagram of the project. 
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Chapter 3 
Systematic review and meta-analysis of 
IHC diagnostic biomarkers for PDAC 
 
Aim: To review, quantify and rank potential diagnostic IHC biomarkers for PDAC. 
What this meta-analysis adds 
Identification of candidate biomarkers: KOC, S100P, maspin, mesothelin and 
MUC1 and discussing the issues around IHC scoring systems and cut-offs. 
What next: Validation of identified biomarkers for differential expression in 
surgical cohort with a relatively large sample size. 
Chapter 4 & 5 
Expression of biomarkers in pancreatico-biliary 
adenocarcinomas: development and utility of a 
potential diagnostic IHC panel. 
 
Chapter 6 
Investigating various thresholds as IHC cut-offs 
for observer agreement  
Aim: To evaluate the expression level, sensitivity/specificity and cut-offs of IHC 
biomarkers in resection specimens.   
What this study adds  
Biomarkers KOC, S100P, maspin and mesothelin are overexpressed in cancer vs. 
normal and achieve good sensitivity/specificity with 10% and 20% cut-offs.  
What next: Investigation of cut-offs for observer agreement and validation of 
biomarkers on cytology samples. 
 
Aim: To investigate consensus based cut-offs for IHC scoring. 
What this study adds 
Cut-offs are important for interpretation of IHC and we found 10%+ cells, 20%+ 
cells and moderate-strong staining intensity as reliable and reproducible cut-offs. 
What next: Validation of biomarkers and cut-offs in cytology samples from 
patients with PDAC. 
 
Chapter 8 Conclusion 
This thesis identifies and validates diagnostic IHC biomarkers for PDAC. A 
panel of KOC, maspin and mesothelin is a good diagnostic panel and 10% cut-
off is a reasonable cut-off achieving high observer agreement. The diagnostic 
accuracy of this panel approaches those of optimal conventional cytology. 
These markers may be appropriate for further clinical validation and potentially 
clinical use in difficult cases. 
 
Chapter 1 Introduction  
What is already known: Diagnosis of pancreatic cancer involves imaging followed by endoscopy with cytology, and is important for patient management. Cytology 
involves the distinction of PDAC from non-neoplastic pancreas, which can be difficult, especially in chronic pancreatitis. Immunohistochemical (IHC) biomarkers could 
help but none is yet routinely used. What this project adds: Identification and validation of diagnostic IHC biomarkers for clinical application in PDAC cytology. 
Aim: To evaluate the expression level, sensitivity/specificity and cut-offs of IHC 
biomarkers for PDAC in cytology specimens. 
What this study adds 
A panel of KOC, maspin and mesothelin is a good panel using10% cut-off for the 
diagnosis of PDAC from cytology samples. 
What next: Further validation of this panel in a large cohort of cytology samples 
from patients with PDAC and a prospective clinical study. 
Chapter 7                                                                    
A panel of KOC, maspin and mesothelin is a 
good working IHC panel for PDAC diagnosis 
from cytology samples 
Identification of 
biomarkers 
Validation of 
biomarkers in tissue 
microarray 
 
Investigation of cut-
offs for observer 
agreement 
Validation of 
biomarkers in 
cytology 
Figure 8.1: Schematic diagram of thesis 
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8.2 Implications for current diagnostic practice 
Biomarkers investigated in this project could help to improve the diagnosis of 
patients from cytology samples in patients suspected of PDAC. IHC is already in 
clinical practice in pancreatic cytology samples from patients with 
neuroendocrine tumours (NET) (153, 154, 371). IHC staining of CD56, 
chromogranin A and synaptophysin is used for confirming the diagnosis of NET 
from pancreatic cytology samples. Hence IHC biomarkers could potentially be 
translated to clinical cytology samples for PDAC. 
Currently, only the morphological features of cells in the cytology samples are 
used for the diagnosis of PDAC. However, like NET biomarkers might be used to 
confirm the diagnosis in difficult cytology cases. Improvement in the diagnosis 
will further advance the diagnostic management of patients with PDAC and will 
remove the uncertainty associated with a PDAC diagnosis in indeterminate cases. 
A diagnostic algorithm (Figure 8.2) can be developed for cost effectiveness of 
IHC biomarkers. One possible algorithm can be as follows: If routine 
haematoxylin and eosin staining is sufficient for confirmation of malignant or 
benign diagnosis, no biomarker panel will be applied. However, in difficult cases 
when the cytologist reports an ‘atypical’ or ‘suspicious’ diagnosis; the panel of 
KOC, maspin and mesothelin could be applied. The presence of at least two 
positive biomarkers in the panel using a 10% cut-off might be considered as a 
cytology adjunct for PDAC diagnosis. It is important to note here that the final 
diagnosis is made by a multi-disciplinary team of oncologists, surgeons, 
radiologists, pathologists and other supporting staff. Therefore, this proposed 
algorithm should be used in combination with all the clinical, radiological and 
pathological findings. 
Some centres are now employing neoadjuvant treatment to all patients eligible 
for surgery and these treatment strategies require confirmation of tissue 
diagnosis. Hence a panel of biomarkers providing increased diagnostic 
confidence from cytology samples will advance the management of patients 
suspected of PDAC.  
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Figure 8.2: Diagnostic suggested algorithm for the diagnosis of PDAC cytology samples 
using different cytology categories and panels of biomarkers 
 
8.3 Implications for translational biomarkers research 
A systematic strategy was adopted in this thesis to address a clinical issue in 
PDAC diagnosis. IHC biomarkers were identified and sequentially validated in 
pancreatic surgical and cytology specimens. We believe that this strategy might 
potentially be useful in addressing clinical problems in other cancer types. This 
is particularly helpful for biomarkers that have been discovered and validated in 
clinical samples addressing a specific clinical issue. In addition, this strategy is 
not limited to diagnostic biomarkers but could provide a platform for prognostic 
and predictive biomarkers. The researcher can start with a clinical problem, 
identify high ranking biomarkers through a meta-analysis and then purposefully 
validate in tissue and cell samples as required. This type of work would require 
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close collaboration between pathologists, surgeons, oncologists, scientists and 
public health researchers.  
In addition, the cut-offs validated for observer agreements in this thesis have 
potential implications for translational research. These cut-offs could potentially 
be used for evaluating the diagnostic or prognostic utility of biomarkers as the 
current study provides evidence that they are reliable and reproducible. 
Biomarkers already using these cut-offs in translational studies could possibly be 
easily translated to clinical practice as the observer agreement for these cut-offs 
is reasonably good. 
8.4 Strengths and Limitations of this thesis 
First I will cover the more specific strengths and limitations of this thesis and 
then I will provide a more general discussion on the strengths and limitations of 
this thesis. 
The strengths of this thesis are as follows: the meta-analysis designed 
specifically for potential diagnostic IHC biomarkers in PDAC. Although good 
reviews (229, 230) on biomarkers for pancreatic cancer are present but such a 
meta-analysis is lacking for diagnostic IHC biomarkers; the validation of 
biomarkers identified in meta-analysis in a single experimental setting and a 
relatively good sample size (n=99 resection specimens cases). Our sample size is 
comparable to studies investigating biomarkers in PDAC resection specimens 
(n=93-96 cases) (171, 235) and sometimes better than other studies (n=27-53 
cases) (186, 234, 237); we have evaluated the diagnostic performance of 
biomarkers across multiple cut-offs which is very limited in PDAC literature. 
Biomarkers investigated in PDAC resection and cytology specimens use only one 
cut-off for biomarker assessment (139, 164, 166, 174, 276); the investigation of 
cut-offs for observer agreement involving seven practicing pathologists. This 
type of study for observer agreement is very limited in PDAC literature; the IHC 
conditions from surgical specimens are usually used for staining the cytology 
samples (159, 165, 176, 186). We optimised antibodies on ‘needling’ cytology 
samples allowing the comparison of different IHC parameters and selecting good 
IHC conditions for final staining. The development of such a resource for IHC 
optimization is lacking in PDAC literature.  
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The limitations of the thesis are as follows: The use of the same tissue 
microarray (TMA) cohort for KOC, mesothelin, S100P and MUC1 but the use of 
another TMA set for maspin; the sample size (n=21 cases) of our cytology project 
was small but was comparable to the published literature reporting IHC 
biomarker in cytology samples (n=15-25 cases) (139, 165, 174, 217, 258, 376); 
S100P though a good marker in resection specimens could not be stained 
successfully in cytology samples; and lastly the sample size of 
cholangiocarcinoma (CCC) was low (n=14). 
New research on diagnostic IHC biomarkers for PDAC has been published since 
our meta-analysis. Of special interest is the paper from Liu et al (167) where the 
authors investigated the utility of 26 candidate biomarkers in PDAC. IHC was 
performed for these 26 biomarkers using TMAs from 60 patients with resection 
specimens. From this initial investigation, four biomarkers maspin, S100P, IMP-3 
(KOC), and pVHL were selected based on their expression levels in tissue 
sections for further investigation in cytology sections. Three biomarkers maspin, 
S100P, IMP-3 (KOC) were positive biomarkers and pVHL was a negative biomarker 
for PDAC. Finally, a panel of maspin, S100P, IMP-3 (KOC), and pVHL was 
suggested for potential clinical use (167). By comparison, we identified 49 
potential IHC biomarkers in our systematic review including 24 of the 26 IHC 
biomarkers investigated in Liu et al’s study. Afterwards, we performed a meta-
analysis and through quantification identified IMP-3 (KOC), maspin, meosthelin 
and S100P as high ranking candidates which are similar to the final proposed 
biomarkers by Liu et al (167). In addition, pVHL as negative biomarker was 
identified in our systematic review but we did not investigate this marker in our 
project. To sum up, a significant amount of time, resource and money might be 
required to conduct a laboratory study when investigating a large number of 
biomarkers. In comparison, a systematic review and meta-analysis can review 
the available evidence, quantify the performance of existing biomarkers and 
help in selecting better candidates with significantly less time and resource. It 
may be of value first to perform a focused meta-analysis in biomarker research 
to address a specific clinical problem.  
Other candidate IHC diagnostic biomarkers reported since our meta-analysis as 
potentially differentiating PDAC from non-neoplastic pancreas include Ki-67, 
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Smac (377), PAM4 (378), ApoE (137), CRABP-II (379), MUC4 and MUC16 (380). 
Three biomarkers CRABP-II, MUC4 and MUC16 in particular have been 
investigated in fine needle aspiration cytology and are worth validating in other 
cohorts.   
First let us discuss the markers investigated in resection specimens and compare 
their specificities and sensitivities with the markers investigated in resection 
specimens in the current project. The specificity/sensitivity of differentiating 
PBA from normal pancreas for KOC is 100%/84%, maspin 99%/96%, S100P 
100%/83% and mesothelin is 92%/88%. In comparison, the specificity and 
sensitivity of Ki-67 in differentiating PDAC from normal pancreas was 84% and 
94%. Similarly, the specificity and sensitivity of Smac (a pro-apoptotic 
mitochondrial protein) was 92% and 100% (377). The sample size of this study 
was relatively small (n=47) but Smac appears to be a good candidate for further 
investigation (377). PAM4 was investigated in PDAC and chronic pancreatitis 
cases. The sensitivity of PAM4 was 79%, while the specificity was 81% if staining 
in the pancreatic intraepithelial neoplasias associated with CP were included. 
However, the specificity was 100% if staining in the PanINs is excluded from the 
specificity analysis. PAM4 could thus be a candidate for further investigation in 
cytology samples (378). The specificity and sensitivity of ApoE in differentiating 
PDAC from normal pancreas was 85% and 78% (137). These markers in particular 
Smac and PAM4 may be worth validating in cytology samples. Their diagnostic 
accuracies are good and the specificity and sensitivity of Smac is comparable to 
markers investigated in the current PhD project. However, KOC, maspin and 
mesothelin have been investigated in various studies from independent research 
groups. The new markers might thus require independent validation studies on 
FFPE tissue sections from patients with PDAC to further explore their diagnostic 
potential in PDAC.   
Three markers CRABP-II, MUC4 and MUC16 appear promising (379, 380). CRABP-II 
was investigated in both resection specimens and cytology specimens, while 
MUC4 and MUC16 were investigated in cytology specimens. The sensitivity and 
specificity of CRABP-II in differentiating PDAC from normal pancreas and chronic 
pancreatitis in resection specimens was 100% and 100%. However, the sensitivity 
dropped to 61% in cytology samples but the specificity was still 100% (379).   
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MUC4 and MUC16 are highly specific biomarkers (specificity 100% for both) with 
74% and 63% sensitivities respectively (380). Due to their high specificity they 
might potentially be used as a panel and appear to be good potential diagnostic 
candidates. However, their sensitivities are less than KOC (sensitivity 92%) and 
comparable to mesothelin (sensitivity 72%) and maspin (sensitivity 54%) as shown 
in our archival cytology project. Independent validation is required to further 
explore the clinical utility of CRABP-II, MUC4 and MUC16. 
8.5 Future research 
Referring back to the phases of biomarker development and factors delaying the 
clinical translation of biomarkers discussed in chapter 1 (specifically Section 
1.9.2 and 1.10); we have now identified potential biomarkers and validated 
them in our surgical and cytology cohort. However, independent validation is 
very important for translation of biomarkers into clinically useful tools (142, 181, 
199). Future research should therefore focus on validation studies enabling the 
clinical translation of biomarkers for pancreatic cytology samples. 
The panel of KOC, maspin and mesothelin would require validation in 
retrospective and prospective studies. The analytic phase of these biomarkers is 
well analysed and reproducible in our laboratory. However, the pre-analytic 
handling and processing of tissues should be standardized to allow for the 
reproducibility of staining and diagnostic impact in other laboratories. A larger 
retrospective study on archival cytology samples would further determine the 
clinical utility of this panel. The retrospective study allows comparison of 
multiple biomarkers and helps in the development of algorithms for clinical use 
(381, 382). For example, a trend can be established whereby two or more 
biomarkers can be found positive in one clinical scenario for example in a 
‘suspicious’ diagnostic category. Furthermore, retrospective longitudinal studies 
are relatively quicker than prospective studies. This holds particularly true for 
pancreatic cancer where very few cases are seen in most centers compared to 
cancers from other organs. A retrospective study could thus provide a solid and 
quick platform for the usefulness of candidate biomarkers investigated in PDAC. 
Sample selection in retrospective studies is very important in evaluating the 
diagnostic utility of biomarkers.  The application of the proposed panel for PDAC 
cytology samples should thus be from a range of atypical, suspicious and positive 
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for malignancy diagnosis. This will provide more information on the diagnostic 
potential of biomarkers in difficult to diagnose cases. 
After evaluating the clinical utility of biomarkers in retrospective samples the 
next validation step is the application of panels to prospective cytology samples. 
The purpose of the prospective study is to determine if the biomarkers could 
deliver the proposed diagnostic utility in routine clinical practice (382). These 
prospective clinical studies are therefore important to show the true clinical 
utility of biomarkers for improving the diagnosis of PDAC from cytology samples. 
Finally, the utility of our proposed panel in independent pathology laboratories 
will further enhance their clinical utility for routine diagnostic use. 
8.6 Final conclusion (an amalgamation of all results 
chapters) 
IHC biomarkers have been extensively investigated to improve the diagnosis, 
prognosis and prediction of response to treatment for a variety of cancers 
including pancreatic cancer. The aim of this project was to improve the 
diagnosis of PDAC from cytology samples using IHC biomarkers as an adjunct. To 
achieve this goal, the project involved the identification of IHC biomarkers from 
literature through meta-analysis and validation in PDAC resection and cytology 
samples. This project also involved the investigation of scoring systems and 
consensus based cut-offs. 
The fact that many potentially diagnostic IHC biomarkers for PDAC already exist 
in the literature was demonstrated by our systematic review. Current evidence 
shown by our systematic review is that biomarkers identified are validated singly 
with less utilisation of panel approach. Moreover, panels of biomarkers are 
randomly selected for validation studies with a no ‘evidence based’ approach. In 
this project biomarker identification was through meta-analysis and a panel of 
biomarkers was proposed. Interestingly, the sensitivity and specificity values of 
biomarkers in our validation cohort agree with the values reported in our meta-
analysis. This demonstrates the utility of meta-analysis in biomarker research to 
prioritise candidates for potential validation from a pool of biomarkers 
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The interpretation of IHC staining for diagnostic purposes requires a cut-off for 
assigning patients into positive or negative categories. From the TMA work five 
diagnostic cut-offs were identified. But for clinical translation the cut-offs 
should have high observer agreement. Consensus based cut-offs were therefore 
investigated among practicing pathologists. It was found that all three cut-offs 
(10%, 20%, +2/+3) achieve reasonable strength of observer agreements. The 
work presented here is evidence that these cut-offs are reliable and 
reproducible and might be used in other areas of cancer pathology and could 
potentially be applied to cytology samples in PDAC. 
The technique of developing a ‘needling’ cytology resource presented here 
shows the value of generating such a resource for IHC optimisation purposes. The 
rationale behind this optimisation was to achieve better staining in archival 
cytology samples. After addressing the issues hindering the clinical translation of 
biomarkers a pilot study on the precious but scarce archival cytology samples 
was performed to elucidate the clinical potential of biomarkers. A panel of KOC, 
maspin and mesothelin was applied to the archival cytology samples. Individual 
biomarkers have relatively low sensitivity but as a panel they achieve good 
sensitivity and specificity. In addition, the observer agreement for 10% cut-off 
was very good for all three biomarkers in cytology samples.  
In brief, the approach of identification of biomarkers presented here 
demonstrates the value of utilising the published literature for addressing the 
clinical problems. The successful panel of biomarkers subsequently developed 
through validation in resection and cytology samples addresses an important 
clinical issue in the diagnosis of PDAC from cytology. The diagnostic accuracy of 
this panel approaches the optimal conventional cytology. These markers may be 
appropriate for further clinical validation and potentially routine use in difficult 
cases. 
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